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Chapter 1
General Introduction
1.1 Introduction
At the time Watson and Crick elucidated the molecular structure of
deoxyribose nucleic acid (DNA) in 1953, the general conception was that DNA
served as a cellular library and was therefore thought to be unalterable (1). However,
later, it became clear that DNA is continuously exposed to a plethora of endogenous
and exogenous compounds that are able to induce DNA damage by interacting with
various sites in the DNA (2). DNA damage may result in the misincorporation of a
nucleotide opposite to the damaged site during DNA replication or error-prone
DNA repair. As a consequence, the nucleotide sequence is altered and the normal
function of DNA or its translation products can be changed. Interference with the
structural integrity of DNA is thought to be a critical initial step in chemically
induced cancers, because mutations in specific cell-cycle regulatory genes may
disrupt normal cell growth (2).
Many chemicals are able to interact with DNA, but most studies on chemical
carcinogenesis have concentrated on alkylating agents and aromatic compounds. A
lot of work has been carried out on the DNA-binding properties of polycyclic
aromatic hydrocarbons (PAH)(3). PAH form a large group of structurally related
compounds with two or more condensed benzene rings that are formed as products
of the incomplete combustion of organic materials. The evidence that PAH are potent
carcinogens in laboratory animals is overwhelming and the main organs in which
rumors occur after PAH exposure seem to be skin, pulmonary, gastric and mammary
tissues depending on the route of administration (4). PAH are also suspected to be
carcinogenic in humans (5). PAH are widely distributed in the environment and it
would be surprising if the human population was not placed at increased risk of
developing cancer as a result of environmental pollution by PAH. Examples of
environmental PAH sources are power plants, domestic and industrial hearing
systems, combustion engines, refuse burning and as a more localized source tobacco
smoke. These sources produce mixtures that contain 100-300 different PAH, which
are not all equally potent carcinogens. Benzo[a]pyrene [B(a)P], a typical PAH, is
considered to be one of the main contributors to the carcinogenic properties of
mixtures (3) and is commonly used as indicator of the pollution level of PAH in, for
example air samples. The first clear recognition of chemically induced cancers in
man by a PAH-containing mixture can be traced back to 1775 when the London
surgeon Pott attributed the common occurrence of scrotum cancer in chimney
sweeps to the prolonged exposure of skin to soot (6). In the beginning of the 20th
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century, Yamagawa and Ichikawa demonstrated the induction of skin carcinomas on
rabbit ears by repeated topical applications of coal tar (7). In the 1930s,
dibenzo(a,h)anthracene (8) and B(a)P (9) were identified as highly carcinogenic
constituents of coal tar. Important evidence that PAH-DNA binding pl.n ^ .i role in
carcinogenesis was provided in 1964 by Brookes and L^wley (10), who demonstrated
a correlation between the carcinogenic potency of six PAH and the extent to which
they became covalently bound to DNA, but not to RNA or proteins. Miller and
Miller (11) proposed that most carcinogens, including PAH, an* not active
themselves, but require metabolic activation before they can interact with cellular
macromolecules.
1.2 Carcinogenicity of PAH in exposed rodents and humans
A Exposure /«re/s and
The general population is exposed to PAH via three different routes; ingestion,
inhalation and dermal absorption. PAH are found in substantial quantities in many
foods, depending on their origin and the method of cooking, preservation and
storage. High concentrations of PAH were found in charcoal broiled and smoked
foods and also in leafy green vegetables (4, 12). PAH levels in the latter paralleled
with the atmospheric burden, indicating that PAH are taken up or deposited from
the atmosphere (4). In the past, uptake of B[a|P via ingestion has been measured or
estimated in several studies. However, large inconsistencies .in.I JIM trp.iiuies were
found and still there is a lot of discussion about the aiun.u.) ot the estimated
exposure levels (13). It was estimated that intake of B[a]P by ingestion varied
between 0.03 ug B[a]P/day (14) and 2.2 ug B[a]P/day (15). In the Netherlands,
dietary intake of B[a]P was measured between 1984 and 1986, and was found to be
approximately 100 ng B[a]P per day and dietary exposure to total PAH was
estimated to be 6 ug/day (16,17).
Inhalatory exposure to PAH is well studied in the Netherlands; the mean
concentration of B[a]P in air was found to be 0.5-0.6 ng/m-\ with peak-
concentrations up to 4 ng/m^ near certain factories, or even 70 ng/rrP in indoor air
by the use of an open fireside (17). Assuming that adult humans inhale ca. 12 m^ air
per day and the PAH deposition rate amounts to about 50%, uptake of PAH by
inhalation may theoretically result in 6 ng and 420 ng B|a]P per day for respectively
clean (<1 ng B[a]P/m3) and heavily polluted air (70 ng B[a]P/m^). For comparison,
the average total B[a]P content of mainstream smoke of one cigarette can vary
between 20 ng and 40 ng. A total human environmental exposure study on B[a]P
examined all possible pathways of contact at one time (14). The results indicated that
the PAH intake by food and by inhalation were equally important; dominance of one
pathway or the other depended upon personal dietary habits and the indoor
combustion source used.
Dermal uptake of PAH is of minor importance for the general population.
However, under certain circumstances dermal exposure to PAH can be very high.
For example, considerable PAH exposures were found in occupational settings, such
as in the aluminum industry, in workers handling molten tar, pitch or asphalt
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(roofing, paving), chimney sweeps and foundry workers (18). A substantial part of
the body may be exposed to PAH if clothes become contaminated. Another group of
individuals with extremely high levels of exposure via dermal contact is represented
by patients with skin diseases (e.g., psoriasis, eczema, dandruff or skin infections),
who were treated with coal-tar containing ointments (19, 20). In a recent study, BfaJP
concentrations in coal-tar ointments were found to be higher than 1.5 mg B[a]P/kg
ointment (20). Thus, if a patient is treated with for example 100 g of ointment, the
delivered total dose of B[a]P on the skin would be as high as 0.15 mg, a dose capable
of inducing skin rumors in laboratory rodents (see next paragraph).
B. Gjrc7no£«i/Wry /« rWafton fo exposure route
In animal experiments, carcinogenic PAH become effective predominantly at
the site of application and the animal species investigated so far show very similar
reactions (4).
In laboratory rodents, orally exposed to B[a]P, tumors of the esophagus and
forestomach were observed (21). Although absorption of lipophilic B[a]P after oral
application is normally hampered by the mucous layer of the gastrointestinal tract,
B[a)P penetrates quite easily the forestomach epithelium of mice, almost irrespective
of the vehiculum used to administer the B(a]P. At higher doses, oral applications of
B|a|P also induce systemic carcinogenic effects in various animal species. For
example, in mice fed with a diet containing B[a]P (250 ug/g of food), lung adenomas
and leukemia's developed in addition to tumors of the forestomach (22). In some
strains of rats, oral administration of B[a]P and related compounds very easily
induced carcinomas of the mammary gland as well (23). It was even possible to
induce skin papillomas in mice after a single gavage of 3 mg B[a]P and subsequent
treatment of the skin with croton oil (24). PAH in our food may also exert a
carcinogenic effect in the gastrointestinal tract of man. Indeed, the incidence of
stomach cancer in 50 to 69 year-old subjects in an area of the USA with high air
pollution was almost 100% higher as compared with areas with lower air pollution
(25). However, this information is not sufficient to permit final conclusions.
Inhalatory exposure (or intratracheal instillation) of laboratory rodents to B[a]P
predominantly resulted in the induction of lung tumors (21). PAH exposure of
humans by inhalation is thought to be responsible, at least partly, for the higher lung
cancer frequency in smokers than in non-smokers, in urban populations than in rural
populations, and in some groups of workers compared with the general population.
For example, epidemiological studies on gas, coke and aluminum workers, who are
exposed to high concentrations of PAH in the ambient air, showed increased risks of
respiratory cancers (26, 27). Furthermore, epidemiological data suggest that smoking
tobacco is additionally related to cancer of the upper aerodigestive tract, pancreas,
renal pelvis, bladder and cervix (28).
Studies in experimental animals treated topically with PAH or PAH containing
mixtures, show clear evidence of local carcinogenicity (4). Evidence for skin
carcinogenicity of PAH in humans has mainly come from studies on the frequency of
cancer among workers exposed to coal-tar or soot (29). For instance, recent studies
showed that skin cancer risks were significantly increased in road pavers and
12
highway maintenance workers (28). The number of reports regarding coal-tar treated
patients is surprisingly low. In fact, skin tumors induced by the therapeutic use of
coal-tar are seldomly noticed in the clinical profession.
13 PAH metabolism and DNA adduct formation •
PAH are lipid soluble and tend to accumulate in individuals who come into
contact with them, unless they are metabolized to more water soluble derivatives
that can be excreted in urine or faeces (3). Paradoxically, PAH would not be
carcinogenic if they were not metabolized. The initial step in the metabolism of
unsubstituted PAH is the formation of epoxides, the addition of an oxygen across a
double bond, by cytochrome P450 dependent mono-oxygenases (31).
• "
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Figure 1. Stereoselective metabolism of B[a]P to BPDE via cytochrome P450 (CYP450) and epoxide
hydrolase (EH) dependent reactions (adapted from reference 3).
Further metabolism results in hydration by epoxide-hydrolase to dihydrodiols,
isomerizarion to phenols, or conjugation with glutathione by glutathione-S-
transferases. Glutathione conjugated PAH are water soluble and can easily be
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excreted in faeces or urine as mercapturic acids (see Chapter 1.5). Phenols and
dihydrodiols are conjugated with glucuronic acid or sulfuric acid by respectively
glucuronyl-transferases, located in the endoplasmatic reticulum, and
sulphotransferases which are cytosolic enzymes (3). As a result, predominantly
water soluble derivatives are formed, but occasionally the enzyme system will
activate the parent compound to biologically reactive forms, that are able to
covalently bind to cellular macromolecules, such as protein, RNA and DNA.
Many studies have focused on the metabolic activation of B[a]P to certain
reactive dihydrodiol epoxide derivatives (32). At first, B[a]P is metabolized by
cytochrome P450 to B(a]P-7,8-epoxide, which exists as a pair of enantiomers (Figure
1). Subsequently, this epoxide is hydrated by epoxide-hydrolase, which results in
two B[<i]P-dihydrodiols. The next step involves the addition of a second oxygen
across the 9,10 double bond resulting in B(a]P-7,8-dihydrodiol-9,10-epoxide (BPDE),
either as the SI/H- or n/if/'- form (the epoxide oxygen on the same (syn) or the opposite
(a/if/) face of the benzene ring as the hydroxyl group at the C7-position) (32).
Epoxidation of the B|a|P-7,8-diol is also accomplished by non-cytochrome P450
mediated reactions. For example, peroxyl free radicals are capable of inserting
oxygen atoms across the 9,10 double bond of the B[a]P-7,8-diol (33). The steps
catalyzed by mono-oxygenases are highly stereoselective and the main metabolite
appears to be (+)rt»//'-BPDE, which has been found to possess greater biological
activity than the other three metabolites (3, 34), and therefore most of the studies
regarding the interaction of BPDE with DNA have been performed with this
compound or in combination with its enantiomer ((+)<JM//-BPDE or (-)<j;jr;-BPDE).
The predominant adduct found in DNA or polyribonucleotides after exposure
to (+)<JHf/-BPDE is a covalent interaction product between the 2-amino group of
guanine (N^) and the ClO-position of B[a]P (35, Figure 2). This adduct is considered
to be chemically stable. Several other interactions of dihydrodiol epoxides have been
shown to occur, such as binding at the N7 position of guanine and the exocyclic
amino groups of adenine and cytosine. Other PAH, such as 7,12-
dimethylbenzo(a)anthracene, benzo(a)anthracene, benzo(c)phenanthrene, chrysene,
5-methylchrysene, dibenzo(a,e)fluoranthene and dibenzo(a,h)anthracene, are also
converted into reactive dihydrodiol epoxides that bind to DNA (3, 34). A unique
structural feature of these diolepoxides is that the epoxide group is located in the
bay-region of the molecule, formed by the presence of an angular benzene ring (36).
The high chemical reactivity of bay-region diol epoxides can be attributed to the fact
that they easily undergo ring opening to a carbonium ion while enzymatic
detoxification by epoxide hydrolase is sterically obstructed. However, in such a
structurally diverse group of compounds as PAH, it is obvious that exceptions can
not be excluded, but it is believed that the general mechanism of metabolic activation
is by the formation of bay-region dihydrodiol epoxides.
B[a]P can also be activated via a one-electron oxidation pathway, which
generates a radical cation (B[a]P*+) with the positive charge mainly localized at the
C6 position of the molecule (37). This metabolic pathway can be catalyzed by various
enzyme systems, such as cytochrome P450, prostaglandine-H-synthetase and
peroxidases (38), and may be of practical importance since certain target organs (e.g.
14
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lung and stomach) for B[a]P and other PAH are generally low in told <
P450 concentrations, but have significant levels of prostaglandine-H-svnthetase. The
most potent PAH possess relatively low ionization potentials and aro therefore easily
metabolized via both the one electron-oxidation and via the diol-epoxide pathway.
B(a]P-radical cations predominantly form labile DNA adducts at the N7 position of
guanine and adenine, which are lost by depuhnation and leave apurinic sites in the
DNA (39). If not properly repaired, >.]
Benzo[a]pyrene
One-electron
Oxidation
Activation to BPDE
8-OHdG BP-N7Gua BP-C8dG BPDE-N7 Gua BPDE-N*dG
Figure 2. Schematic overview of the induction of DNA damage by B[a)P via various metabolic
pathways. The left side of the figure represents the one-electron oxidation pathway, whereas the right
side of the figure represents the activation of B[a]P to bay-region diol epoxides.
these sites may induce mutations through mispairing (40). Analysis of DNA adducts
in mouse skin treated with B[a]P, showed that the one electron oxidation pathway
may also induce some stable DNA adducts (41). Probably the B[a]P-6-C8-
deoxyguanosine is involved, since this adduct was found as stable DNA adduct in /«
f/fro studies (33, Figure 2).
Furthermore, the B[a]P radical cation functions as an intermediate metabolite in
the formation of 6-OH-B[a]P, which is a labile phenol (37). Auto-oxidation of this
derivative may ultimately result in the formation of B[a]P quinones. B[a]P quinones
are almost invariably found after metabolism of B[a]P, sometimes accounting for
more than 50% of the total metabolic yield (42). The B[a]P quinones formed are 6,12-,
15
1,6- and 3,6-B[a]P quinones, which can undergo redox-cycling to their corresponding
B[a]P diols coupled with molecular oxygen to form superoxide and hydroxyl
radicals by the Haber-Weiss and Fenton reactions (43). The hydroxyl radicals
produced can give rise to oxidative DNA damage, e.g. 8-oxodeoxyguanosine (8-oxo-
dG) formation and DNA single and double strand breakage.
1.4 PAH-DNA adducts and their role in carcinogenesis
Chemically induced carcinogenesis is a complex multistage process, which
involves mutations in growth-regulatory proto-oncogenes (e.g. ras) and tumor-
suppressor genes (e.g. p.53) (2). The initial step is thought to be the interaction of
electrophilic metabolites with DNA, which may result in a changed nucleotide
sequence due to misincorporation of a nucleotide opposite the damaged base.
Aberrant gene products or modified gene expression may ultimately disrupt normal
regulatory processes of cell growth.
There are several lines of evidence regarding the role of PAH-DNA adducts in
transformation of normal cells into cancerous cells. Firstly, experiments with
cultured cells exposed I»I i»/7ro to PAH. Secondly, studies using animal models,
particularly laboratory rodents. Thirdly, studies in healthy human volunteers and
cancer patients, who were exposed to PAH.
A /
Important evidence for the promutagenic role of DNA adducts in mammalian
cells was provided by m v/tro studies using shuttle vectors with DNA adducts at
specific localization's (44). However, the best evidence for the role of PAH-DNA
adducts in human cancer has emerged relatively recently in a study by Denissenko cf
a/. (45). It was found that the strong and sequence-specific formation of BPDE-DNA
adducts in p53 of bronchial epithelial cells m ui/ro occurred at the same positions as
the major mutational hotspots in p53 found in DNA from human lung cancer tissue.
Furthermore, other studies on cultured cells /« uifro exposed to PAH, showed that
aromatic carcinogens have the potential to alter or "activate" H-ras proto-oncogenes
(46-48). In these studies, the most predominant point mutations induced by BPDE
were G to T transversions and to a lesser extent G to A transitions, similar to those
found in ras oncogenes and p53 tumor suppressor genes in human cancers (49).
Recent studies strongly suggest that both preferential adduct formation and slow
repair lead to such mutational hotspots (50).
B. S/iftfrVs /« Laboratory Roitenfs
Despite this convincing body of evidence supporting the critical role of DNA
adducts in PAH-induced cancers, much remains to be uncovered about the
quantitative relationship between PAH-DNA adduct formation and cancer risk in
i»/w. One might expect that higher concentrations of PAH-DNA adducts would
imply a higher likelihood of critical mutations leading to cancer. However, studies
with laboratory rodents have led to the understanding that there is no simple
algorithm for translating DNA adduct levels into cancer risk. For example, DNA
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adducts appeared to be not specific for target organs, but are tbo formed in tissues
in which no rumors are induced (51, 52). Thus, DNA adducts are not solely
responsible for tissue specific cancers, but additional factors are involved. However,
the overall data in target organs of animal models seem to point out that tho level of
DNA adducts is actually related to cancer risk. In some cases, but not all, the target
organs of sensitive animal species had higher adduct levels than the same organs in
resistant species (53).
Chronic administration of a carcinogen resulted in the attainment of steady-
state DNA adduct levels, which were related to the dose over a wide range and were
generally correlated with the carcinogenic outcome (54). Furthermore, inhibition of
adduct formation resulted in decreased carcinogenicity of B|a|P (55). In studies
concerning acute exposure to a single dose of a carcinogen, the relationship betwivn
DNA adducts and the carcinogenic outcome is more complex, bt\ uis, I >\A .uhluct
levels change as a function of time and may follow different ph.um.uokiiuik.s lor
different carcinogens. Ross ?/ a/ (56) showed that the adduct level integrated over
time (i.e., area under curve) correlated with the induction of lung carcinoma by
several PAH. This suggests that both formation and removal of PAH-DNA adducts
determine their carcinogenic potency. This was also suggested in a study by IX* Vries
et al. (57) in which knock-out mice deficient in nucleotide excision repair (NHK) were
orally exposed to B|a]P. In B|a]P exposed NER-deficient mice, an enhanced mutation
frequency in lymphocytic cells was observed, which coincided with lymphotnas
residing in the spleen (57).
C. Studies in Humans
In humans, no prospective studies that directly link DNA adduct levels with
cancer outcome have been performed yet. Many studies were on a cross-sectional
basis, which may obscure the temporal relationship between exposure, DNA adduct
formation and cancer (the presence of a tumor may affect DNA adduct levels).
However, there is sufficient evidence to assume that DNA adducts are actually
related to cancer risk in man. For example, Perera et al (58) reported a correlation
between DNA adduct levels and the /'» zwo mutation frequency in individuals
occupationally exposed to PAH. Although the gene (HPR7^ and tissue (white blood
cells, WBC) under investigation, are not relevant in occupationally related
carcinogenesis, their results provide evidence for the mutational effects of PAH ;'w
two in humans. In general, aromatic-DNA adduct levels in critical organs and cancer
risks are both related to PAH-exposure (59, 60). Moreover, correlations have been
observed between DNA adduct levels in various groups of exposed subjects and
their corresponding cancer risk. For instance, higher adduct levels were observed in
lung of smoking females as compared with males (61), which is in line with
epidemiological data showing that women are at a greater risk of tobacco-induced
lung cancer (62, 63). Furthermore, higher PAH-DNA adduct levels in lung
parenchyma (64) and peripheral blood leukocytes (65) were observed in lung cancer
patients as compared with healthy controls.
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Thus, taken together all the available in rrc'fro and in OTPO data, it can be
concluded that it is possible to use DNA adduct data to estimate human cancer risk,
but also that this area of research clearly requires further attention.
1.5 Susceptibility for PAH-DNA adduct formation
/I.
All living mammalian cells possess a certain capacity to cope with the presence
of reactive PAH-derivatives and to prevent formation or accumulation of DNA
damage. Electrophilic metabolites may be detoxified by glutathione-S-transferases
(GST's) before they might react with cellular macromolecules (3). GST's form an
important group of enzymes involved in the nucleophilic addition of the tripeptide
glutathione (GSH) to lipophilic substrates that have electrophilic functional groups.
The GST's can be divided into four classes, Alpha (a), Mu (u), Theta (t) and Pi (re),
based on structural and catalytic properties (66). The existence of a multiplicity of
isoenzymes made the nomenclature very confusing; therefore, a new nomenclature
was introduced and agreed upon by many of the principal workers in the field. The
new designation of these dimeric proteins was based on an international system for
human gene-nomenclature (67, shortly reviewed in ref. 66) and will be used in this
thesis. For example, a dimeric GST-protein containing two subunits of the u-class is
now designated as GSTM1-1, and the corresponding gene is designated GSTM2.
Especially GSTM1-1 and GSTP1-1 seem to have a high affinity towards epoxides,
and may thus play an important role in the protection against reactive PAH-diol-
epoxides. BPDE has a slow spontaneous rate of reaction with GSH. However, if this
rate is sufficiently enhanced by GST-catalysis, the resulting reaction may compete
effectively with DNA adduct formation (66). Interestingly, the expression of GST's is
highly variable between different tissues and individuals. For example, about 50% of
the Caucasian population lack the GSTM2 gene and has therefore no GSTM1-1
activity and it has been reported in molecular epidemiological studies that these
individuals might have an increased risk for developing lung cancer (68). In some
studies, the absence of the GSTM1-1 isoenzyme in lung of smoking individuals was
associated with relatively high PAH-DNA adduct levels, which implies an important
role of GSTM1 in scavenging reactive PAH-metabolites (66, 69-71). On the other
hand, in a recent study by Schoket et al. (72) such a relationship was not found.
Other important PAH-detoxifying enzymes are UDP-glucuronosyl transferase
(UGT) and sulfotransferase (ST), which catalyze the conjugation of PAH-derivatives
that posses -OH functions with respectively glucoronic acid and sulfate (3). The
dose-dependent conjugation of mainly quinones and phenol metabolites results in
sufficiently hydrophilic compounds that can be excreted in urine or faeces. Generic
polymorphisms of glucuronidation and sulphation are known to exist (73), although
the characterization and assessment of the importance of these variations are
hampered by the lack of appropriate studies in humans with suitable and safe model
compounds.
Human exposure to PAH via diet or cigarette smoke always coincides with
exposure to other aromatic compounds, such as aromatic amines. Aromatic amines
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can be acerylated by N-acetyl transferases (NAT) and at least two genes are involved,
Ny4Tl and AMT2 (74). Generally, N-acetylation of aromatic amines is considered to
be a detoxifying mechanism, because it competes with N-oxidation by cytochrome
P450 1A2 which produces reactive hydroxylamines that can be further metabolized
to DNA binding electrophiles. Approximately half of the Western population is slow
acetylating (74), which was observed to be associated with high levels of DNA
damage caused by aromatic amines (75) and a greater susceptibility to bladder
cancer in smokers and occupational!)' exposed subjects (68). On the other hand, rapid
acetylators seemed to have a higher risk for developing colorectal cancers (68, 76).
The N/4T polymorphisms seem to be more relevant at low exposures as compared to
high levels of exposure, as suggested by the more pronounced effect of the N/4T2-
polymorphism on 4-amincvbiphenyl (=aromatic amine)-hemoglobine adducts in low
as compared with heavy smokers (77).
B.
Activities of other enzymes involved in the activation of PAH-metabolites are
highly variable between individuals as well, and the basis for this variability is often
a genetic polymorphism in genes that encode for these enzymes. For example. The
gene that codes for the inducible cytochrome P450 (CYP) isoenzyme CYIM Al, which
is characterized by affinity for planar substrates like PAH and its ability to oxygenate
molecules in conformationally hindered positions (bay-regions), was found to be
polymorphic in the 3' noncoding region (78). A Ms/>/ restriction site polymorphism
seemed to be associated with an increased risk for lung cancer as initially reported
by Kawajiri et al. (78). In another study, they postulated that the Msp/ polymorphism
was genetically linked with an Isoleusine—»Valine polymorphism in exon 7, which is
related to a stronger capacity of the enzyme to bind the substrate (79). In a Japanese
population, individuals with the susceptible CYPI/U Msp/ genotype combined with
deficient GSTM2 had a remarkably high risk for developing carcinoma in lung
(OR=16). The risk was even higher in individuals who had the exon 7 susceptible
genotype of CYPM2 (Va//V<jO combined with the GSTM7 null genotype (OR=41)(80).
So far, the number of reports supporting Kawajiri's first observation for populations
outside Japan is limited (68, 81, 82). The influence of the CYPMJ polymorphism on
DNA adduct levels in lung is still not clear; although most genotyping studies were
unable to find a relationship between both parameters; recently Rojas c/«/. (71) found
a clear effect of the combination of CYPJ/U and GSTM2 genotypes on the formation
of specifically BPDE-DNA adducts in human lung and lymphocytes. A study
involving phenotyping showed a clear correlation between aromatic-DNA adducts
and CYP1A1 activity among smokers (83). Overall, it is thought that the balance
between activation and inactivation of PAH may play a significant role in the
susceptibility towards the formation of DNA adducts and subsequent risk for
developing chemically induced cancers. Thus, it is expected that assessment of the
complete set of putative high risk genotypes' will allow the identification of
susceptible individuals or subgroups. Currently, however, investigating all
genotypes that might be involved in the metabolism of complex chemical mixtures
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seems impossible and if biological responses (induced by DNA damage) are taken
into account, the whole picture will be even more complex.
C. P53 /tccwmM/tffion and DAM repair . , . , , • . - , .
An important biological response as a consequence of DNA damage is the
accumulation of wild-type p53 tumor suppressor protein. Two functions have been
proposed for p53 accumulation after DNA damage; induction of apoptosis and
induction of pathways that arrest cells in the Gl phase of the cell-cycle to provide
sufficient time for efficient DNA repair (84). Wild-type p53 protein is a sequence
specific DNA binding protein, capable of binding to and regulating transcription of
other genes that contain p53 responsive elements, like Ga<#45, Mdm2 and
p2JW/W'/un, involved in cell-cycle regulation (85). P53 accumulates in mammalian
cells after exposure to various DNA damaging compounds, such as UV (86-88), y-
rays (89, 90), bleomycin and actinomycin D (91), cisplatin, nucleotide analogues (92,
93) and BPDE (94). Thus, p53 accumulation may prevent the consequences of DNA
adduct formation and the onset of carcinogenesis by selection in favor of efficiently
repaired cells, against heavily damaged cells. The contribution of DNA repair in
PAH-DNA adduct persistence is of relevance. In m uifro studies using BPDE or B[a]P
treated lymphocytes of healthy volunteers, a broad range in repair capacity was
observed (95, 96). This range included individuals with an apparent complete lack of
DNA repair of bulky DNA adducts. This interindividual variation was not due to
differences in exposure or the extent of initial adduct formation, but rather reflected
true differences in DNA repair capacities. In individuals with efficient DNA repair,
most of the DNA adducts were removed within the first 24 hours after treatment.
The importance of DNA repair in the inhibition of mutagenesis and carcinogenesis is
especially illustrated by studies on DNA repair deficient animals (57) and the high
incidence of cancer in individuals with DNA-repair defects, such as xeroderma
pigmentosum, Bloom's syndrome and ataxia telangiectasia.
1.6 Exposure monitoring
Epidemiological studies that intended to evaluate the health risks of
environmental agents are usually compromised by the lack of quantitative exposure
data for individuals within exposed populations (97). The incorporation of
measurements of physiological, cellular, subcellular and molecular events into
epidemiological research (called mo/t'cu/ar ep/dmiw/ogy), may be very useful in
improving the precision of carcinogen exposure and health risk estimates. These
measurements are refered to as b/'o/og/ca/ marfcm or Womarfars. Biomarkers can be
classified as markers of exposure, markers of effect and markers of susceptibility.
Exposure marker analysis comprises the assessment of agents or their metabolites
either in tissues, secreta, excreta or any combination of these, to evaluate exposure as
compared with an appropriate reference. An effect marker is a measurable
biochemical, physiological or other alteration within an organism that can be
recognized as an established or potential health impairment or disease. Finally, a
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susceptibility marker is an indicator of an inherent or acquired limitation of an
organism's ability to respond to the exposure to a specific xenobiotic agent (97).
The Framework
The former paragraphs can be summarized as shown in Figure 3, which forms
the theoretical basis for molecular epidemiology and provides a broad
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Figure 3. The frame work of molecular epidemiology, which provides a theoretical background for the
application of biological markers as early end-points in cancer prevention studies.
range of possible biomarkers or measurements that might be of use in studies
regarding PAH-exposure. For instance, the internal dose of PAH can be assessed by
measuring PAH concentrations or PAH-metabolites in body fluids, of which urine is
most commonly used (98). However, such measurements do not necessarily
represent the biologically effective dose, which is the dose of a carcinogen that
actually affects the DNA in a tissue in which ultimately tumors may occur (i.e., target
organs, see Chapter 1.2). Therefore, the most promising biomarker seems to be the
measurement of DNA adducts, since it takes into account individual differences in
exposure, absorption and distribution of the chemical, its metabolism into DNA
reactive forms, detoxification of reactive intermediates, as well as cell turnover and
repair of DNA damage. However, for the effective use of DNA adducts in PAH-
exposure monitoring studies, several additional aspects of PAH-DNA adduct
formation need to be known, which will be discussed in the next paragraphs.
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1.6.2 Validity criteria for biological markers of exposure
A Surrogate T/ssure
Practical and ethical considerations limit the types of tissues available for
analysis of DNA adducts in man. Most target organs for PAH induced
carcinogenesis can not be reached for routine sampling. Therefore, DNA adducts
have predominantly been studied in easily available peripheral white blood cells
(WBC). Gupta et al. (99) demonstrated the capacity of human peripheral blood
lymphocytes to »n t'/fro metabolize a number of carcinogens, including B[a]P, to their
DNA binding species and high interindividual variations (up to 62 fold) in binding
capacity of reactive PAH derivatives were observed. This variation in B[a]P related
DNA ad duct formation ;H z»(7ro was found to be genetically controlled (100) and may
be indicative of individual differences in lung cancer susceptibility (101, 102).
However, WBC are not necessarily target cells for PAH or the most sensitive cells for
DNA adduct formation and the question remains whether these cells provide a
reliable estimate of PAH exposure /'n w'w. Studies on occupationally exposed
workers showed that, in general, adducts can be detected in a significant proportion
of the exposed workers and to a lesser extent in control subjects (reviewed in ref.
103). Studies on smokers and nonsmokers showed conflicting results on the effect of
smoking on PAH-DNA adduct levels in WBC. Several studies did not reveal any
significant differences in PAH-DNA adduct levels between the two groups (104-106),
suggesting that adducts in WBC may result from other sources than tobacco
smoking. In a study among rtxifers, PAH-DNA adduct levels in WBC correlated with
the amount of PAH in skin wipes, but not with the amount of PAH in personal air
samples, indicating that dermal contact might be a major route for DNA adduct
formation in WBC (107). Furthermore, several studies showed that the consumption
of PAH-containing foods significantly enhanced DNA adduct levels in peripheral
blood lymphocytes (108-110). The possibility for multiple routes of exposure may
also complicate the relationship between adduct levels in target tissues and
surrogate tissues. For example, Phillips ?f a/. (I l l) and Van Schooten ef a/. (112) did
not find a clear relationship between DNA adduct levels in WBC and lung from lung
cancer patients. However, more recent studies did find relationships between DNA
adducts in potential target organs (lung and skin) and isolated peripheral blood
lymphocytes (20,113).
WBC can be subdivided in monocytes (5-10% of total WBC), lymphocytes (20-
40%) and granulocytes (40-75%). The life-span of lymphocytes varies from a few
days to several years and these cells are therefore potentially useful in determining
long-term exposure. On the other hand, the half-life of monocytes and granulocytes
is much shorter (hours-days) and therefore DNA adducts in these cells may
represent recent exposure only. The variable life-span of WBC-subsets makes the
number of adducts persisting in total WBC after a given amount of time extremely
uncertain; any immune-disturbance, like a common cold, may profoundly affect
numbers and life-span of WBC subtypes. Furthermore, it has been observed that the
various WBC-subpopulations differ in metabolic and repair capacities (114, 115).
Thus, separation of the different WBC-subpopulations might be necessary to obtain a
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more reliable estimate of DNA adduct levels. Indeed, studies using isolated
lymphocytes, monocytes or mononucleated blood cells (i.e., monocytes plus
lymphocytes, MNC) showed clear differences between smoking and nonsmoking
individuals (113,116).
Other kinds of surrogate tissues have been used in the assessment of PAH
exposure. Izotti et al., (117) and De Flora et al. (118) suggested that cells obtained by
broncho-alveolar lav age (BAL) can be used as source of exposed DNA, specifically
for inhaled carcinogens. The predominant cell-type in BAL is alveolar m.icroph.iges
(AM), which can be considered as a nonperipheral WBC-subfraction, since these cells
are thought to originate from peripheral blood monocytes that have left the
circulation by passing through the walls of the alveolar capillaries.
Still, it is not clear which of these subtypes is/are the most reliable surrogate for
assessing exposure to PAH and may serve as a molecular index for aromatic-DNA
adduct formation in more remote tissues, like lung. Therefore, these cell-tvpes
should be compared with one another in the same study. This aspect, related to the
routes of exposure, is described in this thesis. Furthermore, we should k«vp m mind
that the applicability of surrogate tissues in field studies largely depends on their
accessibility, and therefore the WBC-subpopulations seem to have the advantage
above BAL-cells, but recent developments made it possible to use sputum induction'
to obtain alveolar macrophages via an easy and relatively noninvasive procedure
(119).
B. DW?M«/ P/Hirmaroltmrf/rs am/ TVmjHmj/ RWrtwmr
Knowledge on dose-response relationships and adduct persistence is
inexpendable for exposure monitoring studies, which use DNA adduct levels as end-
points (97). For example, researchers should know how, and how fast adduct levels
might change upon changes in exposure. Thus, understanding the kinetics of DNA
adducts in surrogate and target tissues will guide the interpretation of adduct data in
humans and is important in designing future studies for choosing the frequency and
timing of sampling (97). The dose-response relationship between PAH-exposure and
subsequent DNA adduct formation should be studied to evaluate the strenght of
DNA adduct measurements to distinguish between two or more different exposure
levels. In laboratory rodents exposed to low doses of PAH, adduct formation seemed
to follow first-order kinetics, i.e. the degree of binding in target organs is
proportional to the administered dose. However, human data on adduct formation
do not demonstrate a strong proportional relationship between exposure and adduct
levels (120-122). In lung tissue of smokers, a correlation was found between DNA
adduct levels and the amount of cigarettes smoked per day (59), but further studies
are necessary to determine the course of the dose-response relationship in WBC
(subpopulations), which is studied in this thesis.
PAH-DNA adduct measurements should have the ability to integrate exposure
to PAH over a relatively long (a few weeks up to a few months) period of time and
also detect previous exposures after a long period of nonexposure. In lung tissue,
DNA adduct levels were found to decrease after smoking cessation (72, 123-125).
Removal of aromatic-DNA adducts from lung tissue apparently occurred in two
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phases; an initial fast reduction of DNA adduct levels, which is followed by a period
in which adduct elimination is much slower. Studies in mice, suggest that adduct
loss in lung is largely due to cell turnover (126). The persistence of PAH-DNA
adducts in blood lymphocytes was studied by Mooney ef a/. (127). After 8 months of
smoking cessation, a significant reduction of PAH-DNA adduct levels was found.
Nonetheless, the characterization of elimination curves of aromatic DNA adducts in
WBC needs further attention and therefore this aspect of adduct formation is further
elucidated in this thesis.
C. L/n<frrs/flMdiM# inter-
Inter- and intra-individual variations should be characterized before PAH-
DNA adducts can be applied as exposure marker in large scale studies (97). It is
known that DNA adduct formation is subject to a greater variability than external
exposure assessment, because the body actively participates in the absorption,
distribution, and elimination of PAH. In other words: two individuals with a similar
level of external exposure, might have different aromatic-DNA adduct levels. As
already mentioned, variations may be due to differences in metabolic phenotypes,
possibly related to genetic polymorphisms in a variety of enzymes involved in the
activation or detoxification of PAH (Chapter 1.5) or repair of PAH-DNA adducts.
Furthermore, possible confounders must be taken into account including age, sex,
diet and race. Since the variation in adduct formation within or between individuals
can be high, the question remains whether aromatic-DNA adduct levels in WBC can
be applied to discriminate between individuals in various exposure or risk groups.
Such discrimination is practically possible only if the inter-individual variation is not
overshadowed by intra-individual variations or uncertainties in laboratory
measurements, since these two factors are putatively unrelated to the exposure level
or cancer risk (128). Thus, the observed range in DNA adducts in WBC is related to
three factors: interperson variability, intra-individual variation and measurement
uncertainty. Unfortunately, only few studies focused on intra-individual variations
in DNA adduct formation in WBC (128), and several sources of inter-individual
variation need more study.
D. Com/wnsoH w/f/j of/uv ;m?rta'rs o/P/lH-erposwre
Several kinds of biomarkers, or combinations of these, have been used to assess
exposure to PAH. Comparing one potential biomarker to another can provide useful
information on marker characteristics, but does not constitute validation (97). In
occupational settings (e.g. road-pavers, coke-oven workers and employees in the
aluminum industry) the urinary excretion of hydroxylated PAH is considered to be
the 'golden standard' for exposure assessment (reviewed in ref. 98, 129). However,
hydroxylated PAH-metabolites in urine can only be used to asses the internal dose
after recent exposure to PAH. PAH metabolites that have been detected in human
urine include 1-hydroxypyrene, 1-hydroxypyrene-O-glucuronide, 3-hydroxy-
benzo[a]pyrene and 7,8,9,10-tetrahydroxybenzo[a]pyrene. The most widely used
analysis of these is 1-hydroxypyrene-O-glucuronide, which is often measured as 1-
hydroxypyrene after deconjugation of the glucuronide by (J-glucuronidase (129).
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Studies regarding these urinary metabolites have been performed in occupational
settings, but also in smokers, individuals that consumed charbroiled meat and
eczema or psoriasis patients topically treated with coal-tar ointments (20, ^8).
Although the measurement of these metabolites is useful in av»i-ssmg recent
exposure, it does not represent the biologically effective dose. A limited number of
studies have examined the association between urinary i'AH-metabolite
concentrations and DNA adduct levels (20, 130-132). However, the results were not
consistent, which was probably due to differences in periods and timing of the
collection of urine and sampling of blood. Further research on the comparison of
both parameters is necessary. *?<*. ,• . . • ^,a ,-idj
1.7 Aim and outline of this thesis • - • .
In weighing the advantages and disadvantages of biological and environmental
monitoring to define exposure, it is clear that DNA adduct measurements have at
least three theoretical advantages over traditional exposure assessment. Firstly, they
can smooth the extreme variability in exposure which is typical for environmental
toxicants and therefore reduce the monitoring effort. Secondly, biological monitoring
of DNA adducts in WBC accounts for all routes, i.e. inhalation, ingestion and dermal
absorption. Finally, DNA adducts may account for interindividual differences in
uptake, elimination, distribution, metabolism and repair amongst exposed
individuals. On the other hand, sampling and analytical demands as well as the
imprecision of assays may lead to significant measurement errors, which will tend to
attenuate the underlying relationships. Furthermore, the interpretation of DNA
adduct data in the context of exposure-response relationships is sometimes limited.
Therefore, the aim of the present thesis is the evaluation of DNA adduct assessment
in various surrogate tissues as measure for exposure to polycyclic aromatic
compounds, using the validity criteria for biological markers of exposure as
mentioned in Chapter 1.6 (Table 1).
C/wpfer 2: A comparison was made between several sources of surrogate tissues in
smoking individuals, and in m w'fro exposed WBC-subpopulations of nonsmoking
volunteers. Owpfer 3: The relationship between the level of exposure and DNA
adduct levels was studied in MNC and BAL cells of smoking individuals and in
WBC of occupationally exposed aluminum workers. In the same study, the intra-
individual variation was assessed in smoking individuals over a period of 2 or 6
months. C/wpfer 4: The impact of different exposure routes on the relationship
between DNA adduct formation in WBC and target organs was studied in rats
acutely exposed to B[a]P. C/wpfcr 5: The persistence of smoking related aromatic-
DNA adducts in MNC was investigated in individuals who stopped smoking for a
period of 6 months. In the same study, the effect of confounding variables such as
age, sex and body composition on the dose-response relationship was investigated to
obtain further insights in sources of inter-individual variation. Oiapfer 6: Inter-
individual variation is thought to come, at least partly, from genetic polymorphisms
in genes that encode for enzymes involved in PAH-metabolism. The impact of
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GSTM7 and N/IT2 polymorphisms on aromatic-DNA adduct levels in MNC of
current smokers was studied. C/wpfCT" 7: DNA adduct formation was studied in WBC
subpopulations and skin of atopic eczema patients topically treated with coal-tar
ointments, to obtain more information regarding the relationship between DNA
adducts in surrogate tissues and a potential target tissue in humans. Additionally,
urinary excretion of PAH-metabolites was studied to assess the whole PAH-body
burden. C/iapter 5: In the same eczema patients, the relationship between DNA
damage and the accumulation of wild-type P53 in the basal layer of the epidermis
was studied. Otapffr 9. Exposure to B[a]P may generate reactive oxygen species. In
this chapter the formation and repair of oxidative DNA damage was studied after
acute oral exposure of rats to B[a]P. C/wpfer 10 a«d 11. Some technical aspects in
DNA adduct analysis are discussed in these chapters. The focus will be on the
quantitative assessment and identification of specifically BPDE-DNA adducts.
Ultimately, all studies are summarized and discussed in c/wp/fr 12.
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Table 1. Outline of this thesis in relation to the validity criteria tor biological mariemof oqposurv tv>
PAH as mentioned in Chapter 1.6. The first column represents the subject of research; th* SWUKI
column indicates the chapters) m which this subject is described; The third and fourth column
indicate which study-populations and corresponding samples were used, respectively.
Criteria Chapter Study-population(s) Samples
Comparison of
Surrogate Tissues
Dose-Response
Relationships
Impact of
Exposure Route
Adduct Persistence
Infra-individual
Variation
Interindividual
Variation
Surrogate re. Target
Early Biological
response
Other Biomarkers of
PAH exposure
Technical Aspects in
DNA adduct analysis
5
3
5,6
47
8
4,7,9
10,11
Smokers
In Pitro
Smokers
Aluminum Workers
WBC, MNC, BAL
WBC-Subaeto
WBC, MNC, BAL
Animal-model (rats) WBC. Lung, Skin
Stomach
Smoker*
Smokers
Smokers
Animal-model (rats)
MNC
MNC, BAL
MNC, BAL
WBC, Lung, Skin
Stomach
Atopic Eczema Patients WBCSubwts
Skin
Atopic Eczema Patients Skin
/n I'lfro MNC
Animal model (rats) Lung, Liver, Heart
Atopic Eczema Patients Urine
MNC
Liver, Lung, Heart
/« pif
Animal model (rats)
MNC, mononuclear cells;
lavages.
WBC, total white blood cells; BAL, cells obtained by broncho-alveolar
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Abstract
The ^-P-postlabeling assay for DNA adduct quantification gives the opportunity to
examine endogenous exposure to DNA reactive compounds. Most human
biomonitoring studies applied white blood cells (WBC) or cells obtained by
broncho-alveolar lavages (BAL) as source of DNA, but still it is not clear what cell
type represents the most reliable indicator for exposure to cigarette smoke
associated genotoxins. At first, we examined DNA adduct levels by means of
nuclease PI (NP1) enriched 32p-post!abeling in separated WBC subpopulations after
HI wfro incubations for eighteen hours with 10 uM benzo[a]pyrene (B|a]P). DNA
adduct levels were highest in monocytes (10.7±2.9 adducts/Hr nucleotides, n=8),
followed by lymphocytes (5.9±1.7, n=8), and granulocytes (0.5±l).2, n=8). Secondly,
aromatic-DNA adduct levels were determined in BAL cells and WBC-subsets from
(non)smoking volunteers. In smoking individuals, adduct levels were in the ranking
order: BAL cells (3.7±1.0, n=5)> monocytes (2.0±0.5, n=8) > lymphocytes (1.6±0.4,
n=8)> granulocytes (0.8±0.2, n=8) by NPl-enrichment and monocytes (9.0±3.2,
n=5) > lymphocytes (8.0±2.1, n=6)> granulocytes (2.1 ±0.3, n=7) by butanol enriched
32p-postlabeling. Aromatic-DNA adduct levels were significantly higher in WBC-
subsets of smokers as compared to nonsmokers, except for DNA adducts in
granulocytes using butanol enrichment. Thirdly, dose-response relationships were
investigated in mononuclear white blood cells (MNC i.e. monocytes plus
lymphocytes) and BAL-cells of a larger group of smoking individuals (n=78).
Adduct levels in MNC were related to daily exposure to cigarette-tar (r=0.31,
p<0.01). Adduct levels in BAL cells seemed to be correlated with pack-years, but
after correction for age this relationship was lost. Butanol extraction resulted in 5-6
fold higher DNA adduct levels in MNC, whereas butanol extraction of BAL-DNA of
the same individuals yielded only 2-fold higher adduct levels. The two enrichment
procedures of ^p.postlabeling were correlated in BAL cells (r=0.86, p<0.001, n=12).
We conclude that particularly MNC are good surrogates for the detection of
smoking-related DNA adducts.
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Introduction
The general population is exposed to polycyclic aromatic hydrocarbons (PAH)
via drinking water, food and polluted air (cigarette smoke). In tobacco smoke over 40
compounds including PAH, tobacco specific nitrosamines and aromatic amines were
found to elicit cancer in experimental animals. Recently Denissenko et al. (1)
confirmed that the environmental pollutant benzo[a]pyrene (B[a]P) plays an
important role in the etiology of lung cancer. PAHs exert their carcinogenic effects
via covalent interactions of reactive metabolites with DNA. The resulting DNA
adducts have been studied as a measure of the biologically effective dose and as an
indicator for cancer risk in PAH treated animals (2-4). ^P-postlabeling is frequently
used to study carcinogen-DNA adducts in humans. It is sensitive and can be
successfully applied to monitor exposure to complex mixtures. To enhance the
sensitivity of this assay, adduct enrichment procedures are performed by either
but.uiol extraction of adducted nucleotides, or by selective dephosphorylarion of
unadducted nucleotides by nuclease PI (NP1). Overall, the butanol enhancement
method seems to be more sensitive, but for assessing exposures to unknown
chemical mixtures both enhancement methods are recommended (5). Samples of
target tissues are difficult to collect and white blood cells (WBC) are often used as a
surrogate. The validity of measurements in surrogate sources of DNA however is a
matter of discussion. In the human lung, hydrophobic aromatic DNA adduct levels
appeared to be linearly related to the amount of cigarettes smoked per day (6).
Conflicting results have been reported on the occurrence of PAH-DNA adducts in
peripheral blood cells of smokers (7-10). No clear differences between PAH-DNA
adduct levels in WBC of smokers and non-smokers have been found and moreover
large interindividual variations were observed. WBC can be divided in three
subpopulations: short living granulocytes (40-75%) and monocytes (5-10%), and long
living lymphocytes (20-40%). They also differ in metabolizing (11) and repair
capacity (12). Consequently, their contribution to DNA adduct concentrations in
total WBC-DNA will be variable. Another surrogate source of exposed DNA is
derived from cells obtained by bronchoalveolar lavages (BAL) as suggested by Izotri
et al. (13) and De Flora et al. (14). Alveolar macrophages (AM), the predominant cell-
type in BAL, can be considered as a non-peripheral subtraction of the WBC
population, because these cells are thought to originate from peripheral blood
monocytes that have left the circulation. Although these various cell types have been
applied in several human studies to assess the biologically effective dose, they were
never compared in the same study. It was the aim of this study to examine the
differences in aromatic DNA adduct levels of alveolar macrophages and
subpopulations of white blood cells from smokers. In view of the heterogeneity of
the total WBC population, we examined the in I'ifro formation of DNA adducts in
three subpopulations of human peripheral white blood cells: monocytes,
lymphocytes and granulocytes after treatment with B[a]P for 18 hours. Furthermore,
we investigated the presence of DNA adducts in separated WBC-subsets and BAL-
cells of eight smoking patients suffering from pneumoconiosis or COPD. Adduct
levels were determined by means of NP1 or butanol enriched ^-P-postlabeling with
36
thin layer chromatography (TLC). Subsequently, aromatic-DNA adduct levels were
investigated in mononuclear white blood cells (MNC, i.e. monocytes plus
lymphocytes) and BAL cells of a second, larger study population of healthy smokers
(n=78) to establish dose-response relationships. Furthermore, WBC subsets of
nonsmoking volunteers were sampled to assess background levels of aromatic DNA
adducts.
Materials & Methods
C/irm/ca/s
All solutions used were sterile. B[a)P was purchased from Sigma (St. Louis, M Q
USA). RPM1 1640, streptomycin/penicillin, L-glutamin and fetal calf serum (PCS)
were all obtained from Gibco (Europe). Lymphoprep™ (1.077 g/ml) was obtained
from Nycomed (Oslo, Norway). All other chemicals were purchased from Merck
(Darmstadt, Germany). Water was purified by means of a milli-Q purification
system.
The overall characteristics of the study populations are summarized in Table I.
Study population Maastricht' (MAAS-I) involves blood from eight healthy male,
non-smoking volunteers (age: 27±2 yr., range 23-36) and WBC-subpopulations of
these individuals were in t'ifro exposed to B[a|P as described below. The second
'Maastricht' study population (MAAS-II) involves 5 male and 10 female putatively
unexposed, nonsmoking volunteers (age: 33±3, range 18-52). WBC-subpopulations
of these individuals were used as control. In study population 'Lanaken' (LAN)
blood and BAL was obtained from 8 smoking male patients (age: 63±7, range 31-81)
from the St. Barbara Hospital (Lanaken, Belgium). BAL was performed in these
individuals as a part of the diagnostic process in patients with putative
pneumoconiosis, COPD or lung cancer. Patients with an active inflammatory
process were excluded. Sampling of blood and BAL was performed from April to
July 1995. Study population Amsterdam' (AMS) consisted of 26 male and 52 female
healthy smoking volunteers (age: 43±9, range 25-64). Blood and BAL were sampled
over the period October 1994 to September in 1995. These studies were approved by
the medical ethical committees of the Netherlands Cancer Institute (AMS) and the
Maastricht University (Maas I and II, LAN) and informed consent was obtained in
all cases.
o/sufrpopu/afions o/hwrnan white Wood ce//s/or in ui/ro incubations
Fifty ml of peripheral blood of eight healthy nonsmoking volunteers was sampled
by venapuncture into EDTA-rubes. Polymorphonuclear cells (granulocytes) were
separated from MNC by gradient centrifugation on lymphoprep according to
Boyum (15). Both fractions were washed with PBS. The granulocyte fraction was
treated with lysis buffer (155 mM NH4CI, 10 mM KHCO3,10 mM EDTA, pH 7.4) to
lyse the erythrocytes and washed with PBS. In a next series of in u/fro experiments,
total white blood cells were collected after precipitation of erythrocytes in gelatin
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(1% w/v). The WBC were washed with PBS, 0.1% BSA and separated into
mononuclear cells and polymorphonuclear cells as described above.
Table I: Overall characteristics of the study-populations of Maastricht (MAAS-1 and MAAS-1I) and
Amsterdam (AMS) in the Netherlands and Lanaken (LAN) in Belgium.
MAAS-I
Healthy'
Nonamoken
n 8
Male/Kemale 8 /0
Age (mean*sc)27±2 33±3
(Range) 23-36
Sampling I'cnod 1994
Samples WBC-Subsets
BAL diflrmUMfitm count (%)
Alveolar Macrophage* NP.
rulyniorphtmuclrar C«U»
Lymphocytes
Epithelial Cells
MAAS-II
Healthy'
Nonsmokers
15
5/10
43*9
18-52
July-Dec.
1996
WBC-Subsets
MNC
NP.
AMS
Healthy'
Smokers
78
26/52
63±7
25-64
Oct. 1994-
Sept. 1995
MNC
BAL
78±10
0±0
<1
22±10
LAN
Smoking COPD
Patients
8
8/0
31-81
Apr.-June
1995
WBC-Subsets
BAL
80±10
12±7
S±2
4±3
NP., not performed
/H Di'rro /mi/moif o/w/ii/f Wood cW/s u»if/i bi'Mzopy
Cells were suspended at a concentration of 2x10* cells/ml in RPM1 1640,
supplemented with 10% FCS, 2 mM L-glutamin, 10 IU/ml penicillin and 10 ug/ml
streptomycin. B[a]P was dissolved in dimethylsulfoxide (DMSO) and added to the
cells to yield a final concentration of 10 uM. In all incubations the DMSO
concentration did not exceed 0.5%. Cells were incubated for 18 hours (37°C, 5% CO2:
95% O2). Viability was checked by means of trypan-blue exclusion. After the
incubations, granulocytes and lymphocytes, were collected, centrifuged and washed
twice with PBS. The remaining monocytes, which adhere to plastic surfaces, were
washed twice with PBS buffer and immediately lysed within the T.C.-flask for DNA
isolation.
(>/ WBC sutyrai't iiws o/fwfli'Mfs a/iJ /ira/f/iy
Mononuclear white blood cells and granulocytes were isolated from 10 ml
peripheral blood as described above. Monocytes and lymphocytes were
resuspended in RPM1 1640 (supplemented with 10% FCS, 2 mM L-glutamin, 10
1U/ml penicillin and 10 ug/ml streptomycin) at a concentration of ca. 1x10*" cells per
ml and separated by adherence of monocytes to plastic T.C.-flasks for 40 minutes at
37°C Cells were stored at -20°C until DNA-isolation.
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Bronchoscopy in the AMS study population was performed under local anesthesia
(lidocaine). The bronchoscope was placed into the right middle lobo bronchus and
180 ml of sterile saline (37°C) was instilled in nine aliquots of 20 ml each. The dwell
time was about 3 minutes. BronchoaK eolar lavages of the LAN study population
was performed by introducing 50 ml of 0.9% normal saline into the lung. Then,
immediately suction (60 mm Hg) was applied. This procedure was performed four
times. BAL fluids were directly collected in plastic tubes and placed on ice. C ells
were counted and after centrifugation (4°C, 1500g, 10 minutes), the cell pellet was
stored at -70°C until DNA isolation.
DN/4 /so/a/ion
WBC-subpopulations were lysed with 2.5 ml SDS/NEP (75 mM NaCI, 25 mM
EDTA, 50 ug/ml Proteinase K, 1% SDS) and incubated for 4 hours at 37'C. DNA
was extracted with phenol: chloroform: isoamylalcohol (25:24:1, v /v /v ) and
chloroform: isoamylalcohol (24:1, v/v) respectively. The DNA was precipitated with
two volumes of cold ethanol after addition of 1 /30 volume 3M sodiumacetato, pi 1
5.3 and washed with 70% ethanol. Subsequently, DNA was dissolved in 2 mM Iris,
pH 7,4. Concentration and purity were determined spectrophotometrically by
absorbance at 230, 260 and 280 nm. The mean spectrophotometrical ratios of
A26O/A28O and A230/A260 were respectively 1.67 (range: 1.55-1.83) and 0.45 (0.42-
0.50). The final volume was adjusted to achieve a DNA-concentration of 2 mg/ml.
The -*2p-postlabeling assay was performed as described by Reddy and Randerath (16)
with some modifications. All samples were analyzed blindly. DNA (10 jig) was
digested using micrococcal endonuclease (0.4 Units) and spleen phosphodiesterase
(2.8 ug) for 3 hours at 37°C. Subsequently, half of the digest was treated with
nuclease PI (6.3 ug) for 40 minutes at 37°C. Butanol enrichment was performed
according to Gallagher et al. (17). The modified nucleotides were labeled with ly-^P]-
ATP (50 uCi/ sample) by incubation with T4-polynucleotide kinase (5.0 Units) for 30
minutes at 37°C. [y^Pl-ATP was synthesized in the laboratory using carrier free 32p
(Dupont, Brussels, specific activity: 8500-9120 Ci/mmol). NP1-efficiency and ATP-
excess were checked with an aliquot of the NP1 treated fraction by one-dimensional
chromatography on poly(ethylene imine)(PEl)-cellulose sheets from Merck,
Germany (solvent: 0.12 M NaF^PCVj pH 6.8). Radiolabeled adduct nucleotide
biphosphates were separated by chromatography on PEI-cellulose sheets from
Machery Nagel (Germany). The following solvent systems were used: Dl, 1 M
NaFbPOt pH 6.5; D2, 8.5 M urea, 5.3 M lithium formate pH 3.5; D3, 1.2 M lithium
chloride, 0.5 M Tris, 8.5 M urea pH 8.0; D4, 1.7 M NaH2PC>4 pH 6.0. In each
experiment, 3 standards of ['H]BPDE modified DNA with known modification
levels (1 per 10 ,^ 10 ,^ 10' nucleotides) were run parallelly for quantification purposes.
Quantification was performed by using phosphor-imaging technology (Molecular
Dynamics™, Sunnyvale, CA, USA) with a detection limit of <1 adduct per 10*
nucleotides for individual spots. The detection limit of a diagonal radioactive zone
(DRZ) was around 5 adducts per 10' nucleotides. The remaining half of the digest
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was used to determine the final amount of DNA in the assay; the normal nucleotides
were diluted and labeled with [y-32p]-ATP (15 p Q / sample) by incubation with T4-
polynucleotide kinase (2.5 Units) and a 10-fold molar excess of unlabeled ATP for 30
minutes at 37°C. A dAp standard (27.5 pmole/ul) was labeled in each experiment for
quantification purposes. Nucleotides were separated by one-dimensional
chromatography on PKI-cellulose sheets from Merck (solvent: 0.12 M NaH2PO4 pH
6.8); samples with apparent protein or RNA contamination were discarded.
Staff's/res
Results are presented as mean ± standard error of the mean. Nonparametric-tests
were applied for differences between blood cell subsets (Wilcoxon, paired samples),
and for comparison of smokers versus nonsmokers (Mann-Whitney, unpaired
samples). Linear regression was used to assess the relations between cell-types,
enrichment procedures and to assess dose-responses. P<0.05 was considered
significant.
Results
/n PI'/TO frfafmcnf o/to/ii'ff Wood cW/s iwf/i BMP
After 18 hours of HI t»/7ro incubation with B[a)P, the predominant adduct
detected in DNA of hum.in WBC-subpopulations comigrated with the major adduct
of the PH] BPDE-DNA standard, putatively BPDE covalently linked with
deoxyguanosine (BPDE-dG), The BPDE-DNA adduct standard is shown in the
adduct profiles of Figure 1 (Panel E). Highest DNA adduct levels were found in
monocytes, 10.7±2.9 BPDE-DNA/10* nucleotides (range 3.0-25.3), followed by
lymphocytes, 5.9±1.7 BPDE-DNA/10" nucleotides (range 0.6-12.8), whereas
granulocyte DNA contained substantially lower levels, 0.5±0.2 BPDE-DNA /10®
nucleotides (range 0.04-1.7), using the NP1 method for DNA adduct enrichment
(Figure 2). Adduct levels in monocytes and lymphocytes differed significantly from
adduct levels in granulocytes (respectively p=0.012 and p=0.008). Most individuals
(7/8) showed higher adduct levels upon in z>ifro incubation in monocytes as
compared with lymphocytes, although the means did not differ significantly. Large
interindividual variations were observed; 8, 20 and 42 fold differences in
respectively monocytes, lymphocytes and granulocytes (percentage of variance were
respectively 76%, 83% and 135%). To assess the total experimental variation of the in
I'/fro experiment, lymphocytes obtained from 5 healthy male volunteers, were
exposed to B[a]P in triplicate and analyzed for DNA adducts using the NP1
enriched ^-P-postlabeling assay; the mean coefficient of variation was 18.2 ± 2.9 %
(range: 2%- 40%, n=5) for parallel experiments.
After separation of the polymorphonuclear cells and mononuclear cells, the
granulocytes were treated with lysis buffer to remove the erythrocytes. To exclude
an effect of lysisbuffer on the PAH-DNA adduct forming capacity of granulocytes,
in a separate set of experiments (n=3) the erythrocytes were removed from the
diluted whole blood by gelatin precipitation. Using this less drastic method for
erythrocyte removal, the results were similar (data not shown).
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In smoking individuals (LAN-study population. Table 1) diagonal radioactive
zones (DRZ) were found, which are typical for exposure to cigarette smoke (Figure
1, Panel A and B). In monocytes and lymphocytes, but not in granulocytes of some
individuals (5/8) also distinct adduct spots were observed, of which some
comigrated (3/8) with the BPDE-DNA adduct standard (Figure 1, Panel C). Total
adduct levels were highest in respectively BAL-cells (3.7±1.0, n=5), peripheral blood
monocytes (2.0 ± 0.5, n=8), lymphocytes (1.6 ± 0.4, n=8) and granulocytes (0.8 ± 0.2,
n=8, p<0.05) using NPl enriched ^p.postlabeling (Figure 2). Similarly, butanol
extraction resulted in DRZ's and distinct adduct spots (Figure 1, panel F, G and H),
although individual adduct profiles were not always identical when compared with
the NPl-method. For example, adduct spots in lymphocytic DNA as shown in
Figure 1 panel H, were found in this subject after application of butanol extraction,
whereas after NPl enrichment a DRZ was observed. To ensure that the observed
adduct spots were no background spots, as occasionally seen with the butanol
procedure, samples were analyzed in two or three independent experiments.
Furthermore, these spots were absent in control samples of the same experiment.
Total adduct levels in WBC subsets were ca. 6 fold higher by the butanol procedure
as compared with NPl enrichment: monocytes (9.0±3.2; n=5), lymphocytes (8.0±2.1;
n=6) and granulocytes (3.0+0.9; n=7) (Figure 2) (the amount of BAL-DNA was too
small for analysis by NPl and butanol enrichment).
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Figure 2. DNA adduct levels in BAL cells (B), monocytes (M), lymphocytes (L) and granulocytes (G).
(A) After in vitro treatment with lOuM B|a|P for 18h. (B) Determined by NP1 enriched 32p.
pmtlabcling in smokers ( • ) and nonsmoki-rs ( • ). (C) Determined by butanol enriched -^P-
pontlabfling. # P<U.U5 and * I'<0 10, as compared to nonsmokers.t No BAL was performed in
noniimokc™.
In DNA of WBC subsets of most nonsmoking controls (12/15) neither DRZ's
nor adduct spots were found by NP1 enrichment. For statistical reasons, adduct
levels of these samples were arbitrarily set at one half of the detection limit for
DRZ's (0.25 adducts per 10" nt). In three nonsmokers, a faint DRZ was observed and
adduct levels were marginally increased above the detection limit. Mean aromatic
DNA adduct levels in monocytes, lymphocytes and granulocytes were respectively
0.35±0.07, 0.34±0.05 and 0.33±0.04, which were significantly lower as compared with
smoking individuals (monocytes: p<0.01, lymphocytes: p<0.001, granulocytes:
p=0.034) (Figure 2). When butanol enrichment was applied, adduct spots could be
detected in 8/15 nonsmokers (Figure 1), but quantitative and qualitative differences
between nonsmokers and smokers were present. In nonsmokers, mean adduct levels
were 1.7±0.3 in monocytes (n=4, p=0.021 as compared to smokers), 3.8±1.3 in
lymphocytes (n=9, p=0.09) and 2.5±0.8 in granulocytes (n=9, p=0.56) (Figure 2).
rW<ifKws/t>/>$ /« MNC and BAL/rom
In the larger group of healthy smoking volunteers (Table I, AMS-study
population) dose-response relationships between smoking and adduct levels in
MNC and BAL were investigated. Overall, adduct levels in MNC and BAL were
respectively 1.8±0.1 (n=78) adducts per 10** nucleotides and 6.3±0.4 (n=53) by NP1
enrichment. The butanol procedure resulted in respectively 8.2±0.8 (n=14) and
13.9±1.2 (n=20). The amounts of cigarettes consumed per day (cig/day), exposure to
cigarette-tar per day (mg tar/day; calculated on basis of cig/day and the tar content
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of the cigarettes) and pack-years (Daily cigarette consumption/20 multiplied with
the number of years the individual smoked) were used as indices of exposure.
Nonsmoking individuals were excluded from the analysis (Table II). A modest but
significant linear relationship was observed between aromatic-DN A .uiduct levels in
MNC determined by NP1 mediated ^P-postlabeling and tar exposure (excluding
nonsmokers: r=0.31, p=0.005. Figure 3), but not cigarette consumption (r=0.18,
p=0.100) or pack-years (r=0.14, p=0.239). In some of the heavy smokers (>30
cig/day) relatively low DNA adduct levels were found, that could possibly be
explained by the low tar content of the cigarette brand they consumed. Aromatic-
DNA adduct concentrations in BAL-cells were not found to be related to the
exposure level.
Table II: Linear regression analysis between DNA adducts in MNC or BAt.-i-elk .inct exposure indicts
in AMS study population 1. Cigarettes per Day 2. Cigarette-tdr per >!.n .not » I'.ukyean.
Nonsmokers were excluded from the analysts.
MNC
(NPt)
MNC
(Butanol)
BAL
(NP1)
BAL
(Butanol)
Cigarettes
r
0.18
0.04
0.20
0.36
/Day
P
0.100
0.902
0.150
0.122
Cigarette-tar/ Day
' P
0.31
0.06
0.01
0.33
0.005*
0.842
0.989
0.160
Pack-Years
r
0.14
0.29
0.12
0.56
P
0.239
0.322
0.383
o.or
n
78
14
53
20
After application of butanol extraction, a significant relationship was observed
between DNA adduct levels in BAL cells and pack-years (r=0.561, p=0.01). However,
pack-years were also correlated with age and additional statistical analysis by
multiple regression showed that the levels of aromatic-DNA adducts in BAI.-cells
were age-dependent. Consequently, after correction for age the relationship between
pack-years and DNA adducts in BAL disappeared. DNA adduct levels in BAL cells
and MNC were not significantly interrelated (r=0.19, p=0.33). Although DNA adduct
levels in BAL cells after butanol enrichment were about 2-fold higher as compared
with NP1 enriched adduct levels, both enrichment procedures were highly
correlated (r=0.86, p<0.001, n=12). On the contrary, in MNC of smoking individuals
no such relationship could be observed (r=0.01, p=0.97, n=12). When sufficient
amount of DNA was available then DNA samples were analyzed in two or three
independent experiments to assess interassay variation ± SE which was for
lymphocytic DNA 19.1 ± 2.4% (53/78) and for BAL-DNA 10.9 ± 2.5% (18/53).
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Discussion
In this study, we examined DNA adduct levels in separated WBC
(lymphocytes, monocytes or granulocytes) after exposure to B[aJP m wfro or
cigarette smoke m uiw. DNA adduct levels were higher in human monocytes and
lymphocytes compared with granulocytes after in y/7ro incubation with B[a]P and in
smoking individuals the ranking order was BAL-cells> monocytes > lymphocytes>
granulocytes. DNA adduct levels in the WBC were significantly higher in smokers
as compared with nonsmokers by NPl as well as butanol enriched ^p.postlabeling,
except for aromatic-DNA adducts in granulocytes assessed by butanol enrichment.
A substantial amount of data on the presence of PAH-DNA adducts in WBC
has been collected during the last decade (7, 9, 18-21). The relationship between the
level of external exposure and the biologically effective dose is uncertain,
presumably because DNA adducts were measured in total WBC (18-21). Depending
on a person's health, WBC subpopulations differ in life-time and relative quantities.
Consequently, the contribution of WBC subpopulations to the amount of DNA
adducts in total WBC is different and variable. Monocytes and granulocytes are
short living and DNA adducts in these cells are therefore expected to give
information about recent PAH exposure. On the other hand, lymphocytes may live
for years and may reflect exposures that occurred both recently and in the past.
Several human studies found that smoking related DNA adduct levels, PAH-DNA
adducts as well as 7-methylguanine levels, were lower in granulocytes when
compared to lymphocytes (7, 22). Some of the studies that compared WBC DNA
from smokers and non-smokers by -^P-postlabeling have shown conflicting results
on the formation of DNA adducts (7,9-10, 23-24). Other studies suggest that adducts
in WBC DNA may result from PAH sources other than tobacco smoking, for
instance oral or dermal exposure (25-30). Rothman et al. (26, 27) and van Maanen et
al. (31) found a rapid appearance and removal of adducts in human WBC after
consumption of charcoal broiled beef. This indicates that short living monocytes or
granulocytes rather than long living lymphocytes are involved in DNA adduct
formation in WBC. In this respect, more detailed and controlled studies are required
on PAH-DNA adduct formation in the various WBC subpopulations.
After HI wrro incubation of separated WBC-fractions with B[a]P, we found that
the level of B[a]P-DNA adducts in monocytes is 22-fold higher compared to
granulocytes and about 2-fold higher than in lymphocytes. Furthermore, large
interindividual variation in m i'/fro adduct formation has been found; variation was
lower in monocytes and lymphocytes compared with granulocytes, indicating that
separation of cell types might decrease interindividual variability. Similarly, Gupta
et al. (32) observed 18-fold interindividual variations in isolated lymphocytes after
exposure to 30 pM B[a]P. This variation could be due to differences in metabolic
activation and/or DNA-repair (33, 34). It is shown that interindividual differences in
in t'lfro formation of B[a]P-DNA adducts are genetically controlled (35) and that an
increased carcinogen-DNA adduct formation may indicate a constitutionally
enhanced lung cancer risk (36-38).
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Figure 3. Linear regression between aromatic DNA adducts in MNC of smoking volunteers (AMS-
study population) detennined by NPl enriched ^P-postlabeling (Adducts per 10* nt) .ind daily
exposure to cigarette-tar (mg/day) (excluding nonsmokers: r=0.31, P-0.005, ii"7H, Including
nonsmokers: r=0.50, P=0.0001, n=93). The dashed line indicates the limit of detection (dl)
In MNC a significant linear relationship was observed between exposure to
cigarette tar and the levels of aromatic DNA adducts. This is in line with previous
observations of a relationship between DNA adducts in lung tissue and the amount
of cigarettes smoked per day (6, 24, 39). Adduct levels in BAL-cells, predominantly
alveolar macrophages, were higher than DNA adduct levels in WBC-
subpopulations. Thus, BAL-cells may represent a more sensitive surrogate tissue,
because at low levels of inhalatory exposure, aromatic DNA adducts in BAL cells
may still be detectable and at the same time DNA adduct levels in peripheral WBC
are below the detection limit of the techniques currently in use. On the contrary, no
significant correlations were found between DNA adduct levels in BAL-cells and
exposure to cigarette smoke, but as recently demonstrated by Van Schooten et al.
(40) the absence of a quantitative relationship could be due to saturation of adduct
formation at high exposure levels. BAL cells are directly and highly exposed to
cigarette smoke and in the present study BAL cells of heavy smokers were used (>20
cig/day), therefore saturation may have occurred. Aromatic-DNA adduct levels in
BAL were positively correlated with age. In lung tissue, Tang et al. (41) recently
found an inverse relationship between adduct levels and age. In other studies
concerning lung tissue, no influence of age was reported (6, 24, 39). Therefore, until
now a possible relationship between DNA adduct levels in BAL cells and lung tissue
remains unclear and should be further investigated.
It has been reported that '"P-postlabeling with NPl enrichment detects
predominantly PAH, whereas butanol enrichment detects in addition to PAH also
aromatic amines and nitroaromatics (5, 17). In all cell types that were examined in
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WBC sutywpu/a/ums and B/1L cd/s
the present study, adduct levels were higher by butanol as compared with NP1
enrichment, which was also found by Binkova et al. (18) in environmentally exposed
individuals. This suggests that the formation of DNA adducts by aromatic amines or
tobacco specific nitroaromatics is substantial, because differences between these two
methods were 6-fold in MNC and 2-fold in BAL-cells. However, other studies report
the opposite for white blood cells (42). In the present study, aromatic-DNA adducts
were detected in WBC of nonsmokers by butanol enrichment, but not by the NP1-
method. Apparently, for reasons unknown, the NPl-method seems to be more
specific for tobacco smoke exposure. In BAL-cells, but not in MNC, a significant
correlation was observed between NP1 and butanol enrichment. This can be
explained by the fact that DNA adducts in BAL-cells mainly represent exposure by
inhalation, although in BAL cells no clear dose-response with smoking was
observed. On the other hand, DNA adduct levels in WBC may originate from
different sources such as ingestion of food-borne carcinogens. These differences in
exposure source could also explain the absence of a relationship between smoking
behavior and DNA adduct levels in MNC when butanol enrichment was applied.
Our results show that mononuclear cell fractions should be used for
monitoring exposure to PAH. Application of BAL-cells might represent a more
sensitive and specific surrogate for inhaled PAH, but further studies are necessary.
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Abstract
DNA adducts may serve as a molecular dosimeter of exposure to cigarette smoke
associated carcinogens such as polycyclic aromatic hydrocarbons (PAH). Target
tissues for cigarette smoke induced carcinogenesis are rarely accessible, therefore
peripheral blood cells or cells obtained by broncho-alveolar lavage (BAL) may be
used as surrogate sources of exposed DNA. However, the relation between cigarette
smoke exposure and aromatic-DNA adducts in White blood cells and BAL-cells is
still unclear. In this study, we examined DNA adduct formation in lymphocytes and
BAL-cells in several populations of smoking individuals by means of ^2p.
postlabeling. Significant correlations between the amount of cigarettes smoked per
day and the level of aromatic DNA adducts were found in lymphocytes. In BAL-
cells, DNA adduct levels were associated with age (P=0.05) and gender (P=0.10)
after adjustment for smoking behavior. Adduct formation leveled off at higher
exposure levels, suggesting less efficient adduct formation; decreases in the
formation of adducts per unit of exposure were found in lymphocytes (rs=-0.80,
P<0.001) and BAL-cells (rs=-0.72, P<0.001). To assess intra-individual variation in
adduct levels at constant smoking behavior, sampling was repeated after a period of
two and six months. In lymphocytes, repeated measurements with an interval of 2
months were highly correlated (r=0.84; P=0.009; n=8), whereas repeated
measurements with an interval of 6 months showed no correlation (r=0.30; P=0.27;
n=16). Repeated measurements in BAL-cells showed a significant correlation after 6
months (r=0.68; P=0.03; n=10). Furthermore, in a group of occupationally exposed
aluminum workers, adduct levels in total white blood cells were correlated with the
average concentrations of PAH in the ambient air of workers who smoked
cigarettes, whereas in nonsmokers no such a relationship was found. We conclude
that cigarette smoking may directly or indirectly influence DNA adduct levels and
saturation of DNA adduct formation may occur, leading to nonlinear dose-response
relationships.
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Introduction , ;• a
Molecular epidemiologists need sensitive tools to assess environmental or
occupational exposure to carcinogens such as polycyclic aromatic hydrocarbons
(PAH). Measurements of the external or internal dose of PAH are usually not
satisfactory, since these parameters do not represent ultimate carcinogenic
metabolites at critical sites. Therefore, carcinogen-DNA adducts are used as
indicators for the biologically effective dose (I). Several techniques haw Invn
developed to study PAH-DNA adducts, of which the ^P-postlabeling assay is most
commonly applied. This technique is sufficiently sensitive to detect low levels of
adducts in small quantities of DNA, and is applicable to unknown adducts that may
be formed upon exposure to complex chemical mixtures such as cigarette smoke. In
most organs which are susceptible towards cigarette smoke induced diseases (e.g.
lung, cervix, larynx and heart), relationships were found between aromatic ON A
adduct levels and daily cigarette smoking. In organs which are not considered to be
associated with cigarette smoke induced diseases (e.g. breast and liver) no such
relationships were observed (2). However, susceptible tissues can rarely be obtained
and more accessible sources of exposed DNA have been analyzed in most human
studies. For instance, DNA of peripheral white blood cells (WBC) was analyzed as a
surrogate in smoking individuals (3-5). in these studies, large interindividuai
variation in aromatic-DNA adduct levels was observed and no clear differences
between smokers and non-smokers were found. Studies with isolated
subpopulations of WBC seemed more promising, but were still not conclusive (6-9).
To overcome some of the problems encountered by the use of WBC, other sources of
non-target DNA have been studied. Izotti et al. (10) and De Flora et al. (11)
concluded that the detection of carcinogen-DNA adducts in pulmonary alveolar
macrophages (PAM), obtained by broncho-alveolar lavages (BAL), might represent a
specific biomonitoring tool for inhaled PAH. Also in these studies considerable
variations in DNA adduct levels were reported. In order to further validate DNA
adducts as a measure of exposure, it is necessary to have sufficient information on
dose-response relationships and inter- and intra-individual variations. Additionally,
we and other investigators found that cigarette smoking has a synergistic effect on
DNA adduct formation in combination with occupational exposure to PAH (12,13).
In the present study we examined DNA adduct formation in two types of
surrogate cells, peripheral blood lymphocytes and BAL-cells of smoking individuals,
and determined dose-responses. To assess the intra-individual variation,
lymphocytes and BAL-cells were resampled at 2 and at 6 months. To study the
influence of smoking on dose-responses, the relationship between exposure and
subsequent aromatic-DNA adduct formation was examined in total WBC of
smoking and nonsmoking aluminum workers, which were exposed to high
concentrations of PAH in the ambient air.
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Materials & Methods -
Sfudy-popu/af/ons
This study was performed in two separate populations of cigarette smoking
individuals and a third group of occuparionally exposed aluminum workers. The
characteristics of the two groups of smokers are presented in Table I.
Table I: Description of study populations I and II.
NUBVMT
Male/female
Age
Cigarettes/ day
Tar (mg)/ day
Adducts in Lymphocytes
Resampling
Adduct* in BAI.-cells
Resampling
Population I*
13
4 / 9
41 ±7
29 ±16
266 ± 342 (n=7)
2.8 ±0.8 (n=13)
1.7±0.2(n=8)
7.7±1.4(n=9)
9.9 ± 2.8 (n=4)
Population 0*
41
1 4 / 2 7
43 ± 10
27 ± 13
-
1.5±0.1(n=41)
2.5±0.3(n=16)»
5.9 ± 0.5 (n=28)
5.6 ± 0.6 (n=12)
a: Repeated sampling .iiu-r 2 months
b: Repealed sampling after 6 months
#: l'<0.05, compared to first sampling
Adducts in lymphocytes and BAL-cells were analyzed as described below. In study
population I, 4 male (age: 40 ± 5 years) and 9 female (42 ± 7 years) volunteers were
included. Blood and BAL-cells were sampled in October 1994 and resampled in
December 1994. Study population II consisted of 14 male (40 ± 9 years) and 27 female
(45 ± 10 years) volunteers. Blood and BAL-cells were obtained in February-April
1995 and were resampled in August-September 1995. As controls 5 nonsmokers (age:
30 ± 4 years, 3 males and 2 females) were included, from these persons only
lymphocytes were obtained. The study was approved by the medical ethical
commission of the Netherlands Cancer Institute and informed consent was obtained
in all cases. Study population III was a subset of 105 occuparionally exposed workers
(41 ± 8 years), employed in a primary aluminum production plant consisting of three
highly exposed groups; 7 workers from the pot-relining department (0.9-1709 ug
PAH/nv\ smokers vs. nonsmokers: 5/2); 6 workers from the anode factory (1.1-854
ug PAH/nv*; 1/5) and 16 workers from the bake oven department (3.0-107 ug
PAH/m\- 6/10), a moderately exposed group of 14 workers from the electrolysis
department (0.3-4.6 ug PAH/m-\ 5/9), and a low exposure group of 14 workers from
the foundry department (0.1-3.8 ug PAH/m-\- 7/7). Details on the study design and
the results of DNA adduct analyses and ambient air monitoring have been reported
previously (12). In the present study, we performed additional statistical analyses to
further investigate the relation between PAH exposure and DNA adduct formation.
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CtapfrrJ
All participants answered a comprehensive questionnaire about their smoking
habits.
/so/afion
Peripheral blood was obtained by venapuncture into EDTA-tubes. Lymphocytes
were isolated by centrifugation on lymphoprep according to Boyum (14),
Lymphocytes were washed with PBS and frozen in -20°C until DN A isolation. ?
Bronc/jo-a/ivo/ar /ai>a£? and obtaining pw/rmxiary a/ivii/ar
Bronchoscopy was performed under local anesthesia (lidocaine). The bronchOtCOp*
was placed into the right middle lobe bronchus and 180 ml of sterile saline (37 "C)
was instilled in nine aliquots of 20 ml each. The dwell time was about 3 minutes.
BAL fluid was directly collected in plastic tubes and placed on ice. Cells were
counted and after centrifugation (4 °C, 4000 rpm, 10 minutes), the cell-pellet was
stored at -70 °C until DNA isolation.
DM4 iso/afion
Lymphocytes and BAL-cells were lysed with 2.5 ml SDS/NEP (75 mM NaCl, 25 mM
EDTA, 50 pg/ml or 1 mg/ml proteinase K respectively, 1% SDS) and incubated
overnight at 37 °C. DNA was extracted with phenolxhloroform: isoamylalcohol
(25:24:1, v /v /v) and chlorofomrisoamylalcohol (24:1). The DNA was precipitated
with two volumes of cold ethanol after addition of 1/30 volume 3 M sodium acetate,
pH 5.3, and washed with 70% ethanol. DNA was dissolved in 5 mM Tris and RNase
Tl (50 U/ml) and RNase A (100 pg/ml) were added, followed by 30 minutes of
incubation at 37 °C. The solutions were extracted with chloroform:isoamylalcohol
(24:1). DNA was precipitated from the aqueous phase with cold ethanol, washed
with 70% ethanol and dissolved in 2 mM Tris, pH 7.4. Concentration and purity were
determined specrrophotometrically by absorbance at 230, 260 and 280 nm, The final
volume was adjusted to achieve a DNA-concentration of 2 mg/ml.
The 32p.postlabeling assay was performed as described by Reddy and Randerath (15)
with some modifications. DNA (10 pg) was digested using micrococcal endonuclease
(0.4 Units) and spleen phosphodiesterase (2.8 pg) for 3 hours at 37 °C. Subsequently,
half of the digest was treated with nuclease PI (6.3 pg) for 40 minutes at 37 °C. The
modified nucleotides were labeled with [y-^PJ-ATP (50 pCi/ sample) by incubation
with T4-polynucleotide kinase (5.0 Units) for 30 minutes at 37 °C. [y-^Pj-ATP was
synthesized in the laboratory using carrier free ^ p (Dupont, Brussels). NP1-
efficiency and ATP-excess were checked with an aliquot of the NP1 treated fraction
by one dimensional chromatography on poly(ethyleneimine) (PEI)-cellulose sheets
from Merck, Germany (solvent: 0.12 M NaH2PC>4 pH 6.8). Radiolabeled adduct
nucleotide biphosphates were separated by chromatography on PEI-cellulose sheets
from Machery Nagel (Germany). The following solvent systems were used: Dl, 1 M
NaH2PC>4 pH 6.5; D2, 8.5 M urea, 5.3 M lithium formate pH 3.5; D3, 1.2 M lithium
chloride, 0.5 M Tris, 8.5 urea pH 8.0; D4,1.7 M NaH2PC>4 pH 6.0. In each experiment,
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Saturation at fc/g/i «rposurr /fivfe
3 standards of PHjBPDE modified DNA with known modification levels (1 per 1(F,
10", 10^ nucleotides) were run parallel for quantification purposes. Quantification
was performed by using phosphor-imaging technology (Molecular Dynamics-™.,
Sunnyvale, CA, USA) with a detection limit of 1 adduct per 10" nucleotides. The
remaining half of the digest was used to determine the final amount of DNA in the
assay; the normal nucleotides were labeled with [y-^P]-ATP (15 uCi/ sample) by
incubation with T4-polynucleotide kinase (2.5 Units) for 30 minutes at 37°C.
Nucleotides were separated by one dimensional chromatography on PEI-cellulose
sheets from Merck (solvent: 0.12 M NaH2PO4 pH 6.8); samples with apparent protein
or RNA contamination were discarded. A dAp standard (27.5 pmole/ ul) was
labeled in each experiment for quantification purposes. Each sample was analyzed in
three independent experiments; the mean ± SE inter-assay variation for lymphocytic
DNA was 19.1 ± 2.4% (n=53) and for BAL-DNA was 10.9 ± 2.5% (n=18).
Results are presented as mean ± standard error of the mean. Linear regression
models were applied to study the relationship between exposure and DNA adduct
levels. Multiple regression analysis was carried out with DNA adduct levels as
dependent and age, gender and smoking behavior as independent variables. Adduct
levels per daily cigarette consumption were calculated (i.e. 'efficiency' of adduct
formation) and analyzed by means of spearman-rank correlations. In aluminum
workers, spearman-rank correlations between exposure to individual PAH and DNA
adducts in WBC were determined. Values of P<0.05 are considered as significant.
Results
B/lL-ce// cowHfs and cW/ c/iarflcfmzflf/oH
In study population I and II, the total amount of cells obtained by BAL were
14.5x HV(± 13.6x 10 )^ ^ d 9.85x 10? (± 4.2x 10?), respectively. The BAL-cells were
predominantly PAM (78.2 ± 3.3%; range: 68.4 - 96.9%; n=10). Furthermore, broncho-
epithelial cells (21.8 ± 3.3%; range: 3.1 - 34.5%) and, occasionally, lymphocytes and
erythrocytes were present in the BAL.
DN/\ oi/c/ui'r /ci'c/s m /ymp/nvi/'cs fl>i<i B/lL-cW/s
In lymphocytic- and BAL-DNA of smoking subjects, a diagonal radioactive
zone (DRZ) was found by ^P-postlabeling, representing a large number of aromatic-
DNA adducts (Figure 1). No qualitative differences were seen between adduct
patterns in lymphocytes and BAL-cells. In Table I the overall quantitative results of
study population I and 11 are summarized.
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Figure 1. DNA adduct profiles determined by ^-I'-postlabeling The origin is UxaU-d at the lower loft
comer and was excised before analysis. Representative chromatograms ol lyniplux-ytic DNA of a
smoker (A), of a non-smoker (B), BAL cell DNA of a smoker (C) and of |*H|BPDE modified DNA (1
adduct per 10* nucleohdes) (D).
DN/4 fldducf Inds and exposure to cr^arffff-smoitf or cigarr f fr-far
In first instance no clear association between the amount of .I.u'lv cigarettes
consumed and DNA adduct levels in lymphocytes could be observed in both groups
of smokers (group I: first sampling r=0.25, P=0.41, n=13; group II: first sampling
r=0.02, P=0.92, n=41). However, significant relations were observed when the
nonsmoking controls were included in the analysis (Figure 2); correlation coefficients
were low due to large interindividual variation in DNA adduct levels (group I: first
sampling r=0.49, P=0.04, n=18 and second sampling r=0.87, P<0.001, n=13; group II:
first sampling r=0.38, P=0.01, n=46 and second sampling r=0.49, P=0.02, n=21). From
a number of persons of group I the daily cigarette-tar exposure (mg/day) could be
calculated and a better fit of the regression line was found (first sampling including
nonsmokers r=0.76, P=0.004, n=12 and second sampling including nonsmokers
r=0.92, P<0.001, n=9). At high exposures (>200 mg tar/day), adduct levels seemed to
plateau and were found lower than expected from linearity, suggesting that
saturation occurred. After splitting the study populations into light/moderate
smokers (<20 cig/day) and heavy smokers (>20 cig/day), correlations between
adduct levels in lymphocytes and the amount of cigarettes smoked per day were
improved in the group of non and light/moderate smokers (group I: first sampling
r=0.79, P=0.004, n=ll and second sampling r=0.98, P<0.001, n=9; group II: first
sampling r=0.90, P<0.001, n=18 and second sampling r=0.94, P<0.001, n=10). No
correlations were found between smoking habits and aromatic DNA adducts in
BAL-cells of mainly heavy smokers (>20 cig/day) (r=0.06; P=0.76). We observed a
saturation of DNA adduct formation in both lymphocytes and BAL-cells suggesting
less efficient adduct formation at higher doses. Expressing the adduct level per unit
of exposure as a way of expressing the 'efficiency of adduct formation'; a decrease is
observed when the dose is increased. In study population II, the adduct levels per
cigarette decreased significantly in both lymphocytes (Spearman rank rs=-0.80,
P<0.001) as well as BAL-DNA (rs=-0.72, P<0.001) at higher doses (first sampling;
Figure 3); in second sampling the same phenomenon was seen (rs=-0.64, P=0.006
respectively rs=-0.89, P=0.001). Furthermore, similar results were found for
lymphocytes (rs=-0.61, P=0.01) and BAL-cells (rs=-0.72, P=0.01) of study population I.
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Multiple regression analysis showed that adducts in BAL-DNA were associated with
age (P=0.05) and gender (P=0.10) after adjustment for daily cigarette smoking; a
higher age was associated with increased DNA adduct levels (simple regression:
r=0.39, P=0.04, n=28) and women had higher adduct levels compared to males (6.7
vs. 4.9 adducts per 10** nt., P=0.06). No such associations could be found for
lymphocytic DNA, only that persons having first degree relatives with lung cancer
revealed significantly higher adduct levels in lymphocytes (2.0 ± 0.3 adducts per 10&
nt., n=7) compared with persons having no relatives with lung cancer (1.4 ± 0.8
adducts per 10* nucl, n=31)(P=0.017), although the amount of smoking and age in
both groups were comparable.
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Figure 2. Relationship between the number of cigarettes smoked per day and aromatic-DNA adduct
levels in lymphocytes of study population I (1) and study population II(II). Linear regression: I, r=0.49,
p=0.04; and II, r=0.38, p=0.01, NS, nonsmokers.
To examine the intra-individual variation, from a number of persons a repeated
sample of lymphocytes and BAL-cells was taken. In study population I from 8
persons a second sample of lymphocytes after 2 months was obtained; DNA adduct
levels were comparable (2.0 ± 0.5 versus 1.7 ± 0.2; P=0.25) and measurements were
highly correlated (r=0.84; P=0.009) (Figure 4). Adduct levels in BAL-DNA had not
significantly altered after two months (6.2 ± 2.0 versus 9.9 ± 2.8; P=0.30; n=4). In
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study population II an interval of 6 months was studied and 16 paired lymphocytes
were not significantly interrelated (r=0.30; P=0.27). Furthermore, levels increased
significantly from 1.5 ± 0.2 to 2.5 ± 0.3 per 10" nt. (P=0.02), although self-reported
smoking behavior did not change. In BAL-DNA no difference in adduct levels was
found after 6 months resampling (6.0 ± 0.7 versus 5.9 ± 0.7; P=0.87; n=lO) and both
measurements correlated significantly (r=0.68; P=0.029) (Figure 4).
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Figure 3. Relationship between the number of cigarettes smoked per day and adduct forming
efficiency in lymphocytes and in BAL-cells (first sampling, study population II). Lymphocytes: rg=-
0.80, p<0.001; BAL<ells: rg= -0.72, p<0.01.
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No significant correlation was found between DNA adduct levels in peripheral
blood lymphocytes and DNA adducts in BAL-cells (r=0.19; P=0.32). Mean DNA
adduct levels in BAL cells were 3 to 8 times higher compared to levels in
lymphocytes. In population I during first sampling from 9 persons both lymphocytes
and BAL-cells were obtained; adduct levels were respectively 3.1 ±1.2 and 7.7 ±1.4
adducts per 10" nt. In second sampling 4 paired observations were obtained showing
levels of 1.5 ± 2.0 resp. 9.9 ± 2.8 adducts per 10" nt. In population II paired adduct
levels in lymphocytes and BAL-DNA were 1.5 ± 0.1 resp. 5.9 ± 0.5 adducts per 10** nt.
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(n=28). In second sampling 12 paired observations were obtained; 2.4 ± 0.3 resp. 5.6 ±
0.6 adducts per 10* nt. were found. , , , . . . .
2.0 2.5 3.0 3.5 4.0 4.5
1.0 2.0 3.0 4.0 5.0 6.0 7.0 8.0 9.0 10.0
DNA adducts per 10*nucleorides (sample 1)
Figure 4. Relation between DNA ndduct levels in lymphocytes and BAL-cells of repeated
measurements. Upper panel: resampling of lymphocytes after an interval of 2 months (r=0.84,
p=0.009). Lower panel: resampling of BAL-cells after an interval of 6 months (r=0.68, p=0.029).
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As shown in Table II, in highly exposed smoking aluminum workers (anode
paste factory, bake oven, pot-relining), significant correlations between the average
PAH-DNA adduct values and the average concentration of some individual PAH in
the work atmosphere were found. In non-smoking subjects, no such relationships
could be found. Interestingly, PAH in the ambient air that are known to give DNA
adducts through the formation of reactive diol-epoxides, fluoranthene,
benz[<i]iinthracene, chrysene, benzofb]- and benzo[k]fluoranthene, benzo[a]pyrene,
and also dibenz|a,h]anthracene and indeno(l,2,3-cd]pyrene, show strong
correlations with average PAH-DNA adduct levels in WBC of smokers, whereas
pyrene, a non-DNA binding PAH, does not show a relationship. Saturation of DNA
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adduct formation was found in WBC of both smoking and non-smoking workers,
since DNA adduct levels reached a plateau in the highly exposed job categories
(Figure 5A). Lower DNA adduct levels were found per ug/nrv* of PAH in the
ambient air of the highly exposed groups compared to low exposure groups; the
•efficiency of adduct formation' seem to decrease at higher doses of exposure (1-igure
5B).
(anode paste factory, bake oven and pot relining).
Aromatic
Hydrocarbon
Fluoranthene
Pyrene
Benzo[ a [anthracene
Chrvsene
Benzo[b)fluoranthene
+ Benzolk|fluoranthene
Benzo[a)pyrene
Dibenz[a,h]anthracene
Benzofghi jpery lene
Indeno[l,2,3-cd]pyrene
Total PAH
Smokers
(n=12)
rs
0.434
0.300
0.628
0.561
0.700
0.694
0.599a
0.524
0.646
0.573
KaoMMpmfei
P
0.080
0.172
0.014
0.029
0.006
0.006
0.143
0.040
0.012
0.026
at nigruyexpoMagr
Non-smokers
(n-15)
-0.077
0.068
0.023
-0.082
0.057
0.123
0.384b
0.229
0.181
0.021
nipt
P
0.393
0.405
0.454
0.385
0.420
0.331
0.174
0.215
0.278
0.471
n= number of persons, * n= 5, " n= 6
Discussion
In the present study, we obtained evidence for a saturation of DNA adduct
formation in peripheral blood lymphocytes and BAL-cells at high exposure levels in
smokers, and in WBC of occupationally exposed aluminum workers. Total adduct
levels in lymphocytes were related to the amount of cigarettes smoked per day,
moreover correlations were better in light/moderate smokers when compared to
heavy smokers. No dose-response relationships were found in BAL-DNA, possibly
because only BAL-cells of heavy smokers were studied. In this group interindividual
variation was high and saturation might have occurred. Saturation is reflected by a
significant decrease of the 'efficiency' of adduct formation at high levels of exposure
to cigarette smoke, analogous to environmentally and occupationally exposed
subjects as described by Lewtas et al. (16). DNA adduct levels in lymphocytes
resampled after 2 months correlated significantly with DNA adduct levels of the first
sampling. Although the level of exposure to cigarette smoke remained constant,
adduct levels in lymphocytes after 6 months were significantly higher and no longer
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related to the first sampling. On the other hand, in BAL-DNA a significant
relationship was found between the first sampling and that of 6 months later. Thus,
DNA adduct levels in lymphocytes and BAL-cells reflect exposure to cigarette smoke
associated carcinogens with relatively low inrra-individual variation. The observed
higher adduct levels in lymphocytes after six months might be related to seasonal
influences which has been described earlier (17).
In PAH exposed laboratory rodents, DNA adducts were readily detected in
organs as well as WBC by ^p.postlabeling (18,19). Recently, DNA adducts in organs
were linked to mutations in oncogenes and subsequent tumorigenesis (19, 20).
Furthermore, significant correlations were found between PAH-DNA adducts in
WBC' and target organs (21). Such a relationship was also found for other
carcinogens as methylating agents (22) and heterocyclic arylamines (23, 24). These
results seem to justify the application of WBC as a molecular dosimeter for DNA
adduct formation in internal organs and subsequent risk assessment.
In humans, smoking related aromatic-DNA adducts could be detected by '^P-
postlabeling in internal organs. Generally, the aromatic-DNA adduct concentrations
in organs susceptible towards tobacco induced cancers (e.g. lung, cervix, bladder and
pancreas) are related with daily cigarette smoking (2, 25). In addition, a relationship
between DNA adduct levels and smoking has been found in heart tissue, which may
also be considered as a target tissue for tobacco-smoke; in a study with operable
hi-.irt patients, significantly higher heart DNA adduct levels were found in persons
suffering from severe coronary heart disease than those with no or mild coronary
heart disease (26). A similar result was obtained in placental tissue showing DNA
adduct levels to be related to smoking and inversely associated with birth weights of
the infants (27). Conversely, in organs such as breast and liver which are not
associated with tobacco induced disease, no quantitative relations between DNA
adducts and smoking have been observed (2, 28). However, in breast tissue,
qualitative differences in adduct patterns of smokers and non smokers were seen
(28). The data suggest that tobacco-associated DNA damage in internal organs may
be indicative of smoking related diseases. The present study indicates a quantitative
relation between smoking and aromatic DNA adducts in lymphocytes and
accordingly some epidemiological evidence is available that tobacco smoking is
related to lymphoid cancers such as leukemia's (29), although the relation with
specific compounds is unclear.
In the present study, a good correlation between the number of cigarettes
smoked per day and aromatic-DNA adduct levels in peripheral blood lymphocytes
was found, but at high doses (>20 cig/day) saturation seemed to occur. Analogously,
in rats exposed to increasing concentrations of diesel exhaust, lung DNA adduct
levels determined by ^P-postlabeling did not increase (30). Reanalysis of DNA
adduct data obtained from lung tissue of lung-cancer patients (31) and heart tissue of
smoking patients undergoing open heart surgery (26), shows a decline in the
efficiency of DNA adduct formation at increasing levels of exposure to cigarette
smoke (data not shown). This indicates that saturation may eventually occur in
human tissues and dose-response curves will deviate from linearity, which we also
found for lymphocytes and BAL-cells in the present study.
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Figure 5. DNA adduct levels (A) and efficiency of DNA adduct formation (B) in (O) smoking and (•)
non-smoking aluminum workers exposed to PAH. 1, foundry; 2, electrolysis; 3, bake oven; 4, anode
factory; 5, pot-relining department.
Studies using the total fraction of WBC showed increased levels of aromatic-
DNA adducts in smokers, but often DNA adduct levels were not significantly
different from 'unexposed' controls (3, 5). The application of isolated lymphocytes
(20-40% of total WBC) is more promising, probably because in the most predominant
WBC-subtype (granulocytes; 40-75%) only low levels of DNA adducts have been
found (8, 17). Thus, separation of WBC prior to analysis might be helpful to
overcome the observed inter- and intra-individual variations. Indeed, in the present
study intra-individual variation appeared to be low in isolated lymphocytes of
smoking individuals and also in BAL-cells at a steady smoking behavior. Still, large
interindividual variation was observed. Several studies indicate that this variation
could be due to differences in DNA-repair (32, 33). Other studies suggest that this
variation is genetically controlled (34) and that an increased carcinogen-DNA adduct
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formation may be one factor of a constitutionally enhanced lung cancer risk (35, 36).
This phenomenon is also seen in the present study; higher adduct levels were found
in smokers having first degree relatives suffering from lung cancer compared with
those having no such relatives. We found in BAL-DNA higher adduct levels in
females compared with males, which is in accordance with another study in which a
similar result was found in lung DNA (37) and with epidemiological studies
showing that women are at greater risk of tobacco-induced lung cancer (38, 39).
Moreover, an increase of BAL-DNA adduct concentrations was found with
increasing age, which may be explained by a decrease of DNA repair activities (32).
In aluminum workers, DNA adduct levels in WBC were related to exposure,
but at the individual level no significant correlations were found (12). However,
when the exposure groups were divided into smokers and nonsmokers, correlations
were found between exposure to individual PAH and aromatic-DNA adducts in
smokers. Interestingly, the two PAH (B[a]P and benzo(b)fluoranthene) showing the
strongest correlation with adduct levels were also responsible for the formation of
DNA adducts in lung of mice treated with manufactured gas plant residues (40). The
combination of occupational exposure and cigarette smoking may act synergistically
and influence dose-response relationships. A synergistic effect of smoking on adduct
levels in WBC has also been observed by using an HPLC/fluorescence detection
method (13).
The relationship between DNA adducts in WBC and internal organs is still
unclear. Some studies on lung cancer patients suggested that adducts in WBC-DNA
did not reflect binding of aromatic compounds to lung DNA (5, 41). However, in the
study of Van Schooten et al. (41), in a group of patients that actually smoked at the
day of collecting lung tissue and blood, some correlation was observed between
these two parameters (r=0.5, P=0.19, n=8). Recent studies show that adducts in
leukocytes or mononucleated white blood cells are correlated with adducts in lung
tissue of lung cancer patients (42, 43). Furthermore, Szyfter et al. (44) recently
demonstrated a high correlation between the level of aromatic DNA adducts in
larynx cells and leukocytes of humans with primary larynx tumors. Therefore, taken
together, the available data from rodent and human studies suggest that DNA
adducts in lymphocytes might be suitable as surrogates for target tissue. We
conclude that DNA adduct formation in both target tissues as well as in lymphocytes
are correlated with daily cigarette consumption, and that at high doses saturation of
adduct formation may occur.
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Abstract
Understanding the kinetics of formation and removal of aromatic-DNA adducts in
target tissues and white blood cells (WBC) would enhance the applicability of WBC
as surrogate source of DNA in biomonitoring studies. In the present study, rats were
acutely exposed to benzo[a]pyrene (B[a]P, 10 mg/kg bw) via intratracheai (i.t.),
dermal and oral administration. DNA adducts were analyzed in relevant target
organs and WBC by nuclease PI enriched ^P-postlabeling at 1, 2, 4, 11 and 21 days
alter exposure. Additionally, the internal dose was assessed by measurement of
in in.u\ excretion of 3-hydroxy-B[a]P (3-OH-B|a]P). In WBC, two adduct spots were
observed independently from the exposure route. Total B[a]P-DNA adduct levels in
WBC were highest after i.t. and oral administration, whereas DNA adducts were
hardly detectable after dermal exposure. Highest adduct levels in WBC were
reached at 2 days after exposure. In lung tissue, DNA adduct levels reached
maximal values at 2 days and were highest after respectively it., oral and dermal
exposure. DNA adduct levels in WBC were significantly lower as compared with
lung. In target organs, highest DNA adduct levels were observed in skin after
topical application and lowest in stomach after oral administration of B[a]P.
Although differences in DNA adduct levels were observed between WBC and target
organs after exposure to B(a]P via different exposure routes, overall B[a]P-DNA
adduct levels in WBC were significantly related with those in lung. Furthermore,
DNA adduct levels in WBC were related with DNA adduct levels in skin after
dermal exposure and stomach after oral administration. Two fold higher levels of 3-
OH-B[a]P were excreted after i.t. administration of B[a]P as compared with dermal
or oral exposure. Urinary 3-OH-B(a]P concentrations were correlated with DNA
adduct levels at the site of B[a]P application. Overall, it can be concluded that WBC
can be applied as surrogate source of DNA for the site of application of B[a]P. DNA
adduct levels in WBC reflect binding to lung DNA, independent of the exposure
route.
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Introduction
Polycyclic aromatic hydrocarbons (PAH) are widely distributed in the
environment in complex mixtures, such as automobile exhaust, cigarette smoke,
foods, water and urban air. Human body burden occurs via inhalation, ingestion and
dermal absorption, and probably contributes to the overall human cancer risk (1).
PAH are thought to elicit cancer via covalent interactions with DNA, so-called PAH-
DNA adducts (1), which offer a potential dosimeter for the body load of exposed
individuals by these environmental genotoxins. PAH exert their carcinogenic
activities at the site of application (1). Also, systemic effects have btvn observed and
the respiratory tract seems to be the most predominant site of B|a|P induced cancers.
Unfortunately in humans, most target tissues for genotoxic agents are not readily
accessible for monitoring DNA adduct formation and therefore peripheral white
blood cells (WBC) most often serve as surrogate source of exposed DNA (2-6). Still,
the reliability of WBC as surrogate for target organs needs further research. In
particular it is not clear how DNA adduct formation in WBC" and relevant target
organs may differ dependently on the exposure routes, lnhalatory exposure to PAH
in smokers or in occupationally exposed workers does not seem to be the only
predominant route (7, 8). Other exposure routes, especially via food, appear
important for adduct formation in WBC as well. For instance, several studies showed
that the consumption of PAH-containing foods enhanced DNA adduct levels in
lymphocytes and the excretion of 1-hydroxypyrene in urine (7-9). Additionally,
cutaneous application of coal-tar based ointments may result in the formation of
measurable amounts of PAH-DNA adducts in total WBC (10) or separated WBC
subpopulations (6). Therefore, understanding of the influences of exposure routes on
DNA adduct formation in WBC is relevant for exposure monitoring studies. Ideally,
nontarget cells should have similar properties as compared with tissues that are
targets for tumor induction, with regard to carcinogen metabolism, DNA binding
and repair and cell turnover. Detailed knowledge of these parameters for both target
tissue and WBC might improve the utility of the latter as surrogate for target tissues.
In the present study, we investigated the relationship between DNA adduct
levels in WBC and internal organs in rats acutely exposed to B[a]P weight via three
different exposure routes; gavage, dermal administration or intratracheal instillation.
Since in animal experiments, carcinogenic PAH become effective predominantly at
the site of application (11), B[a]P-DNA adduct levels were studied in lung, stomach
and skin by the ^p.postlabeling assay. WBC were analyzed by ^p.postlabeling as
surrogate-tissue. Additionally, excretion of the major B[a]P metabolite 3-hydroxy-
B[a]P (3-OH-B[a]P) was assessed in 24 hours urine to assess the whole body dose of
B[a]P.
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Materials & Methods !
Cfwm/ca/s
All solutions used were sterile. B[a]P was purchased from Sigma (St. Louis, MO,
USA). Tricaprylin was obtained from 1CN Biochemicals Inc. (Ohio, USA). All other
chemicals were purchased from Merck (Darmstadt, Germany). Water was purified
by means of a milli-Q purification system.
o/fl/fl/P-so/ufions/or on/ma/
B[a)P was initially dissolved in acetone at a concentration of 10 mg/ml, which was
used for the dermal application of B[a]P as described in the next section. Six ml of
this solution was added to an equal volume of trycaprylin and subsequently the
acetone was evaporated under nitrogen, resulting in a concentration of 10 mg
B[a]P/ml tricaprylin. This solution was used for oral administration of B[a]P as
described in the next section. Identically, 6 ml of B[a]P in acetone was added to 3 ml
tricaprylin. Hvaporation of the acetone resulted in 20 mg B(a]P/ml, which was used
for the intratracheal administration of B(a|P. To prevent heterogeneous distributions
of B|a|P within these solutions, all were vortexed for 24 hours before use.
Fourty five (n=45) male Lewis rats weighing 250-320 g were acutely exposed to B[a]P
(10 mg/kg body weight) via oral (n=15), intratracheal (n=15) or dermal
administration (n=15). Rats were randomly allocated over the three exposure
groups. Nine rats were used as controls (3 rats per exposure route; received
vehiculum only). Oral exposure: B[a]P was administered through a gavage needle
(UK) ul/lOOg body weight (bw.)). Immediately thereafter, these rats were
anesthetized by a subcutaneous injection of ketamin/xylazin (respectively 0.1 and
0.05 ml per 100 gram bw.). Anesthetization was applied to prevent differences in
experimental conditions as compared with intratracheal instillation and dermal
exposure. Intratracheal exposure: rats were anesthetized by a subcutaneous injection
of ketamin/xylazin, and subsequently a plastic tube (0: 2 mm) was placed into the
trachea. B[a]P solutions were injected into the lung through this plastic tube (50 p i /
100 g bw.) and artificial respiration was applied briefly. Dermal exposure: rats were
anesthetized by a subcutaneous injection of ketamin/xylazin. Approximately 4 cm*
(2x2 cm) of the skin was shaved (back-side, between shoulders) and B[a]P-solutions
were pipetted on this area (100 ul/100 g bw.).
The animals were housed individually in metabolic cages for collection of urine, in a
room maintained at 25°C, 50% humidity and a 12 hr. light/dark cycle. Standard
rodent lab chow (diet no. RSM-A, Hope Farms, Woerden, The Netherlands) and
water were provided mi liWfum. Each morning, 24 hours-urine was collected
individually. The samples were weighed and stored at -20°C until analysis. To
examine the time-course of adduct formation, the rats were killed 1, 2, 4, 11 and 21
days after treatment (three rats per time-point). Lung, stomach and skin were
removed, washed with PBS and quickly frozen at -20°C until DNA isolation. Blood
was collected by aortic puncture and WBC were isolated by lysis of erythrocytes
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with 3 volumes of lysis buffer (155 mM NH/Z1, 10 mM KHCO,, 10 mM EDTA, pH
7.4) at 4°C and subsequently collected by cenrrifugation at 4°C for 10 minutes (800g).
Separation of WBC subpopulations was not performed, because WBC of Lewis-rats
consist for more than 95% of lymphocytes.
DM4 tsofafion
Approximately 1 gram of tissue was washed with 0.25 M sucrose/ 0.1 M Tris-HCl
(pH 7.4), cut into small pieces and subsequently homogenized with a potter (1000
rpm) in 1% SDS/ 1 mM EDTA. The solutions were incubated overnight at 37°C with
0.5 mg Proteinase K. WBC were lysed with 2.5 ml SDS/NEP (75 mM NaCl, 25 mM
EDTA, 50 mg/ml Proteinase K, 1% SDS) and incubated for 4 hours at 37°C. DNA
was extracted with phenol: chloroform: isoamylalcohol (25:24:1, v /v /v) and
chloroform: isoamylalcohol (24:1, v/v) respectively. The DNA was precipitated with
two volumes of cold ethanol after addition of 1/30 volume 3M sndiumacetate, pH
5.3 and washed with 70% ethanol. Subsequently, DNA was dissolved in 5 mM Iris/
1 mM EDTA, pH 7.4. RNase Tl (50 U/ml) and RNase A (100 Mg/ml) were added,
followed by 30 min. of incubation at 37°C. The solutions were extracted with
chloroform: isoamylalcohol (24:1, v/v) and DNA was precipitated from the aqueous
phase with cold ethanol, washed with 70% ethanol and dissolved in 2 mM Tris, pH
7,4. Concentration and purity were determined spectrophotometrically by
absorbances at 230, 260 and 280 nm. In all cases, A260/A2H0 were -1.8 and A2.10/A2M)
were -0.43. The final volume was adjusted to achieve a DNA-concentration of 2
mg/ml.
The ^P-postlabeling assay was performed as described by Reddy and Randerath
(12) with some modifications. Briefly, DNA (ca. 10 ug) was digested using
micrococcal endonuclease (0.4 Units) and spleen phosphodiesterase (2.8 ug) for 3
hours at 37°C. Subsequently, half of the digest was treated with nuclease PI (6.3 ug)
for 40 minutes at 37°C. The modified nucleotides were labeled with [y-^P]-ATP (50
uCi/ sample) by incubation with T4-polynucleotide kinase (5.0 Units) for 30 minutes
at 37°C. NPl-efficiency and ATP-excess were checked with an aliquot of the NP1
treated fraction by one dimensional chromatography on poly(ethylenimine)(PEI)-
cellulose sheets (solvent: 0.12 M NaH^PC^ pH 6.8 on Merck-sheets, Germany).
Radiolabeled adduct nucleoride biphosphates were separated by chromatography
on PEI-cellulose sheets (Machery Nagel, Germany). The following solvent systems
were used: Dl, 1 M NaHjPO^ pH6.5; D2, 8.5 M urea, 5.3 M lithiumformate pH 3.5;
D3, 1.2 M lithiumchloride, 0.5 M Tris, 8.5 urea pH 8.0; D4, 1.7 M N a H / O ^ pH 6.0.
The remaining half of the digest was used to determine the final amount of DNA in
the assay; the normal nucleotides were labeled with [y-^PJ-ATP (15 uCi/ sample) by
incubation with T4-polynucleoride kinase (2.5 Units) for 30 minutes at 37°C.
Nucleotides were separated by one dimensional chromatography on PEI-cellulose
sheets (solvent: 0.12 M NaH2PC>4 pH 6.8 on Merck-sheets, Germany). A dAp
standard (27.5 pmole/ul) was labeled in each experiment for quantitation purposes.
In each experiment, 3 standards of PHJBPDE modified DNA with known
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modification levels (1 per 10?, 10*, 10* nucleotides) were run parallelly for
quantitation purposes. Quantitation was performed by using phosphor imaging
technology (Molecular Dynamics™, Sunnyvale) with which detection limits of 1
adduct per 1CP nucleotides can be obtained. Interassay variation was <25%.
3-OH-B/a/P in raf ur/w
Detection of 3-OH-B[a]P in 24-hours urine was performed as described by
Jongeneelen et al. (13). The method consisted of enzymatic hydrolysis with 8-
glucuronidase and arylsulphatase, solid phase extraction on a Sep-pak C-18
cartridge and elution with methanol. Reversed phase HPLC (Kratos solvent delivery
system; Column: Hypersil 5 ODS) and fluorescence detection (Perkin-Elmer LS-30)
were applied, using excitation and emission wavelengths of 253 nm and 432 nm.
Peak area was integrated for quantification. The detection limit was 200 ng 3-OH-
B[a]P per liter urine. Day-to-day variation and intra-assay variation were
respectively 14% and 6%.
Results are presented as mean ± standard deviation. Student's t-tests were applied to
assess statistical differences between DNA adduct levels in various tissues and linear
regression was applied to examine the quantitative relationship between DNA
addiii'ts in WBC' and tissues. P< 0.05 is considered significant.
Results
Qi/fl/i7<jf/'iv rcsu/fs o/"<jddi/cf rtna/i/s/s in BMP frfoffd rate
The first two days after treatment of rats with an acute dose of B[a]P, the eating
and drinking behavior was influenced as determined by reweighing the supplied
food and water. Relative weights of lung and stomach (organ weight/ total body
weight) was constant during the experiment.
In WBC-DNA of exposed rats, two DNA adduct spots were observed
independently from the exposure route, of which the predominant one comigrated
with the BPDE-DNA adduct standard. The second adduct spot migrated slower as
compared with the BPDE-DNA adduct standard in both chromatographic directions.
In lung, stomach and skin, two similar adduct spots were observed, but in B[a]P-
treated skin an additional third DNA adduct spot was found (Figure 1). Thus,
overall adduct formation in WBC seemed to be qualitatively in agreement with DNA
adducts found in organs.
rcsu/fs ofmMiicf aria/i/sis /» raf or^ 'dNS umi WBC
Total DNA adduct levels were calculated by adding the levels of individual
DNA adduct spots. In WBC, maximal adduct levels after respectively it. (4.3±0.5
adducts per 10* nucleotides), oral (3.6±1.8) or dermal (0.3±0.2) application of B|a]P
were found at ca. two days after exposure (Figure 2). The estimated half-life of DNA
adducts in WBC was 2 weeks, calculated on basis of a semi-logarithmic plot. In lung
tissue of exposed rats identical adduct kinetics were observed; at day 2 after
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exposure via i.t., oral and dermal administration of B[a]P, DNA adduct levels
reached 20.5±5.1 adducts per 10** nucleotides, 6.9±2.3 and 0.5*0.2, respectively.
Figure 1. Adduct profiles obtained by ^P-postlabeling. Origins are located at the lower left corner and
were excised before analysis. A; WBC DNA of a non-treated rat. B; WBC DNA of a rat exposed to
B[a]P by gavage (t=2 days after exposure). C; Lung DNA of a rat i.t. exposed to B[a]P (t=2 days). D;
Stomach DNA of a rat orally exposed to B[a]P (t=l day). E; Skin DNA of a rat dermally exposed to
B[a]P (t=2 days). F; BPDE-DNA adduct standard (modification level: 1 adduct per 10? nt.)
The removal of DNA adducts in lung-tissue over a period of 21 days appeared
to be inversely related with the maximal DNA adduct level. Highest DNA adduct
levels in lung were observed after i.t. exposure, but adduct levels decreased
relatively fast (at day 21, only 34% of the maximal adduct level was detected). Oral
administration of B[a]P resulted in maximal adduct levels in lung that were ca. 3 fold
lower as compared with i.t. exposure, but adduct persistence was higher (at day 21,
74% of the maximal adduct level was still detectable). Highest persistence of DNA
adducts in lung was observed after dermal application of B[a]P (no decrease of
adducts from day 2 to day 21), whereas maximal DNA adduct levels were only
0.5±0.2 adducts per 10* nucleotides (Figure 2).
Since carcinogenic PAH become effective predominantly at the site of
application, also DNA adduct formation in skin after dermal application and
stomach after oral administration of B[a]P was studied. High adduct levels were
found in skin-DNA at two days after exposure by dermal application of B[a]P
(70.3±14.0 adducts per 10* nucleotides). Total DNA adduct levels in stomach after
oral administration of B[a]P were surprisingly low. In stomach, maximal DNA
adduct levels were observed at day 1 after exposure (1.6±0.5 adducts per 10*
nucleotides), and thereafter adduct levels gradually decreased (Figure 3). Adduct
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persistence appeared to be identical for both tissues, with calculated half-lives of 16
days. .
1
Days after exposure
Figure 2. Kinetics of DNA adduct levels in lung tissue (Panel A) and WBC (panel B) after acute
exposure to B|a]P via i.t. (•), oral ( )) and dermal (LI) application of B[a]P (10 mg/ kg bw.).
5 10 15
Days after exposure
20
Figure 3. Kinetics of DNA adducts in rat lung after it . exposure (•) , in stomach after oral
administration (3 ) and in skin after dermal application (-1) of B[a]P (10 mg/ kg bw.).
DNA adduct levels in WBC after i.t., oral and dermal exposure were significantly
lower as compared with DNA adducts in lung (respectively ca. 5, 3 and 4 fold,
P<0.001). If DNA adducts in WBC were compared with adduct levels at the site of
application, significantly higher adduct levels were found in lung (P=0.0001) and
skin (P=0.0004) after respectively i.t. and dermal application. On the other hand,
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exposure of rats to B[a]P by gavage resulted in ca. 2.5 fold higher adduct levels in
WBC as compared with the site of entry of B(a)P; the stomach (P=0.0012).
's o/' DN/\ adt/ut'/s in WBC ivrsMS fissure
To determine whether DNA adducts in WBC quantitatively represent DNA
adducts in target organs, linear regression models were applied. The relationship
between DNA adduct levels in WBC (as independent variable x) and total DNA
adduct levels in lung tissue (as dependent variable y) was influenced by the
exposure route. The slopes of the regression lines after respectively i.t., oral and
dermal application of B[a]P were respectively 5.0 (95% confidence Interval: 3.7 - h.4,
P<0.001), 1.4 (0.7 - 2.0, P<0.001) and 0.7 (-0.3 - 1.7, P=0.18) (Figure 4A). The overall
relationship between DNA adduct levels in WBC and lung was highly significant
(r=0.83, P=0.0001) (Figure 4B). Identically, highly significant relationships between
DNA adducts in WBC and stomach after oral application of B|a)P (r=l).8O, P=0.0l)01)
and between WBC and skin after dermal application of B[a]P (r=0.61, P=0.(X)77) were
observed.
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Figure 4. Relationship between total DNA adduct levels in WBC (x) and lung tissue (y) after 3
different exposure routes. Panel A; (•) intratracheally, (O) orally, and (A) dermally exposed rats.
Panel B; Overall relationship (r=0.83, p=0.0001).
3-OH-B/u/P excrrf/ow in 24-/iOMrs wr/we
To assess the internal dose, we measured a major B[a]P metabolite, 3-OH-B[a]P,
in 24-hour urine. Highest excretion levels were found after i.t. exposure, which
reached a 'peak' value of 11.5 ug/24 hours at day 2 after exposure. Highest levels of
urinary 3-OH-B[a]P after dermal and oral exposure were respectively 4.8 ug/ 24
hours (at day 2) and 4.5 ug/24 hours (at day 1). Thereafter, the excretion quickly
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sensitive exposure-marker or biomarker for the biologically effective dose in target
organs.
Most carcinogenic PAH become effective predominantly at the site of
application (11). As expected, DNA adduct levels in exposed skin were high.
However, DNA adduct levels in stomach were surprisingly low after oral exposure
to a relatively high dose of B[a]P. This is in line with the local carcinogenic effect of
B[a|P, since considerable higher doses are required after oral exposure as compared
with dermal application of B(aJP to reach a similar incidence of tumors (11). Under
normal circumstances, the mucous layer of the gastrointestinal tract hampers the
absorption of the lipophilic B(a|P. Nonetheless, DNA adduct levels in remote tissues
and the urinary excretion of 3-OH-B[a]P indicated that considerable amounts of
B|a]P were absorbed after oral exposure. Dermal exposure resulted in relatively high
DNA adduct levels at the site of application, but the systemic effect (i.e., adduct
formation in WBC and lung) appeared to be much lower. On the other hand, 3-OH-
B|a|P excretion in dermally exposed animals was not lower as compared with oral
exposed rodents. These observations suggest that the metabolic conversion of B[a]P
to (non)reactive derivatives in skin itself is of importance. However, dermal
exposure to coal-tar ointments (i.e., a complex chemical mixture that contains PAH)
may result in higher systemic effect as compared with dermal treatment with single
PAH (data not shown). Intratracheal instillation of B[a)P resulted in considerable
systemic and local effects regarding DNA adduct formation. Furthermore, analysis
of 24-hours urine showed that ca. 1% of the administered dose was excreted as 3-
OH-B[a]P after i.t. exposure, whereas after respectively oral and topical
administration of B[a]P the cumulative excretion added up to only 0.4 and 0.6 %,
respectively. Also, Jacob et al. (25) found higher levels of monohydroxylated
metabolites of B[a]P in urine after intratracheal instillation as compared with oral
exposure. Furthermore, Jongeneelen et al. (26) reported that the cumulative excretion
of 3-OH-B[a]P in rat urine was only 0.22 to 0.35% of the orally administered dose
after three consecutive high doses of B[a]P.
The urinary excretion of 3-OH-B[a]P correlated significantly with adduct
formation at the site of application of B[a]P. In a recent study, we found 3-OH-B[a]P
concentrations in urine of individuals topically treated with ointments that contained
B[a]P also correlated with BPDE-DNA adduct levels in skin-DNA (6). Most studies
in PAH-exposed humans used 1-hydroxypyrene in urine as dosimeter for the
internal dose of PAH (5, 8, 27, 28), because it can be detected more easily as it is
excreted in high levels. Whereas, the mother compound (pyrene) or its derivatives
do not react with DNA. This might explain the conflicting results in the limited
number of studies that examined the association between urinary 1-hydroxypyrene
and DNA adducts in humans (5, 8, 27, 28). Furthermore, since the changes in urinary
concentrations of PAH-metabolites after exposure to PAH are relatively fast, the
sampling timing and/or period is of major importance. In the present study, levels of
3-OH-B[a]P were back to baseline levels within 11 days after the exposure, thus
measurements of urinary 3-OH-B[a]P seem to represent recent exposures only.
Overall, it can be concluded that aromatic-DNA adduct levels in WBC can be
applied as surrogate source of DNA at the site of exposure and reflect binding of
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B[a]P derivatives to lung DNA, independently from the exposure route.
Furthermore, the urinary excretion of 3-OH-B|a]P coincided with DNA adduct
formation, but measurements of urinary PAH-metabolites represent recent
exposures only.
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Abstract
Carcinogen-DNA adduct measurements have been used to assess human exposure
to polycyclic aromatic hydrocarbons (PAH). However, tissues in which PAH may
induce tumors are not accessible for routine monitoring of DNA adducts. Therefore,
mononuclear blood cells (i.e., monocytes plus lymphocytes, MNC) often serve as
surrogate source of DNA. To evaluate the applicability of DNA adducts in MNC as
a measure of current and/or past exposure to aromatic compounds, aromatic-DNA
adducts were assessed by nuclease PI enriched -^^P-postlabeling in MNC of 24
smoking individuals before and after a non-smoking period of 22 weeks. A group of
10 never-smokers was used to assess background levels of aromatic-DNA adducts.
Before smoking cessation, DNA adducts levels in MNC (0.76±0.41 adducts/ 10"
nucleotides) were positively correlated with cigarette-consumption (r=0.51, p=0.01)
and inversely related with body mass index (weight/height^) adjusted for age and
gender (r=-0.48, p=0.02). After 22 weeks of non-smoking, DNA adduct levels in
MNC declined to 0.44±0.23 adducts/ 10» nucleotides (P=0.002), which was not
significantly different as compared with never-smokers (0.39±0.23). A half-life of 12
weeks was calculated for aromatic-DNA adduct levels in MNC on the basis of a
semi-logarithmic plot and subtraction of the average background level obtained
from never-smokers. When a linear model for the elimination of aromatic-DNA
adducts in MNC was applied, it was calculated that DNA adducts would reach
background levels after 25 weeks of smoking cessation. The persistence of DNA
adducts in MNC was inversely related with the aromatic-DNA adduct level before
smoking cessation (r=-0.55, p=0.033). It can be concluded that DNA adduct levels in
MNC reflect exposure to tobacco associated aromatic compounds and when
exposure to tobacco smoke is stopped, adduct levels in MNC decrease accordingly.
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Introduction
Polycyclic aromatic hydrocarbons (PAH) are ubiquitous environmental
pollutants particularly present in tobacco smoke, which are thought to elicit lung
cancer by covalent interactions with DNA, so-called DNA adducts (1). Theoretically,
the level of DNA adducts indicates the capacity of an individual to cope with
carcinogen exposure. Therefore, the quantitation of PAH-DNA adducts probably is a
good indicator for the biologically effective dose and could be of use in risk
assessment. However, lung tissue is rarely accessible in a non-clinical setting and
white blood cells (WBC) have been used as surrogate source of DNA. Although
several studies showed controversial results regarding the effect of smoking on DNA
adduct levels in WBC (2-5), it has been suggested that the mononuclear cell fraction
(i.e., monocytes plus lymphocytes, MNC) can be used to assess exposure to tobacco
derived aromatic compounds (6, 7). Aromatic-DNA adduct levels in MNC correlated
with the amount of cigarettes smoked per day (7) and moreover, might correlate
with aromatic-DNA adduct levels in lung tissue (6). Nonetheless, measurements of
DNA adducts in MNC require further validation before they can be used in exposure
or risk assessment. For example, it should be known whether DNA adduct
measurements have the ability to integrate PAH exposure over a relatively long (a
few months up to years) period of time and also whether these measurements can
detect previous exposures after a long period of non-exposure. The half-life of PAH-
DNA adducts in lymphocytes was estimated to be between 9 to 13 weeks after
cessation of smoking using a competitive ELISA (8). On the other hand, much lower
elimination rates have been reported for DNA adducts in lung tissue (9, 10). Further
evaluation of elimination curves of aromatic-DNA adducts is necessary.
The uptake and elimination rates of PAH might be influenced by body
composition, since PAH are lipid soluble and tend to accumulate in adipose tissue.
Indeed, in one recent study, a positive correlation was observed between the body
mass index (weight/height^, BMI) and aromatic-DNA adducts in pancreatic tumor
tissues (11). On the contrary, it was consistently found that smokers with a low BMI
have an increased risk for developing lung malignancies as compared with smokers
of average weight (12-16). This inverse relationship is considered by some
investigators to be due to incomplete adjustment for the effect of cigarette smoking
(15). In this respect, DNA adduct measurements give the opportunity to further
investigate the link between BMI and lung cancer risk in smokers. Furthermore, after
smoking cessation, accumulated PAH might be released into the peripheral blood
and would prolong the apparent half-life of DNA adducts in MNC.
Thus, in the present study, the relationship between DNA adduct levels and
cigarette consumption is further investigated by nuclease PI enriched 3^ P-
postlabeling in MNC obtained from 24 individuals who stopped smoking for 22
weeks. Moreover, the impact of BMI on DNA adduct levels and adduct elimination
in MNC was studied.
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Materials & Methods
Hundred healthy smoking subjects, willing to stop smoking, were recruited at the
Asthma Center Homerheide in Horn (The Netherlands) by means of media
advertisement. The weight (kg) and height (m) of these individuals was obtained
and the BMI was calculated (kg/m^). After informed consent, 10 ml blood was
collected at the initial visit, i.e., the day before quitting smoking. The subjects applied
nicotine-patches daily to increase the success-rate of smoking cessation. After 22
weeks, 32 individuals succeeded in continuing complete abstinence from smoking
and blood-samples of 24 individuals (age: 44±8 years, 14 male and 10 female) could
be used for adduct analysis. This group of volunteers had smoked on average 24±9
cigarettes per day over a period of 27±8 years before smoking cessation. A control
group of 10 healthy never-smokers without occupational exposure to PAH (age:
38±12 years, 3 male and 7 female) was selected to assess background levels. Overall
characteristics are presented in Table I.
Table I. Characteristics of the group of individuals who stopped smoking for 22 weeks (study group
I) and the group of never-smokers (study group II).
Study Group I Study Group II
Number of subjects (n)
Gender (Male/Female)
Age (years ± SD)
Cigarettes / day
Smoking Years
Body Mass Index (kg/m^)
Male / Female
24
14/10
44±8
24 ±9
27 ±8
25.5 ± 2.7
26.3 ±2.7 / 24.1 ±2.2
10
3/7
38 ±12
0
0
Unknown
MNC and DN.4 iso/af JOW
MNC were separated from polymorphonuclear cells (granulocytes) by gradient
centrifugation on lymphoprep according to rtoyum (17). The MNC fractions were
washed twice with PBS and stored at -20°C until DNA isolation. MNC were lysed
with 2.5 ml SDS/NEP (75 mM NaCl, 25 mM EDTA, 50 pg/ml Proteinase K, 1% SDS)
and incubated for 4 hours at 37°C. DNA was extracted with phenol: chloroform:
isoamylalcohol (25:24:1, v /v /v) and chloroform: isoamylalcohol (24:1, v/v)
respectively. The DNA was precipitated with two volumes of cold ethanol after
addition of 1/30 volume 3M sodiumacetate, pH 5.3 and washed with 70% ethanol.
Subsequently, DNA was dissolved in 2 mM Tris, pH 7,4. Concentration and purity
were determined spectrophotometrically by absorbance at 230, 260 and 280 nm and
the final volume was adjusted to achieve a DNA-concentration of 2 mg/ml.
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The ^P-postlabeling assay was performed as described by Reddy and Randerath (18)
with some modifications. All samples were encoded. DNA (10 ug) was digested
using micrococcal endonuclease (0.4 Units) and spleen phosphodiesterase (2.8 pg) for
3 hours at 37°C. Subsequently, half of the digest was treated with nuclease PI (6.3
ug) for 40 minutes at 37°C The modified nucleotides were labeled with [y-^PJ-ATP
(50 uCi/ sample) by incubation with T4-polynucleotide kinase (5.0 Units) for 30
minutes at 37°C. NP1 -efficiency and ATP-excess were checked with an aliquot of the
NP1 treated fraction by one-dimensional chromatography on
poly(ethyleneimine)(PEI)-cellulose sheets from Merck, Germany (solvent: 0.12 M
NaH2l'O4 pH 6.8). Radiolabeled adduct nucleotide biphosphates were separated by
chromatography on PEI<ellulose sheets from Machery Nagel (Germany). The
following solvent systems were used: Dl, 1 M Nah^PC^ pH 6.5; D2, 8.5 M urea, 5.3
M lithium formate pH 3.5; D3, 1.2 M lithium chloride, 0.5 M Tris, 8.5 M urea pH 8.0;
D4, 1.7 M NaH2PO4 pH 6.0. In each experiment, 3 standards of PH]BPDE modified
DNA with known modification levels (1 per 10^ , 10", 10** nucleotides) were run
parallelly for quantification purposes. Quantification was performed by using
phosphor-imaging technology (Molecular Dynamics™, Sunnyvale, CA, USA) with a
detection limit of <1 adduct per 10"> nucleotides for individual spots. The detection
limit of a diagonal radioactive zone (DRZ) was around 5 adducts per 10** nucleotides.
Samples with no detectable DNA adduct levels were considered to have adduct
levels of 0.25 adducts per 10" nucleotides (half of the detection limit for DRZ). The
remaining half of the digest was used to determine the final amount of DNA in the
assay; the normal nucleotides were diluted and labeled with [y-^PJ-ATP (15 uCi/
sample) by incubation with T4-polynucleotide kinase (2.5 Units) and a 10-fold molar
excess of unlabeled ATP for 30 minutes at 37°C. A dAp standard (27.5 pmole/ul)
was labeled in each experiment for quantification purposes. Nucleotides were
separated by one-dimensional chromatography on PEI-cellulose sheets from Merck
(solvent: 0.12 M Nar^POj pH 6.8); samples with apparent protein or RNA
contamination were discarded.
Stof isf/fti/ flH(j/ys/'s
Results are presented as mean ± standard deviation. A paired t-test was used to
assess differences in DNA adduct levels at t=0 (before smoking cessation) and t=22
weeks and an unpaired t-test was applied to assess differences between (ex)smokers
and never-smokers. Linear regression models were applied to determine the
relationships between smoking behavior, BMI and DNA adduct levels in MNC. The
half-life of aromatic-DNA adducts in MNC was estimated using linear regression on
log-transformed adduct levels and exact time, adjusting for background levels by
subtracting the average DNA adduct level of non-smoking controls (considered as
background). P<0.05 was considered significant.
82
Results
C/ /rtWs m MNC uf husrfrnr mrasurrmrnfs
DNA adduct profiles obtained by -^-P-postlabeling and subsequent thin layer
chromatography were identical for all smoking subjects; diagonal radioactive zones
(DRZ's) were observed, which are typical for exposure to cigarette smoke (Figure 1).
In never-smokers, only three individuals showed faint DRZ's and no adducts were
detected in the other subjects.
Adduct levels in smokers (0.76±0.41 adducts per 10* nucleotides) were
significantly higher as compared with never-smokers (0.39±0.23, P=0.03). Moreover,
aromatic-DNA adduct levels in MNC of smoking individuals were significantly
related with the self-reported amount of cigarettes smoked per day (r=0.51, p=0.01,
Figure 2), and were inversely related with the BMI adjusted for age and sex (r=-0.48,
P=0.02, Figure 3). This relationship was borderline significant after DNA adduct
levels were corrected for the amount of cigarettes smoked per day (r=0.40, P=0.055).
If both parameters were used as independent variables in a multiple regression
analysis, a significant overall relationship was observed (r=0.63, p=0.007).
Figure 1. Aromatic-DNA adduct profiles observed in MNC of a smoking individual before (A) and
after (B) smoking cessation for 22 weeks. Panel C represents a BPDE-DNA adduct standard with a
modification level of 1 adduct per lO'' nucleotides.
/we/s after 22 awfcs o/smofcm£ c^ssafion
Adduct profiles were not changed by smoking cessation for a period of 22
weeks. Similar DRZ's were observed, but with lower intensities (Figure 1). Adduct
levels had significantly decreased to 0.44±0.23 adducts per 10* nucleotides (P=0.002
as compared with levels before smoking cessation) and were no longer significantly
different as compared with those found in never-smokers (P=0.42). Still, DNA
adducts could be observed in MNC of 15 out of 24 individuals (63%), whereas in
never-smokers this was 3 out of 10 (30%). The apparent half-life of aromatic-DNA
adducts in MNC using a semi-logarithmic plot was 24 weeks. However, a more
reliable estimate of 12 weeks was obtained after correction by subtracting
background levels. Using a linear model for adduct elimination, it was calculated
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that aromatic-DNA adduct levels in MNC would reach the average background
levels at 25 weeks after smoking cessation.
1.8
10 20 30 40
Cigarettes/day
Figure 2. Relationship between daily cigarette consumption and aromatic DNA adduct levels in MNC
of current smokers (r=0.51, P=0.01, n=24).
21 22 23 24 25 26 27 28 29 30
BMI (weight/ heighr)
Figure 3. Relationship between the body mass index and aromatic-DNA adduct levels in MNC of
current smokers (r=-0.48, p=0.02, n=24).
The relative decrease in DNA adduct levels was significantly and inversely
correlated with the initial DNA adduct level (r=-0.55, P=0.03); individuals with high
adduct levels at t=0 showed a stronger decline in DNA adduct levels as compared
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with individuals with low initial DNA adduct levels. In this analysis, to obtain a
reliable estimate for adduct removal only individuals with detectable DNA adduct
levels before and after smoking cessation were used (n=15. Figure 4). Although no
impact of BMI on adduct elimination was observed, the BM1 was found to
significantly influence the initial DNA adduct level, and therefore, an effect of BMI
on decreasing DNA adduct levels can not completely be excluded.
Discussion
In the present study, aromatic-DNA adducts in MNC seemed to reflect
exposure to tobacco smoke and adduct levels significantly decreased after exposure
to tobacco smoke was stopped. Aromatic-DNA adducts in MNC were significantly
related with the current amount of cigarettes smoked per day. After exposure to
tobacco smoke was stopped, DNA adduct levels in MNC decreased accordingly with
an estimated half-life of ca. 12 weeks. Additionally, an effect of the BMI was
observed on the formation of aromatic-DNA adducts in MNC. Lower adducts levels
were observed in individuals with a high BMI.
Previous studies already indicated that the use of MNC would probably reflect
tobacco smoke exposure more reliably as compared with total WBC (6, 7).
Polymorphonuclear cells, quantitatively the most predominant WBC-type in blood,
contain only low levels of DNA adducts (5, 7) and the life-span of this cell-type is
short (hours-days). Therefore, they would reflect recent exposures to PAH only (19).
In the MNC fraction, the life-span of monocytes is also short (several days). Recent
studies showed no clear differences between monocytes and lymphocytes during
continuous exposure (7, 19). On the other hand, if exposure was stopped, adduct
levels in the monocyte fractions were found to decline to baseline-levels within one
week (19). Therefore, the isolation of lymphocytes might be even more promising to
assess past exposures to PAH, since this cell-type has a longer life-span.
Furthermore, a large fraction of the lymphocytes seems to migrate to non-lymphoid
organs, like the lung, are exposed to inhaled carcinogens at that site and slowly
redistribute into the peripheral blood (20, 21). Thus, in the present study, part of the
observed decline in DNA adduct levels in MNC is probably due to the short half-life
of monocytes.
Removal of aromatic-DNA adducts in WBC (22, 23) and lung (9) seems to occur
in two phases; an initial fast reduction of DNA adduct levels, followed by a period in
which adduct elimination is much slower. In the present study, the calculated half-
life of tobacco related DNA adducts in MNC obtained by ^p-postlabeling is in line
with previous results obtained by ELISA (8). Identically, Pavanello et al. (24) and
Paleologo et al. (25) showed a significant reduction of PAH-DNA adducts over a
period of 2-5 months after the end of topical treatment with coal-tar ointments,
which contained high levels of PAH. An inverse correlation was observed between
adduct elimination and the initial DNA adduct level, which indicates that adducts
are more efficiently removed by DNA repair or cell turn-over at higher levels of
DNA damage. Persistence of DNA adducts in lung tissue is reported to be higher as
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compared with DNA adducts in WBC (8-10). Nonetheless, Wiencke et al. (6) found a
correlation between DNA adduct levels in MNC and lung, even if short- and long-
term ex-smokers were included in the analysis. This indicates that DNA adduct
removal from MNC may coincide with DNA adduct elimination in lung after
smoking cessation.
A correlation between BMI and DNA adduct formation was previously
reported for pancreatic tumor tissues by Wang et al. (11). In that study, a high BMI
coincided with higher adduct levels. However, in the present study the opposite was
observed. Similarly, Loft et al. (26) found lower levels of oxidarive DNA damage in
individuals with high BMI's, especially in those who smoked cigarettes. Possible
explanations for these observations is that individuals with a high BMI have
relatively lower metabolic rates as compared with lean individuals (27) and PAH can
be immobilized in adipose tissue.
32
o
0.6
Adducts/10® nucleotides
at t=0 (before smoking cessation)
Figure 4. Relative persistence of DNA adducts in MNC (adduct level at t=22 divided by adduct levels
at t=0) correlated with the initial DNA adduct level in MNC before smoking cessation (r=-0.55,
p=0.033, n=15).
The results of the present study further support the idea that DNA adducts in
MNC can be used to assess lung cancer risk, because the levels of aromatic-DNA
adducts seemed to correlate with several risk factors for lung cancer. For instance,
DNA adduct levels in MNC (7) and lung cancer risk (28) both correlate with the
amount of cigarettes smoked per day and both decrease after smoking cessation (8,
29). Moreover, DNA adducts were inversely correlated with the BMI. Identically, a
low BMI has consistently been identified as a risk-factor for the development of lung
malignancies (12-16).
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After smoking cessation, accumulated PAH mobilized from adipose tissue
might serve as an additional source of PAH exposure. Thus, the elimination rate of
aromatic DNA adducts in MNC may be influenced by the body composition.
Although we observed no direct impact of BMI on adduct reduction, the BMI was
found to significantly influence the DNA adduct level before smoking cessation.
Since adduct removal depended on the initial adduct level, an effect of BMI cannot
be excluded. Furthermore, it can not be distinguished whether the adducts that are
detected after a period of nonexposure are formed due to background exposures,
were already present in longer-lived lymphocytes, and/or are formed due to the
release of PAH from adipose tissue.
In conclusion, DNA adduct levels in MNC reflect exposure to tobacco
associated aromatic compounds and change accordingly if exposure is altered. The
observation that adduct levels in MNC are significantly influenced by the BMI needs
further confirmation.
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Genetic polymorphisms in GSTMl and A/A72 in relation to aromatic-
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Abstract
Carcinogen-DNA adduct levels may be modulated by host polymorphisms in genes
that encode enzymes involved in the metabolism of environmental pollutants, such
as polycyclic aromatic compounds. In this study, aromatic-DNA adduct levels were
examined by nuclease PI enriched -^P-postlabeling in mononucltMr blood cells
(MNC) and cells obtained by broncho-alveolar lavages (BA1.) from smoking
volunteers, and related to generic polymorphisms of glutathione S-lranstorase Ml
(CSTM1) and N-acetyl transferase 2 (N/IT2). DNA adduct levels in MNC were
significantly related with the amount of cigarettes smoked per day (r=0.26, P=0.035)
and were significantly higher in GSTM1(-/-) individuals (1.35±0.55 adducts per 10"
nucleotides) as compared with GSTM1(+) subjects (1.03±0.57, P=0.021). On the other
hand, DNA adduct levels in BAL-cells of these individuals were not significantly
related with the GSTMl polymorphism. The N/4T2 polymorphism was found to be
associated with DNA adduct levels in MNC (respectively 1.32±0.64 and l.(M±0.45
for slow and fast acetylators, P=0.047) and BAL-cells after correction for age and
gender (respectively 6.91±1.78 and 5.37±1.62, P=0.074). When the GSTMl and N/4T2
genotypes were combined, highest DNA adduct levels were observed in MNC of
slow acetylators that lacked the GSTMl-gene (1.45±0.62) and lowest DNA adduct
levels in those with the fast acetylator/GSTMl(+) genotypes (0.86±0.42, I'-O.OIO).
Overall, the observed relationships were still present after adjustment for the
amount of cigarettes smoked per day, but with 'borderline' significances only. These
results indicate that polymorphisms in the GSTMl and N.AT2 genes may influence
the formation of aromatic-DNA adducts in smoking individuals.
Introduction
Many cancers may be attributable to chemical carcinogens such as polycyclic
aromatic hydrocarbons (PAH), which are present in tobacco smoke (1). PAH are
lipid soluble and tend to accumulate in organisms, unless they are oxidatively
metabolized to water soluble derivatives to facilitate excretion in urine or feces.
However, some PAH derivatives become electrophilic and may bind to
macromolecules such as DNA. PAH-DNA adducts have been associated with the
induction of DNA mutations and cancer (2,3) and represent a complex continuum
including exposure, absorption, distribution, activation and detoxification, cell turn-
over and DNA repair. Therefore, DNA adducts were frequently measured in easily
available white blood cells (WBC) or alveolar macrophages obtained by broncho-
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alveolar lavage (BAL) to assess human exposure to PAH. DNA adduct formation in
these tissues was found to vary significantly between individuals with apparently
similar exposures. Genetic polymorphisms in genes that encode for metabolizing
enzymes are thought to be involved (4).
Detoxification of PAH is mediated by Ml-class glutathione-S-transferases
(GSTM1) (5). Glutathione (GSH) has a slow spontaneous rate of reaction with
activated PAH. This rate can be enhanced by GSTM1-1. When the electrophile forms
a covalent bond with GSH, it can easily be excreted and is no longer toxic. The
CSTM1 gene locus is polymorphic; deficiency in this enzyme is caused by
inheritance of a homozygous deletion of the GSTM1 gene [indicated as GSTM1 (-/-),
individuals with at least one expressing allele are indicated as GSTM2(+)] (5). It is
repeatedly reported that subjects with low/no activity of GSTM1-1 or subjects with
the GSTM7(-/-) genotype may have an increased risk for developing squamous cell
carcinoma of the lung (6-8). Furthermore, the effect of GSTMI(-/-) seemed to be
more predominant in heavy smokers than in light smokers (9, 10). Also, an
association between GSTM1-1 expression and lung adenocarcinoma was reported by
Scidegc^rd (II), but genotyping studies could not confirm this (6). Furthermore,
subjects lacking the GSTMJ locus seem to have higher PAH-DNA adduct levels in
lung (5, 12-14). In peripheral blood cells such a relationship could not consistently be
established (15-18). When combined with other polymorphic genotypes, like CYPl/\2
(13, 16) or N-acetyl transferee (AM 72) (17, 19), significant differences in DNA
adduct levels in white blood cells (WBC) were found between GSTM2(-/-) and
GSTM7(+) individuals, but again these observations were not consistent (18).
The N/4T2 gene is also polymorphic in man and has been associated with an
increased risk of developing certain cancers in smokers; slow acetylators with
bladder cancer and rapid acetylators with colorectal cancer (20). Overall, N-
acetylation of aromatic amines is generally considered to be a detoxifying
mechanism, since it competes with N-oxidation. However, in colorectal tissues N-
acetylation might activate rather than inactivate xenobiotics. Approximately half of
the Western population is slowly acetylating (21), which was related to high levels of
protein adducts caused by aromatic amines in smokers (22, 23). The N/4T2
polymorphism seems to be more relevant at low exposures as compared to high
levels of exposure (24).
In the present study, we examined the relationship between the GSTM1 / N/\T2
genotypes and aromatic DNA adducts, assessed by nuclease PI enriched 32p.
postlabeling, in peripheral blood mononuclear cells (i.e., lymphocytes plus
monocytes, MNC) and alveolar macrophages obtained from smoking individuals to
investigate tissue specific effects of GSTM1 and N/4T2.
Materials & Methods
Blood of 70 smoking healthy Caucasian volunteers (males/females: 28/42) with an
average age of 41 ±8 years was analyzed. These individuals smoked 1 to 50 cigarettes
per day (overall mean: 25±11 cigarettes per day) and reported not to be
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occupationally exposed to aromatic compounds. In a subgroup of 22 individuals
(age: 42±8, 9 males, 13 females) who smoked 26±13 cigarettes per day, alveolar
macrophages were obtained by broncho-alveolar lav-ages (BAL). Informed consent
was obtained for all individuals
o/mononur/fnr Mood cr//s
Ten ml of peripheral blood was sampled by venapuncture into EDTA-tubes.
Polymorphonuclear cells (granulocytes) were separated from mononuclear cells
(monocytes plus lymphocytes) by centrifugarion on lymphoprep (Lymphoprep™
(1.077 g/ml), Nycomed, Oslo, Norway) according to Boyum (25). The mononuclear
cell-fraction was washed twice with PBS and stored at -20°C until DN A isolation.
fo obta/n o/tvo/ar
Bronchoscopy was performed under local anesthesia. The bronchoscope was put
into the middle lobe bronchus and 50 ml of sterile saline (37°C) w.is instilled.
Immediately, suction was applied and the effluent was collected in a plastic tube .ind
placed on ice. This procedure was repeated three more times, using lavage volumes
of 50 ml each. The BAL-fluid was strained through two layers of 4x4 gauze into 50
ml conical tubes. Cells were collected by centrifugation (4°C, 200 g, 5 minutes), the
cell-pellet was stored at -20°C until DNA isolation.
DN/4 iso/af/on and -^P-p
DNA was purified by a standard phenol extraction procedure as described
previously (26). The DNA was precipitated with two volumes of cold ethanol after
addition of 1/30 volume 3M sodiumacetate, pH 5.3 and washed with 70% ethanol .
Subsequently, DNA was dissolved in 2 mM Tris, pH 7,4. Concentration and purity
were determined spectrophotometrically by absorbance at 230, 260 and 280 nm. The
final volume was adjusted to achieve a DNA-concentration of 2 mg/ml.
Subsequently, the NP1-enriched 32p-postlabeling assay was performed (26). Briefly,
DNA (± 10 ug) was digested into nucleotide monophosphates and treated with
nuclease PI for 40 minutes at 37°C. Then, nucleotides were 5-labeled with ^ p using
T4-polynucleotide kinase (5.0 Units) for 30 minutes at 37°C. Radiolabeled adduct
nucleotide biphosphates were separated by chromatography on PEI-cellulose sheets
(Machery Nagel, Germany). The following solvent systems were used: Dl, 1 M
NaH2PO4 pH 6.5; D2, 8.5 M urea, 5.3 M lithiumformate pH 3.5; D3, 1.2 M
lithiumchloride, 0.5 M Tris, 8.5 M urea pH 8.0; D4, 1.7 M Nar^PO., pH 6.0. In each
experiment, 3 standards of PHJBPDE modified DNA with known modification
levels (1 per lO'', 10", Iff* nucleotides) were run parallelly for quantitation purposes.
Quantitation was performed by using phosphor imaging technology (Molecular
Dynamics™, Sunnyvale) with which detection limits of <1 adduct per 1C
nucleotides can be obtained.
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Dff^rmrnafion o/flenef/c po/ymorp/nsms /« GSTM1 and N/4T2
The GSTM2 genotype was determined using a polymerase chain reaction (PCR)-
based assay as described by Brockmoller et al. (27). PCR was carried out in a total
volume of 50 ul, containing 0.2 ug DNA, 0.2 mM of each dNTP, 5 mM Tris-HCl, 25
mM KC1, 0.75 mM MgCl2, and 1 uM of each primer. Exact information about the
primers used can be found in Brockmoller et al. (27). After denaturation at 94°C for 4
min, 1.25 U of Taq-polymerase (Pharmacia Biotech, Roosendaal, The Netherlands)
was added, followed by 35 cycles of amplification. An aliquot of 10 pi of the PCR
product was analyzed on a 3% agarose gel for the presence of bands at 338 bp
(control) and 273 bp (CSTM1).
/MT2 genotyping was performed using standard PCR procedures (28). PCR was
carried out in a volume of 100 pi, containing 10 mM Tris-HCl (pH 8.3), 50 mM KG,
1.0 ug DNA, 0.2 mM of each dNTP, 1 ug of each primer and 2.5 Units of Taq-
polymerase. DNA amplification was performed in 30 cycles. Digestion of 2 pi of the
PCR product was carried out in a volume of 40 pi, using the appropriate buffers and
the restriction enzymes Msp I and Kpil, BamHI and Toql, or DtfVI. Digested samples
were loaded on a 5% acrylamide gel containing ethidium bromide, run for 16 hours
at 30 V and visualized and photographed under UV light. Classification of the
subjects in fast, intermediate or slow acetylators was derived from the genotype data
(29).
Sfrtf/sf/rs
Results are presented as mean and standard deviation. Parametric-tests [unpaired t-
tests (2 groups) or one-way ANOVA (>2 groups)] were applied to evaluate statistical
significances. P< 0.05 was considered significant.
Results
Disf rfrufiYwi o/jjenrfjc po/i/wor^/i/sms in M4T2 and GSTM2
The GSTM2(-/-) genotype was found in 34 out of 70 individuals (49%). The
'slow'/intermediate' and 'fast' acetylator genotypes were found in respectively 54%
(38/70), 39% (27/70) and 7% (5/70) of the total study population. For statistical
reasons, the fast and intermediate acetylators were combined into one group of 32
individuals (refered to as fast acetylators). When both polymorphisms were
combined, it was found that 18 slow acetylators had the GSTM2(+) genotype (26% of
total) and the other slow acetylators (n=20) contained the GSTM2(-/-) genotype
(29%). The GSTM2(+) and GSTM1(-/-) genotypes were equally distributed over the
remaining 32 fast acetylators (16 per group, i.e., 23% each) (Table I and II). The
subgroup (n=22), in which additionally alveolar macrophages were analyzed for
aromatic-DNA adduct levels, contained 13 slow acetylators (59%), of which 8
individuals lacked the GSTM2 gene. In the group of fast acetylators (n=9), 3
individuals were found to lack the GSTM2 gene (Table I and II).
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Table I. The effect of GSTM1 and NAT2 polymorphisms on aromatic-DNA adduct levels in MNC and
BAL-cells (adjusted for age and sex) from smoking individuals.
MNC
Cig/ day
BAL-cells
Cig/ day
GSTMK-/-;
135 ±0.55 «
n=34
22 ±10
5.98 ± 2.01
n=ll
28 ±14
CSTM1
GSTMK+;
1.03 ±0.57
n=36
26 ±10
6.01 ± 2.00
n=ll
23 ±10
P-value
0.021
0.100
O.%5
0.373
N/4T2
Slow
1.32 ± 0.64
n=38
25±8
6.91 ±1.78
n=13
24 ±7
Fast
1.04 ±0.45
n=32
23 ±12
5.37 ±1.62
n-9
25 ±12
P-valut
0.047
0.566
0.074
0.877
* Mean ± SD aromatic-DNA adduct level in adducts per 10** nucleotides
Table II. The effect of combinations of GSTM1 and N^T2 genotypes on aromatic-DNA adduct levels
(mean ± SD, in adducts per 10* nucleotides) in MNC of smoking individuals.
GSTM1 (-/-) CSTM1 (+)
Slow Acetylators 1.45 ±0.61 1.17 ±0.65
n=20 n=18
Fast Acetylators 1.22 ±0.43 0.86 ± 0.42*
n=16 n=15
ANOVA: P=0.027, • P=0.010 as compared with GSTM1 (-/-)/ slow acetylators
DAM orfducfs m MNC am/ B/1L ce//s
DNA adduct analysis in MNC and BAL-cells by thin layer chromatography
resulted in DNA adduct profiles which are typical for exposure to cigarette smoke;
so-called diagonal radioactive zones (DRZ) and results have been reported earlier by
Godschalk et al. (1998). The mean DNA adduct level in MNC was 1.22±0.58 adducts
per 10* nucleotides and ranged from <detection limit (adduct level arbitrarily set on
0.25 per 10* nucleotides) to 2.6 adducts per 10* nucleotides. In BAL-cells, adduct
levels were approximately 5-times higher as in MNC and a mean DNA adduct level
of 5.93+2.42 adducts per 10* nucleotides (range: 2.44- 11.00) was observed. A
significant correlation was observed between the self-reported amount of cigarettes
smoked per day and aromatic-DNA adduct levels in MNC (r=0.26, P=0.035), but not
in BAL-cells.
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/mpart o/GSTMl on DN/4 <n/dncf /<w/s m B/1L cW/s and MNC
Mean aromatic-DNA adduct levels in MNC were significantly higher in
individuals with the GSTMI(-/-) genotype (1.35±0.55 adducts per 10** nucleotides) as
compared with individuals that were GSTM1(+) (1.03±0.57 adducts per 10*
nucleotides, P=0.021, Table I). However, individuals that were GSTM1(-/-) tended to
smoke less (22±10 cigarettes per day) as compared with GSTM1(+) subjects (26±10
cigarettes per day, P=0.10). After correction for smoking behavior, DNA adduct
levels in MNC of GSTM1(-/-) individuals were still higher than those in GSTMI(+)
subjects, but with borderline' significance only (P=0.062). Aromatic-DNA adduct
levels in BAL-cells were not significantly related with the GSTMl polymorphism;
GSTMJ(-/-) individuals showed similar DNA adduct levels in BAL-cells (5.96±2.32)
as compared with GS7MI(+) subjects (5.89±2.68, P=0.95). DNA adduct levels in
BAL-cells were significantly correlated with age and gender (26), but even if these
additional factors were taken into account, no relation between the GSTMl
polymorphism and DNA adduct formation in BAL-cells was observed (P=0.96, Table
I).
o/N/tT2 DM DN/4 ocirfuc/ Ifiv/s in B/IL cW/s and MNC
Mean DNA adduct levels in MNC of slow-acetylators (1.32±0.64 adducts per
10" nucleotides) were higher as compared with fast acetylators (1.04±0.45), which
was in the same range as the effect observed for GSTMl (P=0.047, Table I), but again
the statistical significance was lost after adjustment for the amount of cigarettes
smoked per day (P=0.067). At first, the M4T2-polymorphism did not seem to affect
aromatic-DNA adduct levels in BAL-cells (P=0.41). However, after correction for age
and gender, a more pronounced but nonsignificant difference between slow-
acetylators (6.91±1.78) and fast acetylators (5.37±1.62) was observed (P=0.07, Table I).
Table III. The effect of combinations of GSTMl and NL4T2 genotypes on aromatic-DNA adduct levels
(mean ± SD, in adducts per 10* nucleotides) in BAL<elIs of smoking individuals.
Slow Acetylators
Fast Acerylators
ANOVA: P=0.31
GSTMl (-/-)
6.68 ± 1.72
n=8
5.10 ± 2.08
n=3
GSTMl (+)
7.28 ± 2.01
n=5
5.73 ±1.03
n=6
Ctfml>i>i<ir/(>;i$ o/N/4T2 a/n/ GSTMl <ni<i //iri'r im/wrf OH DNA flJduc/ /etv/s
Highest mean aromatic-DNA adduct levels in MNC were observed in slow
acetylators with the GSTM1(-/-) genotype (1.45±0.62 adducts per 10* nucleotides)
and lowest DNA adduct levels were found in individuals which were GSTM1(+) and
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fast acetylator (0.86±0.42, P=0.010). MNC of subjects which were GSTM1(-/-) /fast
acetylator or GSTMJ(+)/slow acetylator contained adduct levels of respectively
1.17±0.65 and 1.22±0.43 adducts per 10» nucleotides (ANOVA, P=0.027, Table 11) but
again, these results were no longer significant after adjustment for the smoking dose
(ANOVA, P=0.08). In BAL-cells, no association between combined genotypes and
DNA adduct levels could be observed (P=0.31, Table 111).
Discussion
It is thought that the balance between activation and inactivation of genotoxic
compounds may play a significant role in the susceptibility towards the formation of
DNA adducts and subsequent risk for developing chemically induced cancers. Thus,
it is expected that the assessment of putative high risk genotypes' will allow the
identification of cancer susceptible individuals or subgroups. In the present study,
we investigated genetic polymorphisms in genes that encode for two phase II
enzymes (i.e., GSTM1 and N,4T2) in relation with the formation of aromatic-DNA
adducts in MNC and BAL-cells of smoking individuals. The occurrences of these
high risk genotypes' were in line with those reported for other Caucasian
populations (5, 28). Exposure to tobacco smoke is a major risk factor for developing
lung cancer, and epidemiological studies documented a dose-response relationship
with the number of cigarettes smoked (30). Identically, a significant relationship was
observed between the amount of cigarettes smoked per day and the level of
aromatic-DNA adducts in MNC. However, the correlation coefficient was low
(r=0.26), which indicates that cigarette-dose alone is not sufficient to explain the
observed variations in DNA adduct levels and genetic polymorphisms may be
involved. Aromatic-DNA adduct levels in MNC of smoking GSTMJ(-/-) subjects
were modestly, but significantly higher than in GSTM7(+) individuals (1.27-fold).
This is in agreement with several previous studies (13, 31), whereas others did not
observe such an association (15, 18). After adjustment for the amount of cigarettes
smoked per day, the observed difference between DNA adduct levels in MNC of
GSTMJ(-/-) and GSTM1(+) subjects was of 'borderline' significance. The influence of
polymorphism in the GSTMJ gene on DNA adduct levels might be more
pronounced when it is combined with other susceptibility genes, for instance the
genetic polymorphism that has been found in the cytochrome P450 isoenzyme 1A1
(CYP2/U) (32). However, the literature regarding the impact of the inducible
CYP]y4I genotype on aromatic-DNA adduct levels in WBC is still controversial (13,
16, 31, 33, 34) and deserves further study. The CYPJ/W polymorphism is rare in
Caucasian populations, and therefore, it is expected that the additional analysis of
CYPMI in the present study would not have resulted in statistically informative
results.
No association was observed between the GSTM1 polymorphism and aromatic-DNA
adduct levels in BAL-cells of the same subjects, which indicates that the expression
or the effect of genetic polymorphisms may not be similar in all tissues of an
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individual. Larger numbers of volunteers would have been required to find
statistically significant differences.
Human exposure to PAH by inhalation of cigarette smoke always coincides
with exposure to other aromatic compounds, such as aromatic amines. DNA adducts
formed by aromatic amines are thought to be sensitive towards the action of nuclease
PI, and might therefore remain undetected in this study. However, Gupta et al. (35)
showed that aromatic amines bound to the exocyclic position of guanine can be
detected by NP1 enriched ^P-postlabeling, which might explain the association
between the N/4T2 polymorphism and DNA-adduct formation in MNC and BAL-
cells. A similar relationship was reported previously by Peluso et al. (19); higher
adduct levels determined by NP1 enriched 32p-postlabeling in slow acetylators as
compared with fast acetylators. In a study by Hou et al. (17), an effect of the M4T2
polymorphism on DNA adduct levels was found only in combination with the
GSTMJ-genotype in bus maintenance workers. In our study, a possible involvement
of both polymorphisms in tobacco smoke associated DNA adduct formation in MNC
is also suggested.
Adduct levels in MNC and BAL-cells were lower in fast than in slow
acetylators. This corresponds with the susceptibility towards bladder cancer (19), but
not lung cancer. Most of the genotyping or phenotyping studies on lung cancer
showed no overall risk related to acetylation capacities (36, 37). Nonetheless,
individuals with high acetylation capacities might have an increased risk of lung
cancer (38).
The results of the present study indicate that polymorphisms in GSTM2 and
N/4T2 may both be involved in interindividual differences in the formation of
aromatic-DNA adducts in MNC. Their influence on adduct levels in BAL-cells need
further study in larger study-populations. Nonetheless, the present study suggests
thdt the N/\T2 genotype is involved in adduct formation in BAL-cells of smoking
individuals.
References
1. IARC (1^87) Overall evaluation of carcinogenicity: an updating of IARC monographs
1-42. Monographs on the evaluation of the carcinogenic risk of chemicals to humans.
IARC Sci. Publ. Suppl. 7
2. Hall, M, Grover, P.L. (1990) Polycyclic aromatic hydrocarbons: metabolism, activation
and tumour initiation. In: Cooper, C.S., Grover, P.L. (eds) Chemical Carcinogenesis and
Mutagenesis. Vol. I, pp 327-372, New York, USA, Raven Press.
3. Dennisenko, M.F., Pao, A., Tang, M., Pfeifer, G.P. (1996) Preferential formation of
r>onzo|a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 18, 430-432.
4. Bartsch, H., Hietanen, E. (1996) The role of individual susceptibility in cancer burden
related to environmental exposure. Environ. Health. Persp.. 104, suppl. 3, 569-577.
5. Ketterer, B., Harris, J.M., Talaska, G., Meyer, D.J., Pemble, S.E., Taylor, J.B., Lang, N.P.,
Kadlubar, F.F. (1<W2) The human glutathione S-transferase supergene family, its
polymorphism and its effects on susceptibility to lung cancer. Environ. Health
Perspect. 98,87-94.
96
6. Zhong, S., Howie, A.F., Kerterer, B., Taylor, J., Hayes, J.D., Beckett, G.J., Wathen, C.G,
Wolf, C.R., Spurr, N.K. (1991) Glutathione S-transferase mu-locus: use of genotyping
and phenotyping assays to assess association with lung cancer susceptibility.
Carcinogenesis. 12,1533-1537.
7. Hirvonen, A., Husgafvel-Pursiainen, K., Attila, S. Vainio, H. (1993) The GS7M1 null
genotype as a potential risk modifier for squamous cell carcinoma of the lung.
Carcinogenesis, 14,1479-1481.
8. Seidegard, J., Pero, R.W., Miller, DC, Beattie, E.J. (1986) A glutathione transferase in
human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis. 7,
751-753.
9. Kihara, M., Kihara, M., Noda, K., Okamoto, N. (1993) increased risk of lung cancer in
Japanese smokers with class mu glutathione S-transferase gene deficiency- Cancer Lett..
71,151-155.
10. Nazar-Stewart, V., Motulsky, A.G., Eaton, D.L., White, E., Harming, S.K., Long, 7.-.T.,
Stapleton, A.G., Weiss, N.S. (1993) The glutathione S-transferase u polymorphism as a
marker for susceptibility to lung carcinoma. Cancer Res.. 53, 2313-2318.
11. Seidegard, J., Pero, R.W., Markowitz, MM., Miller, D C , Beattie, E.J. (1990)
Isoenzymen(s) of glutathione transferase (class mu) as a marker for the susceptibility to
lung cancer: A follow up study. Carcinogenesis. 11, 33-36.
12. Shields, P C , Bowman, ED., Harrington, A.M., Doan, V.T., Weston, A. (1993)
Polycyclic aromatic hydrocarbon-DNA adducts in human lung and cancer
susceptibility genes. Cancer Res.. 53, 3486-3492.
13. Rojas, M., Alexandrov, K., Cascorbi, I., Brockmoller, J., Likhachev, A., Pozharisski, K.,
Bouvier, G., Auburtin, C, Mayer, L, Kopp-Schneider, A., Roots, I., Bartsch, H. (1998)
High Beno[a]pyrene diol-epoxide DNA adduct levels in lung and blood colls Irom
individuals with combined CVPMI Ms/>//Msf>/-GST<VI /*()/*() genotypes.
Pharmacogenet. 8.109-118.
14. Kato, S., Bowman, ED., Harrington, A.M., Blomeke, B., Shields, P. (1995) Human lung
carcinogen-DNA adduct levels mediated by generic polymorphisms HI ww>, I. NatL
Cancer Inst. 87, 902-907.
15. Grinsberg-Funes, R.A., Singh, V.N., Perora, F.P., Bell, DA., Young, T.L., Dickey, C,
Wang, L.W., Santella R.M. (1994) Polycyclic aromatic hydrocarbon-DNA adducts in
smokers and their relationships to micronuclei levels and the glutathione S-transferase
Ml genotype. Carcinogenesis, 15, 2449-2454.
16. Ishiba, M., Hagmar, L., Rannung, A., Hogstedt, B., Alexandrie, A.K., Cartensen, U.,
Hemminki, K. (1994) Aromatic-DNA adducts, micronuclei and genetic polymorphisms
for CYPM J and GST1 in chimney sweeps, Carcinogenesis, 15,1347-1352.
17. Hou, S.M., Lambert, B., Hemminki, K. (1995) Relationship botwoon hprt mutant
frequency, aromatic-DNA adducts and genotypes for GSTM1 and NAT2 in bus
maintenance workers. Carcinogenesis, 16, 1913-1917.
18. Rothman, N., Shields, P C , Poirier, M.C., Harrington, AN., Ford, P., Strickland, P.T.
(1995) The impact of glutathione-S-transferase Ml and Cytochrome P45O 1A1
genotypes on white blood cell polycyclic aromatic hydrocarbon-DNA adduct levels in
humans. Mol. Carcinogenesis. 14, 63H68.
19. Peluso, M., Airoldi, L., Armelle, M., Marlone T., Coda, R., Malaveille, C, Giacomelli,
G., Terrone, C, Caserta, G., Vineis, P. (1998) White blood cell DNA adducts, smoking
and N/1T2 and GSTMI genotypes in bladder cancer: a case-controle study. Cancel
Epidemiol. Biomarkers and Prev., 7, 341-346.
20. D'Errico, A., Taioli, E., Chen, X., Vineis, P. (1996) genetic metabolic polymorphisms and
the risk of cancer: A review of the literature. Biomarkers, 1,149-173.
21. Shields, P.G. (1993) Inherited factors and environmental exposures in cancer risk. J,
Occup.Med.. 32, 34-41.
22. Vineis, P., Caporaso, N., Tannenbaum, S.R., Skipper, P.L., Glogowski, J., Bartsch, H.,
Coda, M., Talaska, G., Kadlubar, F.F. (1990) Acetylation phenotype, carcinogen-
heamoglobin adducts and cigarette smoking. Cancer Res.. 50, 3002-3004.
23. Yu, M., Skipper, PL., Taghizadeh, K., Tannenbaum, S R., Chan, K.K , Henderson, B.E.,
Ross, R.K. (1994) acetylator phenotype aminobiphenyl-hemoglobin adduct levels and
97
Grne/ic po/ymo/p/i/sms m CS7MJ and N/4T2
bladder cancer risk in white, black, and Asian men in Los Angelos, California. I. Natl.
Cancer Ins tit. 86, 712-716.
24. Vineis, P., Bartsch, H., Caporaso, N., Harrington, A.M., Kadlubar, F.F., Landi, M.T.,
Malaveille, C , Shields, P.G., Skipper, D., Talaska, G. (1994) Genetically based N-
acetyltransferase metabolic polymorphism and low-level environmental exposure to
carcinogens, Nature. 369,154-156.
25. Boyum, A. (1976) Isolation of lymphocytes, granulocytes and macrophages. Scand. J.
Immunol.. 5,9-15.
26. Godschalk, R.W.L., Maas, L.M., Van Zandwijk, N., Van t Veer, L.J., Breedijk, A.,
Verhaert, J., Kleinjans, J.C.S., Van Schooten, F.J. (1998) Differences in aromatic-DNA
adduct levels between alveolar macrophages and subpopulations of white blood cells
from smokers. Carcinogenesis. 19, 819-825.
27. Brockmoller, J., Gross, D., Kerb, R., Drakoulis, N., Roots, I. (1992) Correlation between
trans-stilbene oxide glutathione conjugation activity and the deletion mutation in the
glutathione S-transferase class Mu gene detected by polymerase chain reaction.
B i J O l . , 43,647-650.
28. Doll, M.A., Fretland, A.J., Deitz, A.C., Hein, D.W. (1995) Determination of human
/VMT2 acetylator genotype by restriction fragment length polymorphism and allele-
Hpecific amplification. Anal. Biochem.. 321, 413-420.
29. Lin, 11.]., Han, C-Y., Lin, B.K., Hardy, S. (1993) Slow acetylator mutations in the human
polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics and whites:
application to metabolic epidemiology. Am. I. Hum. Genet.. 52, 827-834.
30. I loffmann, D., Hoffmann, I. (1997) The changing cigarette, 1950-1995. I. Tox. Environ.
Health, 50, 307-364.
31. Htilkicwicz, D., Grzybowska, E., Hemminki, K., Ovebro, S., Haugen, A., Motykiewicz,
d., ( Imi.i/.y, M. (1998) Modulation of DNA adduct levels in human white blood cells
and gunulocytes by CYP2/W, CVP2D6 and GS7M2 genetic polymorphisms. Mut. Res..
415,97-108.
32. Kawajiri, K., Nakashi, K., Imai, K., Yoshii, A., Shinoda, N., Watanabe, J. (1990)
Identification of genetically high risk individuals to lung cancer by DNA
polymorphisms of the cytochrome P4501/41 gene. FEBS Lett.. 263,131-133.
33. Whyatt, R.M., Santella, R.M., Jedrychowski, W., Garte, S.J., Bell, D.A., Ottman, R.,
Gladek-Yarborough, A., Cosma, G., Young, T.L., Cooper, T.B., Randall, M.C.,
Manchester, D.K., Perera, F.P. (1998) Relationship between ambient air pollution and
DNA damage in Polish mothers and newboms. Environ. Health. Perspect. 106 Suppl.
3, 821-826.
34. Hemminki, K., Dickey, C, Karlsson, S., Bell, D.A., Hsu, Y., Tsai, W.Y., Mooney, L.A.,
Savela, K., Perera, F.P. (1997) Aromatic DNA adducts in foundry workers in relation to
exposure, life style and CYP1/W and glutathione transferase Ml genotype.
Carcinogenesis. 18,345-350.
35. Gupta, R.C., Early, K. (1988) ^^p-adduct assay: comparative recoveries of structurally
diverse DNA adducts in the various enhancement procedures. Carcinogenesis, 9,1687-
1693.
36. Burgess, E.J., Treffort, J.A.P. (1985) Acetylator phenotype in patients with lung
carcinoma: a negative report. Eur. 1. Respir. Pis.. 67, 17-19.
37. Martinez, C , Agundez, J.A., Olivera, M., Martin, R., Ladero, J.M., Benitez, J. (1995)
Lung cancer and mutations at the polymorphic N/\T2 gene locus. Pharmacogenetics. 5,
207-214.
38. Cascorbi, I., Brockmoller, J., Mrozikiewicz, P.M., Bauer, S., Loddenkemper, R., Roots, I.
(1996) Homozygous rapid arylamine N-acetyl transferase (NAT2) genotype as a
susceptibility factor for lung cancer. Cancer Res.. 56,3961-3966.
Chapter 7 «
Aromatic-DNA adducts in human white blood cells and skin after
- dermal application of coal tar
R.W.L. Godschalk*, J.U. Ostertag*, E.J.C. Moonen',
H.A.M. Neumann^, J.C.S. Kleinjans', F.J. van Schooten'
* Department of Health Risk Analysis and Toxicology,
University of Maastricht, Maastricht, The Netherlands
2 Department of Dermatology,
Academic Hospital Maastricht, Maastricht, The Netherlands.
Cflwcer Epidemio/ogy, Biomarkers &• Prrpenfjon, PO/. 7pp 767-773,1998.
Abstract
A group of eczema patients topically treated with coal tar ointments was used as a
model population to examine the applicability of DNA adducts in white blood cell
(WBC) subpopulations as a measure for dermal exposure to polycyclic aromatic
hydrocarbons (PAH). Aromatic-DNA adducts were examined by -^P-postlabeling in
exposed skin and WBC-subsets and urinary excretion of PAH-metabolites was
determined to assess the whole body burden. Median urinary excretion of 1-
hydroxypyrene and 3-hydroxybenzo[a]pyrene were respectively 0.34 (range: 0.12-
1.57) and 0.01 (range: <0.01-0.04) umol/mol creatinine before dermal application of
coal tar ointments. After treatment for one week, these levels increased to
respectively 139.7 (range: 26.0-510.5) and 1.18 (range: <0.01-2.14), indicating that
considerable amounts of PAH were absorbed. Median aromatic-DNA adduct levels
were significantly increased in skin from 2.9 (range: 0.7-10.0) adducts per 10"
nucleotides before to 63.3 (range: 10.9-276.2) after treatment with coal tar, in
monocytes from 0.28 (range: 0.25-0.81) to 0.86 (range: 0.56-1.90), in lymphocytes
from 0.33 (range: 0.25-0.89) to 0.89 (range: 0.25-3.01) and in granulocytes from 0.28
(range: 0.25-0.67) to 0.54 (range: 0.25-1.58). A week after stopping the coal tar
treatment, DNA adduct levels in monocytes and granulocytes were reduced to 0.38
(range: 0.25-0.71) respectively 0.38 (range: 0.25-1.01), while adduct levels in
lymphocytes remained enhanced, 1.59 (range: 0.25-2.40). Although adduct profiles
in skin and WBC-subsets were not identical and adduct levels in WI3C were
significantly lower as compared with skin, total DNA adduct levels in skin
correlated significantly with adduct levels in monocytes and lymphocytes, but not in
granulocytes. Excretion of urinary metabolites during the first week of treatment
was correlated with the percentage of skin-surface treated with coal tar ointment
and decreased to background levels within a week after cessation of treatment. 3-
Hydroxybenzo(a]pyrene excretion, but not 1-hydroxypyrene, correlated
significantly with levels of DNA adducts in skin that comigrated with
benzo[a]pyrene-diol-epoxide-DNA. This study indicates that DNA adduct levels in
mononuclear WBC can possibly be used as a surrogate for skin DNA adduct levels
after dermal exposure to PAH.
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Introduction
Coal tar is a complex chemical mixture containing high concentrations of
polycyclic aromatic hydrocarbons (PAH), some of which have been found to be
carcinogenic in laboratory animals and are suspected to be carcinogenic for man (1).
Excesses of cancer in skin and scrotum were found in groups of workers handling
pitch, tar and oils, and these cohorts were mainly exposed to PAH via dermal
absorption (2). Non-occupational dermal exposure to PAH predominantly occurs via
coal tar based shampoos or cosmetics and in the treatment of skin diseases. For
example, psoriasis or eczema patients are often treated by dermal application of coal
tar ointments. Since exposures to PAH may involve health risks, interest has risen in
the development of biological markers to assess PAH-exposure in human
populations. A well known example is measuring the excretion profiles of PAH-
metabolites in urine, especially 1-hydroxypyrene (1-OH-pyrene) (3). However, levels
of urinary PAH-metabolites give no direct information about the dose that actually
interacts with DNA. The formation of these DNA adducts is thought to play a
crucial role in the development of cancer and other degenerative diseases (4).
Nowadays, the ^p.postlabeling procedure has emerged as a sensitive tool to assess
aromatic DNA adduct levels in small quantities of DNA, which makes this assay
suitable for human studies when limited material is available e.g. biopsy samples. In
tissues of laboratory rodents topically treated with PAH-containing complex
mixtures, high levels of aromatic-DNA adducts determined by ^p.postlabeling were
found in skin and internal organs (e.g. lung and heart), whereas adduct levels in
WBC were low as compared with tissue levels (5). PAH-DNA adducts were also
detectable by ^p.postlabeling and by immunological assays in human skin treated
with coal tar based ointments (6-8). In humans, however, internal organs are not
readily accessible and therefore white blood cells (WBC) are often used as surrogate
source of DNA. WBC-subpopulations (monocytes, lymphocytes and granulocytes)
vary in metabolic and repair capacity, life span and relative quantities among one
another and as compared with other cells/organs. Therefore, it is still controversial
whether WBC or specific WBC-subsets reflect the binding of aromatic compounds to
the DNA of tissues in which eventually rumors will be induced. Although reports
that investigated a possible link between therapeutic use of coal tar and increased
cancer rates are not conclusive (9), coal tar treated patients form a proper study
population to investigate the relationship between target and surrogate source of
DNA, since the potential target tissue (i.e. skin) can easily be obtained by biopsy.
Other studies focused on DNA adduct levels in WBC and predominantly lung-tissue
from smokers. Overall, in studies that used total white blood cell DNA no significant
correlations were observed (10, 11), whereas DNA adduct levels in mononuclear
blood cells seemed to indicate the biologically effective dose in lung tissue more
reliably (12). So, understanding the possibilities and limitations of DNA adduct
analysis in WBC subpopulations may increase their applicability as a measurement
for exposure to PAH and to estimate adduct levels in nonavailable organs.
Therefore, we investigated aromatic DNA adduct levels in WBC-subpopulations
(monocytes, granulocytes and lymphocytes) and skin-biopsies of ten eczema patients
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before and after treatment with coal tar ointments covering 20-86% of their body-
surface. Furthermore, urinary excretion of 1-OH-pyrene and 3-
hydroxybenzo[a]pyrene (3-OH-B|a]P) was assessed as indicators for the whole body
dose.
Materials & Methods
Samp/e co//«-f»0H o/pafiWtrs froi/ed u»ifJi coa/ tor basetf oinfmcnrs
Three male and 7 female diagnosed atopic eczema patients (age 34±5 yr, range: 18-
52 yr.) were treated with coal tar ointments for 21 ±9 days (range: 7-33 days),
covering 20-86% of their body surface. Treatment started twice a day with 3% pix
lithantracis in petrolatum or in 10% zinc oxide plus 90% petrolatum during the first
2-3 days. In all cases, this treatment was well-tolerated and was intensified by
applying twice a day 5% pix lithantracis in petrolatum/zinc oxide-petrolatum for
another 2-3 days. Subsequently, a 10% coal tar ointment was applied until the
patient was discharged from the hospital. After informed consent, punch biopsies (4
mm) were obtained under local anesthesia, before treatment (t=0) and after one
week of continuous application of coal tar ointments (t=7) from treated areas. Biopsy
samples were stored at -20°C until DNA isolation. Ten ml of peripheral blood were
obtained by venapuncture at several time points: before treatment (t=0), at 7 days of
continuous treatment (t=7) and 7 days after the end of treatment (t=7x).
Polymorphonuclear cells (granulocytes) were separated from mononucleated white
blood cells (MNC, i.e. monocytes plus lymphocytes) by gradient centrifugation on
lymphoprep according to Beyum (13). Both fractions were washed with PBS. The
granulocyte fraction was treated with lysis buffer (155 mM NH^Cl, 10 mM KHCO-,,
10 mM EDTA, pH 7.4) to lyse the erythrocytes, and subsequently washed with PBS.
Monocytes and lymphocytes were resuspended in medium (RPMI 1640
supplemented with 10% FCS, 2 mM L-glutamin, 10 IU/ml penicillin and 10 ug/ml
streptomycin) at a concentration of ca. lxlCK" cells per ml and separated by
adherence of monocytes to plastic T.C.-flasks for 40 minutes at 37°C. Cells were
stored at -20°C until DNA-isolation. Morning urine was obtained at t=0, t=l, t=7 and
t=7x and stored at -20°C for analysis of the urinary metabolites 1-OH-pyrene and 3-
OH-B[a]P.
Pi4H conten/ o/coa/ tor (pur /tf/ianfracis,) boserf o/nfmen/s
To determine the PAH levels of the coal tar ointments with which the patients were
treated, extracts of the ointments were analyzed for the 16 EPA-listed PAH. First, 0.2
g ointment was extracted 5 times with 3 ml hexane. Fractions were pooled and
hexane was added to obtain a final volume of 50 ml. Subsequently, 200-500 pi were
cleaned-up using a 0.5g silica-column (0: 5 mm). After evaporation of the eluate, the
residue was dissolved in acetonitrile and concentrations of the EPA-listed PAH were
measured by reversed-phase HPLC with fluorescence detection using excitation and
emission wavelengths of respectively 250 nm and >350 nm as described by Van
Maanen et al. (14). The individual PAH congeners were identified and quantitated
by comparing retention times and peak areas with those of selected standards. Since
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all ointments were based on pix linthantracis, similar PAH profiles were found for
the different ointments (3%, 5% and 10%). The relative distribution of PAH-
concentrations per percent of pix lithantracis was respectively naphthalene: 375±23
(in mg/kg), acenaphthylene: not detected, acenaphthene: 120±9, fluorene: 15±21,
phenanthrene: 63±4, anthracene: 17±10, fluoranthene: 80±6, pyrene: 60±4,
benzo[a]anthracene: 43±3, chrysene: 55±4, benzo[b]fluoranthene: 53±5,
benzo[k|fluoranthene: 23±1, benzo[a]pyrene: 52±3, dibenzo[a,h] anthracene: 74±8,
benzo|g,h,i]perylene: 51±3, indeno[l,2,3-c,d)pyrene: 24±22.
DAM
Biopsy samples were cut into small pieces and lysed overnight with 2.5 ml SDS (1%),
followed by treatment with RNase A (100 ug/ml) and Tl (50 U/ml) for 30 minutes,
then proteinase K was added to obtain a final concentration of 1 mg/ml and
incubated at 37°C for 4 hours. WBC-subpopulations were lysed with 2.5 ml
SDS/NKP (75 mM NaCl, 25 mM EDTA, 50 ug/ml proteinase K, 1% SDS) and
incubated for 4 hours at 37°C. Samples were extracted with phenol: chloroform:
isoamylalcohol (25:24:1, v/v/v) and chloroform: isoamylalcohol (24:1, v/v)
respectively. DNA was precipitated with two volumes of cold ethanol after addition
of 1/30 volume 3M sodium acetate, pH 5.3 and washed with 70% ethanol.
Subsequently, DNA was dissolved in 2 mM Tris, pH 7,4. Concentration and purity
were determined spectrophotometrically by absorbance at 230, 260 and 280 nm. The
final volume was adjusted to achieve a DN A-concentration of 2 mg/ml.
The ^P-postlabeling assay was performed as described by Reddy and Randerath (15)
with some modifications. DNA (10 ug) was digested using micrococcal endonuclease
(0.4 Units) and spleen phosphodiesterase (2.8 ug) for 3 hours at 37°C. Subsequently,
half of the digest was treated with nuclease PI (6.3 ug) for 40 minutes at 37°C. The
modified nucleotides were labeled with ly-^p]-ATP (50 uCi/ sample) by incubation
with T4-polynucleotide kinase (5.0 Units) for 30 minutes at 37°C. [Y-^P]-ATP was
synthesized in the laboratory using carrier free ^p (Dupont, Brussels). NP1-
efficiency and ATP-excess were checked with an aliquot of the NP1 treated fraction
by one-dimensional ehromatography on poly(ethyleneimine) (PEI)-cellulose sheets
from Merck, Germany (solvent: 0.12 M NaHiPOj pH 6.8). Radiolabeled adduct
nucleotide biphosphates were separated by ehromatography on PEI-cellulose sheets
from Machery Nagel (Germany). The following solvent systems were used: Dl, 1 M
Nah^POj pH 6.5; D2, 8.5 M urea, 5.3 M lithium formate pH 3.5; D3, 1.2 M lithium
chloride, 0.5 M Tris, 8.5 M urea pH 8.0; D4, 1.7 M Nar^PO, pH 6.0. In each
experiment, 3 standards of PH]BPDE modified DNA with known modification
levels (1 per 10~, 10", 10"* nucleotides) were run in parallel for quantification
purposes. Quantification was performed by using phosphor-imaging technology
(Molecular Dynamics'*, Sunnyvale, CA, USA) with a detection limit of <1 adduct
per 1C nucleotides. The remaining half of the digest was used to determine the final
amount of DNA in the assay; the normal nucleotides (nt.) were labeled with [y-^Pl-
ATP (15 uCi/ sample) by incubation with T4-polynucleotide kinase (2.5 Units) for 30
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minutes at 37°C Nucleotides were separated by one-dimensional chromatography
on PEI-cellulose sheets from Merck (solvent: 0.12 M NaHiPO, pH 6.8); samples with
apparent protein or RNA contamination were discarded. A dAp standard (27.5
pmole/ul) was labeled in each experiment for quantification purposes.
Cochromatography was studied by analyzing the distance between the radioactivity-
peaks of the origin and the putative BPDE-DNA adduct, using lmageQuant software
(Molecular Dynamics™, Sunnyvale, CA, USA). Mean interassay variation was 17%
(range: 0.3%47%).
3-OH-BMP "» wrinr
Detection of 1-OH-pyrene and 3-OH-B[a)P in urine was performed as described by
Jongeneelen et al. (3). The method consisted of enzymatic hydrolysis with 6-
glucuronidase and arylsulphatase, solid phase extraction on a Sep-pak C-18 cartridge
and elution with methanol. Reversed phase HPLC (Kratos solvent delivery system;
Column: Hypersil 5 ODS) and fluorescence detection (Perkin-Elmer LS-30) were
employed, using excitation and emission wavelengths of 253 nm and 423 nm for 3-
OH-B[a]P and respectively 232 nm and 384 nm for 1-OH-pyrene. Peak area was used
for quantification. Concentrations were corrected for creatinine excretion, which was
measured using a diagnostic kit of Sigma (no. 555-A). The detection limit was 2(H) ng
3-OH-B[a]P and 80 ng 1-OH-pyrene per liter urine, using a signal / background ratio
of 3. Day-to-day variation and intra-assay variation were respectively 14% and 6%.
Sfaf/sfics
Results are presented as median and range. Overall, due to the relatively small
number of observations (n=10), nonparametric-tests for paired samples were
applied. Spearman rank correlations were used to assess the relationships between
DNA adduct levels in blood cells, skin biopsy samples and urinary excretion of 1-
OH-pyrene and 3-OH-B[a]P. P<0.05 was considered significant.
Results
/Idducf pro/j/^ s an</ /ew/s ;« sttn friops/is a«d WBC
After one week of treatment with coal tar ointments, aromatic-DNA adducts
were readily detectable by 32p-postlabeling in skin DNA as well as in DNA obtained
from WBC-subpopulations. Adduct profiles in skin and WBC, however, were not
completely identical. As shown in Figure 1, in both skin and WBC DNA an adduct
was found that comigrated with the pH)BPDE-DNA adduct standard. Furthermore,
in skin a diagonal radioactive zone (DRZ) was detected with high levels of
radioactivity close to the origin. Whereas, in WBC no clear DRZ's were seen, but
distinct adducts also other than the putative BPDE-DNA were seen at the upper
right corner of the TLC-plates (Figure 1). No adduct spots or DRZ's could be detected
in WBC subpopulations before treatment with coal tar ointments, except for one
individual who smoked 10 cigarettes per day. On the other hand, in all skin-samples
before treatment an adduct spot was detectable (Figure 1). Quantitatively, median
DNA adduct levels in skin were ca. 20-fold
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Figure 1. DNA adduct profiles obtained by -^P-postlabeling in WBC-subpopulations and skin DNA at
t=0 (before treatment), t=7 (after 1 week of treatment) and t=7x (1 week after stopping treatment).
Origins are located at the lower left corner of each panel and were excised before analysis. Panel at the
lower right corner of figure represents a [•'HIBPDE-DNA adduct standard with a modification level of
1 adduct per KV'nuclootides.
increased due to treatment for one week (respectively 2.89 (range: 0.66-10.04 adducts
per 10* nt. before and 63.3 (range: 10.9-276.2) after treatment with coal tar, p=0.005).
Furthermore, DNA adduct levels were increased in monocytes (0.28 (range: 0.25-
0.81) us. 0.8r> (range: 0.56-1.90), p=0.04), lymphocytes (0.33 (range: 0.25-0.89) PS. 0.89
(range: 0.25-3.01, p=0.04) and granulocytes (0.28 (range: 0.25-0.67) i>s. 0.54 (range:
0.25-1.58), p=0.05). Cessation of coal tar treatment for one week resulted in a
significant reduction of DNA adduct levels in monocytes (0.38 (range: 0.25-0.71)) and
granulocytes (0.38 (range: 0.25-1.01)), but adduct levels in lymphocytes were still
elevated (1.59 (range: 0.25-2.40) (Table I and Figure 2).
Although the number of volunteers was low (n=10), a clear effect of gendtr On
aromatic DNA adduct levels in skin DNA after treatment with CT-ointments WU
found; in males, median adduct levels (13.6 (range: 10.9-47.1), n=3, 70±21% of skin
surface was treated) were ca. 8 times lower as compared with female volunteers
(106.7 (range: 23.1-276.2), n=7, p=0.03, 65±24% of skin surface was treated). Analysis
of the relationship between skin and WBC showed that total DNA adduct levels in
skin were related to adduct levels in lymphocytes (rs=0.65, p<0.001) and monocytes
(rs=0.74, p=0.005), but not with granulocytes (rs=0.44, p=0.07)(Figure 3). The absence
of a relationship with granulocyte-DNA can be explained by the observation that
adduct levels in granulocytes were only increased above background in individuals
that were treated with coal tar ointment for >70% of their body surface (6/10),
whereas adducts in skin were increased in all individuals irrespective of the
percentage of treated body surface. Dose-responses (percentage of treated skin
surface as measure of dose, since the amount of ointment per surface area was
constant) were observed if adduct levels before treatment were included in the
analysis (monocytes: r=0.61, p=0.034, lymphocytes: p=0.51, p=0.022, gr.inulocytes:
r=0.63, p=0.003). However, after exclusion of pre-treatment levels from the analysis,
with increasing dose no clear increased adduct levels were observed in WBC-subsets.
o/ l-OH-pi/rcne and 3-OH-B/ajP in
Before treatment, median baseline urinary concentrations of 1-OH-pyrene and
3-OH-B[a]P were respectively 0.39 (range: 0.12-1.57) and 0.01 (range: <O.O1-().O4)
umol/mol creatinine. These levels were significantly increased after topical
application of a 3% coal tar ointment for 1 day (96.5 (range: 21.5-493.2) and 0.45
(range: <0.01-1.59)). Continuation of treatment for one week was reflected by a
further increased to respectively 139.7 (range: 26.0-510.5) and 1.18 (range: <0.01-2.14),
although these increases were not significant. Cessation of treatment resulted in a
quick reduction of urinary concentrations of both PAH-metabolites (Table I); after
one week, concentrations were back to baseline levels. The excretion of 1-OH-pyrene
and 3-OH-B[a]P during the first week (t=0,1 and 7) was related to the administered
dose (expressed as percentage of skin-surface treated with coal tar ointment; 1-OH-
pyrene: rs=0.80, p<0.001 and 3-OH-B|a]P: rs=0.63, p=0.002), but after exclusion of the
pretrearment levels from the analysis, these relationships were lost (1-OH-pyrene:
rs=0.34, p=0.23 and 3-OH-B[a]P: rg=0.16, p=0.70). Overall, 1-OH-pyrene and 3-OH-
B[a]P excretion were interrelated (rs=0.61, p<0.001), but interindividual variations
were observed and individuals with high levels of 1-OH-pyrene excretion did not
necessarily have high 3-OH-B[a]P excretion. The ratio between 1-OH-pyrene and 3-
OH-B[a]P concentrations showed inter-individual variation (range: 44-650), but no
intra-individual variations (ratios at t=l and t=7 were highly correlated; rs=0.92,
p<0.001).
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Table I. Overall results of ^P-postlabeling (adducts per 10* nucleotides) and urinary excretion of 1-
OH-pyrene or 3-OH-B[a]P (umol per mol creatinine) at several time points. Results are presented as
median and range.
Before
Treatment
DNA adducts in:
Skin 2.9 (0.7-10.0)
Monocytes 0.28 (0.25-0.81 )•
Lymphocytes 0.33 (0.25-0.89)
Granukxytes 0.28 (0.25-0.67)
1 day of
Treatment
*
-
1 week of
Treatment
63.3 (10.9-276.2)-
1 week after
Treatment
0.86 (0.56-1.90)*0.38 (0.25-0.71)*
0.89(0.25-3.01)
0.54(0.25-1.58)
1.59(0.25-2.40)
0.38(0.25-1.01)
Urinary excretion of PAH-metabolites
l-OH-pyrene 0.39(0.12-1.57)
3-OH-B|a|P 0.01 (<0.01-0.04)
96.5 (21.5-493.2)139.7 (26.0-510.5) 1.25 (0.51-6.60)
0.45(<0.01-1.59)+ 1.18(<0.01-2.14) 0.01 (<0.01-0.05)
Ovtrall n-10, except for' n-6, • n-7 and * n-8.
3.5
»^ 3.0
©
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Figure 2. Aromatic-DNA adduct levels in WBC-subpopulations (monocytes=M, lymphocytes=L and
Hranulocytes=C'i) Jt different time points, obtained by nuclease PI enriched -^P-postlabeling. Boxes
encompass the 25*^-75'" percontiles; middle lines, medians; whiskers, 10"*-90* percentiles; o, values
beyond lO*'' or 90»h percentiles.
Urinuy excretion of 1-OH-pyrene and 3-OH-B[a]P at the time of biopsy was not
related to the total amount of DNA adducts in skin (l-OH-pyrene z*>. DNA adducts
in skin: rs=-0.2, p=0.55; 3-OH-B(a]P r>s. DNA adducts in skin: rs=0.11, p=0.73).
However, the level of 3-OH-B[a]P excretion at the time of biopsy correlated
significantly with the level of adducts in skin that comigrated with the BPDE-DNA
adduct spot (rs=0.75, p=0.025) (Figure 4).
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Figure 3. Quantitative relationship between DNA adduct levels in skin DNA and DNA obtained from
WBC-subsets from the same individual, before and after treatment with coal-tar ointments.
Relationship between lymphocytes and skin (rg=0.65, p<0.005), monocytes and skin (rg'0.74, p»0.006),
granulocytes and skin (rg=0.44, p=0.07).
Discussion
In the present study, dermal application of coal tar based ointments
significantly increased aromatic-DNA adduct levels in human skin and WBC-
subpopulations. Although aromatic DNA adduct levels in WBC subpopulations
were lower as compared to DNA adduct levels in skin, significant correlations were
observed between adduct levels in peripheral blood lymphocytes or monocytos and
skin-DNA. Furthermore, DNA adducts in monocytes and granulocytes were less
persistent as compared with adducts in the lymphocyte fraction. Urinary excretion of
monohydroxylated PAH-metabolites indicated that large amounts of PAH were
absorbed, and the levels of 3-OH-B[a]P excretion correlated with the level of the
putative BPDE-DNA adduct in skin DNA.
After topical application of coal tar for one week, diagonal radioactive zones
(DRZ) were observed in skin DNA, indicating a broad spectrum of different
aromatic-DNA adducts. Also, an adduct spot that comigrated with the PH)BPDE-
DNA standard was found. Although chromatography on TLC is unable to identify
adducts formed by complex mixtures, ^p.HPLC analysis of mouse skin DNA
demonstrated that the retention time of the major coal tar induced adduct closely
resembled that of the adduct formed by B[a]P (16). Quantitatively, aromatic DNA
adduct levels were 10-fold higher as the levels previously reported in skin of coal tar
treated psoriasis patients (6, 7). Although differences in exposure cannot be
excluded, these adduct levels might be underestimated, because in the study of
Zhang et al. (6) additional immunofluorescence techniques indicated that the adduct
levels could be higher than 1 adduct per 10*> nt. Aromatic-DNA adduct levels were
higher in female patients as compared with male patients. Similarly, enhanced
adduct levels were reported in lung (17, 18) and cells obtained by bronchoalveolar
lavage (19) of female smokers as compared with male smokers. In B[a]P treated skin
of C3H-mice, the decay curves of anti-BPDE related DNA adducts was steeper in
male as compared to female rodents (20). Thus, human as well as rodent studies
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suggest that women are at a greater risk of PAH induced malignancies, which is
confirmed by epidemiological studies on smoking individuals (21,22).
Although coal tar treated patients are highly dermally exposed to PAH,
Pavanello et al. (23) and Santella et al. (24) were unable to find significantly increased
aromatic-DNA adduct levels in respectively lymphocytes and total WBC from coal
tar treated psoriasis patients. On the contrary, in the present study DNA adducts
were readily detectable in WBC-subpopulations of eczema patients after 1 week of
continuous application of coal tar ointments. After cessation of coal tar treatment, a
quick decrease of aromatic-DNA adduct levels was found in monocytes and
granulocytes, which is in line with the half-lives of these cell-types in peripheral
blood (hours-days). In lymphocyte-DNA, aromatic-DNA adduct levels were still
elevated after 1 week. Unfortunately, this period is too short to calculate the
persistence of DNA adducts in lymphocytes. Results of Pavanello et al. (23) and
Paleologo et al. (25) using ELISA for adduct quantitation, showed a significant
reduction over a period of 2-5 months after the end of coal tar therapy. Similarly,
Mooney et al. (26) estimated the half-life of tobacco-smoke related DNA adducts in
lymphocytes between 9 to 13 weeks following smoking cessation.
The applicability of DNA adducts in WBC to assess exposure to carcinogens or
as a measure of the biologically effective dose in relevant tissues is still a matter of
debate. Most studies that tried to validate carcinogen-DNA adduct levels in WBC as
a measure for adduct levels in potential target tissues focused on smoking
individuals (10-12, 27). In the present study, coal tar exposed eczema patients were
used as a model population and aromatic-DNA adduct levels in monocytes and
lymphocytes, but not in granulocytes, were found to be significantly correlated with
adduct levels in skin DNA. Aromatic-DNA adducts in granulocytes and monocytes
disappeared quickly after cessation of exposure. Therefore, for biomonitoring
purposes it might be important to use lymphocytes as a surrogate source of DNA
with more persistent adduct levels. In all WBC subpopulations lower adduct levels
were found as compared with adduct levels in skin DNA, which indicates that DNA
adducts in WBC will probably result in an underestimation of the biologically
relevant dose after dermal exposure to PAH-mixtures. Nonetheless, the results of the
present study indicate that peripheral blood lymphocytes are probably a valid
surrogate for estimating the levels of aromatic-DNA adducts in skin. However,
influences of different exposure routes on adduct formation in target as well as
surrogate DNA should be further investigated. Furthermore, no clear dose-response
relationship was observed; adduct levels in monocytes and lymphocytes were
increased in individuals with the lowest exposure (ca. 20% of their body-surface
covered with coal-tar ointment), but did not further increase if higher exposures
(>70%) were applied. A possible explanation is that at low/moderate exposure
levels, adduct formation is proportional to dose, but at higher levels saturation may
occur as recently demonstrated in environmentally (28) and occupationally exposed
subjects (28,19) and smokers (19).
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Figure 4. Relationship between putative BPDE-DNA adduct levels in skin DNA and the excretion of 3-
hydroxybenzo[alpyrene at the time of biopsy.
The excretion of 1-OH-pyrene is considered to be a well established indicator
for total exposure to PAH (3). As expected, urinary excretion of 1-OH-pyrene and 3-
OH-B(a]P was increased after 1 day and 1 week of treatment. Even though B|.i]P and
pyrene were administered in nearly equal levels, the urinary levels of 1-OH-pyrene
were more than 150 times greater than the levels of 3-OH-B[a]P. During the first
week of exposure the level of excretion was correlated with the surface-area that was
treated with coal tar ointment, but after exclusion of the pretreatment measurements
(t=0) from the analysis these relationships were lost. However, no corrections were
made for differences between anatomical sites that may influence the total uptake of
PAH and consequently concentrations of PAH-metabolites in urine (29).
Furthermore, urinary concentrations of PAH-metabolites may eventually decrease
during continuation of coal tar treatment (30). The levels of 1-OH-pyrene excretion
were higher in patients of the present study as compared with individuals that are
occupationally exposed to PAH mixtures (31-33). Overall, the excretion of 1-OH-
pyrene was correlated with the excretion of 3-OH-B[a]P, but individuals with the
highest levels of 1-OH-pyrene excretion did not necessarily have high 3-OH-B|a]P
excretion. Grimmer et al. (34) suggested that invariant interindividual differences in
PAH metabolite profiles could possibly form a suitable tool to estimate the
individual cancer risks at PAH exposed working places. An invariant PAH-
metabolite profile may indicate an individual and invariant set of PAH-metabolizing
enzymes producing a certain ratio of carcinogenic and non-carcinogenic PAH-
metabolites. Carcinogenic PAH may covalently interact with DNA, whereas non-
carcinogenic metabolites are excreted in urine or feces. Therefore, a correlation
between distinct urinary metabolites and DNA adduct formation can be expected.
Indeed, in the present study the excretion profile of 1-OH-pyrene i*. 3-OH-B[a]P
concentrations showed significant interindividual variation, but low intraindividual
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variations. Moreover, 3-OH-B[a]P excretion significantly correlated with the level of
the putative BPDE-DNA adduct in skin DNA. Thus, it can be suggested that urinary
profiles of monohydroxylated metabolites may reflect exposure to PAH and the
binding of reactive metabolites to DNA, and may therefore play a role in cancer risk
assessments. However, further confirmation is needed.
In conclusion, monitoring PAH-DNA adduct levels in mononuclear WBC by
^P-postlabeling can be a useful molecular index for the quantitative estimation of
the biologically effective dose in relevant tissues. However, the sensitivity of DNA
adducts in WBC subpopulations as a measure of exposure is limited. For that
purpose, measurements of urinary PAH-metabolites seem to be more sensitive.
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Abstract
Background: The cellular response to carcinogen induced DNA damage is often •
p53-mediated cell cycle arrest to provide time for DNA repair or to direct damaged
cells into apoptosis. We examined the impact of the GSTM/ polymorphism on DNA
adduct levels and p53 accumulation in lymphocytes of healthy volunteers HI I'l/rn
exposed to benzo[a]pyrene (B[a]P) diol-epoxide (BPDE) and in skin of atopic eczema
patients before and after topical treatment with coal-tar ointments for one week.
Methods: DNA adduct levels were determined by immunocytochemical staining
(ICC) and 32p-postlabeling. P53 accumulation was studied by ICC. CS7M1
genotypes were assessed by PCR. Additionally in the eczema patients, the internal
dose of polycyclic aromatic hydrocarbons was assessed by urinary 1-hydroxypyrene
and 3-hydroxy-B[a]P excretion. Results: In cultured lymphocytes treated with 2.5
uM BPDE for 18 hours, increased levels of p53 were found, which were correlated
with BPDE-DNA adduct levels assessed by ICC (rs=0.66, P<0.001) and -^P-
postlabeling (rs=0.56, P<0.001) and appeared to be higher in GSTMJ(-/-) than in
GSTM7(+) subjects (P=0.003). In skin biopsies of eczema patients, median DNA
adduct levels were increased from 2.9 adducts per 10" nucleotides (range: 0.7-10.0)
before treatment, to 63.3 adducts per 10* nucleotides (range: 10.9-276.2, P=0.005)
after treatment. P53 was elevated in 7/10 patients and a correlation was observed
between p53 and DNA adduct levels (rs=0.50, P=0.029). GS7M1(-/-) subjects
contained higher levels of p53 in the stratum basale than GS7'M1(+) individuals
(P=0.026), whereas the impact of GSTM1 on DNA adduct levels did not reach
statistical significance. Moreover, highest urinary levels of 1-hydroxypyrene were
found in GSTM1(+) patients, but no such effect was found on 3-hydroxy-B[aJP
levels. Conclusion: These results indicate that p53 accumulation and CSTMJ may
act in concert as protective mechanisms against PAH induced DNA damage in
human cells.
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Introduction
Polycyclic aromatic hydrocarbons (PAH) are well known ubiquitous
environmental carcinogens, of which benzo[a|pyrene (B[a]P) is the most studied one.
Benzo[a)pyrene-diol-epoxide (BPDE) is thought to be the ultimate carcinogenic
metabolite of B[a]P and covalent interactions of BPDE with DNA may be involved in
carcinogenesis (1). For instance, BPDE-DNA adduct formation in skin was correlated
with the initiation of skin cancer in rodent models (2), and inhibition of adduct
formation resulted in decreased carcinogenicity of B(a]P (3, 4). One of the cellular
preventive mechanisms against chemically induced cancers is accumulation of p53,
which inhibits the cell cycle to provide sufficient time for efficient DNA repair (5)
and may also contribute to apoptosis (6, 7). Thus, p53 accumulation may prevent the
onset of carcinogenesis by selection in favor of efficiently repaired cells, against
heavily damaged cells. The important role of wild type p53 in prevention of human
carcinogenesis is especially seen in individuals with inherited defects in one of the
;>5.3 alleles (I.i-Fraumeni syndrome), who are predisposed to cancer (8). Also in
animal models, mutant or absent ;>53 gene alleles resulted in a higher frequency of
spontaneous tumor development (9). Thus, p53 plays an important role in
maintaining the integrity of the genome after damage has occurred.
In addition, DNA damage can be avoided by other preventive mechanisms. For
example, DNA reactive compounds may be inactivated by glutathione; the
electrophile covalently bound to glutathione can be excreted and is no longer toxic.
This reaction is mediated via glutathione S-transferase Ml (GSTM1), which is known
to be polymorphic in humans. The GSTM7 gene locus contains two expressing genes
(1A and IB) and a null allele (10). It is thought that the gene-product of GSTM1 is
involved in the inactivation of epoxides like BPDE (11). Therefore, subjects with
low/no activity of GSTM1-1 or subjects with the GSTM2 null allele may have
increased aromatic DNA adduct levels in target cells (10, 12). Although in human
skin, GST isoenzymes of the Mu-class are present in relatively low concentrations
(13), in the stratum basaie of normal human epidermis clear immunohistochemical
staining for GST's of the Mu-class was observed (14).
In the present study, we investigated the relationship between the level of DNA
damage induced by PAH and subsequent accumulation of p53, m p/fro in cultured
lymphocytes of healthy volunteers and i» p/w in skin of eczema patients treated
with coal-tar ointments for one week. Furthermore, the influence of the GSTM1
genotype on adduct formation and p53 accumulation was investigated. Urinary
excretion of l-hydro\ypyrene and 3-hydroxy-B[a]P was determined in coal-tar
treated patients to assess the whole body burden to PAH.
Materials & Methods
fn rifro <\v;H>snrr c>f/i/mf>/i<vyf(*s um/ s/irft* j
Lymphocytes of 55 healthy volunteers (9 men, all nonsmokers; 46 women, 39
nonsmokers and 7 smokers; age ranged from 20 to 30 years) were isolated by
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gradient centrifugation from 10 ml of heparinized venous bkxxl as described by
Boyum (15). Cells were cultured (cell concentration ixlOVml) in RPM1 1640 medium
supplemented with 10% Fetal Calf Serum, L-glutamine, UK) U/ml penicillin and UK)
ug/ml streptomycin in the presence of 50 ug phytoheamagglutinine/ml medium.
After 24 hours of incubation at 37°C, (±)-anti-benzo[a|pyrene-diol-epo\ido (Midwest
Research Institute, USA) was added at a final concentration of 2.5 uM (n=44), or
DMSO was added as a negative control (n=ll) and incubations wen? continued for
18 hours at 37°C. After the incubations, cells were washed with ice-cold PBS and
hypotonized with 75 mM KC1 for 30 min at 4°C Nuclei were fixed by adding
methanol: acetic acid (3:1), and were pipetted on microscope-slides. Slides were air-
dried overnight.
/f co/ZirftoM o/afopic fC2fm<j ;wfu7i/s /rratai u»»f/j aw/ tar htseii oiri/rrioi/s
Three male and seven female diagnosed atopic eczema patients (age 34±5 yr., range:
18-52 yr.) were treated with coal tar ointments for 21 ±9 days (range: 7-33 days),
which covered 20-86% of their btxiy surface. Treatment started twice a day with 3%
pix lithantracis in petrolatum or in 10% zinc oxide plus 90% petrolatum during the
first 2-3 days. In all cases, this treatment was well-tolerated and was intensified by
applying twice a day 5% pix lithantracis in petrolatum/zinc oxide-petrolatum for
another 2-3 days. Subsequently, a 10% coal tar ointment was applied until the patient
was discharged from the hospital. After informed consent, punch biopsies (4 mm)
were obtained under local anesthesia, two before treatment (t=0) and two after one
week of continuous application of coal tar ointments (t=7) from treated areas only.
One biopsy sample per individual was stored at -20°C until DNA isolation. The other
biopt was fixed in formalin and subsequently inbedded in paraffin. Sections of 5 um
were cut and placed on coated slides. Morning urine was obtained at t=0, t=l and t=7
days and stored at -20°C for analysis of the urinary metabolites 1-hydroxypyrene
and 3-hydroxy-B[aJP. The study was approved by the medical ethical committee of
the Maastricht University.
(7CO/or BPDE-DM4
Fluorescence assays in lymphocytes: Immunocytochemical staining was performed
as originally described by Stierum et al. (16). Slides were dehydrated, rinsed with
distilled water and boiled for 10 min in 10 mM sodium citrate pH 6.0. For analysis of
p53 accumulation in /;; w'fro treated lymphocytes, slides were incubated with a
polyclonal antibody CM-1, raised against a full-length recombinant human p53
(Medical Sciences Institute, Dundee, Scotland, dilution 1:100 in 2% BSA/PBS) and
subsequently a biotinylated goat anti-rabbit IgG was used as secondary antibody
(Vector Laboratories, Burlingame, California, USA, dilution 1:200 in 27., BSA/PBS).
After washing with PBS, slides were incubated for 30 min with fluorescein avidin D
(1:500), washed, dehydrated and counterstained with propidium iodide. As a
positive control, SV40-immortalized human bronchial epithelial cells, BEAS-2B, were
used. These cells have been shown to contain detectable levels of wild-type p53. For
staining of BPDE-DNA adducts, a rabbit polyclonal antibody against BPDE-DNA
(F29 (17), dilution 1:100 in 2% BSA/PBS) was used as first antibody. The following
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steps were identical to the p53 staining. 100 Randomly chosen cells were scored
blindly using a Zeiss Axioskop fluorescence microscope and the level of staining was
expressed as: (cells positively stained/total of scored cells) x 100%.
Peroxidaae assay in skin biopts: Slides were boiled twice in 10 mM sodium citrate
(pH 6.0) for 5 minutes. For analysis of p53 in the biopsy sections, a mouse
monoclonal IgC2b antibody (DO7, raised against recombinant human p53,
Novocastra Laboratories, Newcastle upon Tyne, UK, dilution 1:500) was used as
primary antibody and a biotinylated rabbit anti-mouse antibody as secondary
antibody, lmmunoperoxida.se staining was performed by using an ABC elite kit
Vector [Avidin DH+ biotinylated horse-radish peroxidase H]. Visualization was
achieved by using a DAB-kit for 5 min according to the instructions of the
manufacturer (Brunschwig, Amsterdam, the Netherlands). Slides were blindly
scored by two independent observers as respectively class I: cells of the basal layer of
the epidermis were negative/slightly positive for p53; class II: cells of the basal layer
were clearly positive; and class III: cells of the basal layer were highly positive
(overall agreement of the two observers was 100%). Additionally, p53 levels in the
stratum basale of each skin section were quantitated on a continuous scale using an
Image Processing and Analysis System (Quantimet 500, Leica, Cambridge, England).
Firstly, the transmission/pixel was determined by dividing the measured intensity in
the nuclei by that in the extranuclear area (=background). Secondly, to obtain the
stain density, the absorbance was calculated for each pixel by the negative logarithm
of the transmission and averaged, which is linearly related to the amount of stain in
the cell. Subsequently, the stain density was multiplied by the area fraction
positively stained for p53 (=number of pixels), as compared with the total area that
was scored (stratum basale over a length of 2000-4000 um) to obtain the final relative
stain density (in arbitrary units, a.u.). In order to evaluate inter-coupe variations, two
different coupes on one slide were quantitated; both measurements appeared highly
correlated (r=0.978, p=0.0038, n=5). Moreover, the semi-quantitative assessment of
p53 staining and the quantitative measurements were highly in agreement (class I:
median staining intensity 0.01 a.u. (range 0.002-0.05), class II: 0.09 a.u. (range 0.05-
0.25) and class III: 0.48 a.u. (range 0.17- 0.759), p=0.0001 by the nonparametric
Kruskal-Wallis test). Unfortunately, we were not successful in ICC-staining of skin
biopsy samples for PAH-related DNA adducts.
DN/4
DNA of lymphocytes was isolated using a simple salting-out procedure as described
by Miller et al. (18), with a small modification by applying one additional extraction
with chlorofornvisoamylalcohol (24:1). DNA of biopsy samples was isolated using a
phenol extraction method. ^P-postlabeling analysis of all samples was performed as
described earlier (19). After digestion of 10 ug DNA with micrococcal endonuclease
(0.4 units) and spleen phosphodiesterase (2.8 ug) for 3 h at 37°C, the digest was
treated with nuclease PI (b.3 ug) for 41) min. Labeling was carried out with excess of
[y-32p)-ATP and 5 Units of T4 polynucleohde kinase. Adducts were resolved on
poly(ethylenimine)-cellulose TLC sheets (Merck, Germany) using the following
solvents: Dl, 1 M Nar^POi pH b.5; D2, 8.5 M urea, 5.3 M lithium formate pH 3.5;
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D3, 1.2 M lithium chloride, 0.5 M Tris, 8.5 M urea pH 8.0; D4, 1.7 M NafyPC^ pH
6.0. In each experiment, 3 standards of pHJBPDE modified DNA with known
modification levels (1 per 10?, 10", 10** nucleotides) were run in parallel lor
quantification purposes. Quantification was performed by using phosphor-imaging
technology (Molecular Dynamics™, Sunnyvale, CA, USA). A detection limit for
BPDE-DNA adducts of <0.1 adducts per 10* nucleotides was reached. lnter-ass«iy
variation was <20%. u
GSTMI
The GSTMI genotype was determined using a polymerase chain reaction (PCR)»
based assay as described by Brockmoller et al. (20). PCR was carried out in a total
volume of 50 pi, containing 0.2 ug DNA, 0.2 mM of each dNTI\ and 25 ul PCR
buffer containing 15 mM MgCl2. Exact information about the primers used can be
found in Brockmoller et al. (20). After denaturation at 94°C for 4 min, 1.25 U of Taq-
polymerase (Pharmacia Biotech, Roosendaal, The Netherlands) was added, followed
by 35 cycles of amplification. An aliquot of 10 pi of the PCR product was analyzed
on a 3% agarose gel for the presence of bands at 338 bp (control) and 273 bp
(GSTMI).
3-/jydro;n/-B/a/P m Mrmr o/frro/frf /wf/
Detection of 1-hydroxypyrene and 3-hydoxy-B[a]P in urine was performed as
described by Jongeneelen et al. (21). The method consisted of enzymatic hydrolysis
with fi-glucuronidase and arylsulphatase, solid phase extraction on a Sep-pak C-18
cartridge and elution with methanol. Reversed phase HPLC (Kratos solvent delivery
system; Column: Hypersil 5 ODS) and fluorescence detection (Perkin-Elmer LS-30)
were employed, using excitation and emission wavelengths of 253 nm and 423 nm
for 3-hydroxy-B[a]P and respectively 232 nm and 384 nm for 1-hydroxypyrene. Peak
area was used for quantification. Concentrations were corrected for creatinine
excretion, which was measured using a diagnostic kit of Sigma (no. 555-A). The
detection limit was 200 ng 3-hydroxy-B[a]P and 80 ng 1-hydroxypyrene per liter
urine, using a signal / background ratio of 3. Day-to-day variation and intra-assay
variation were respectively 14% and 6%.
Results are presented as median and range. Spearman rank correlation coefficients
were applied to assess correlations between several parameters or measurements.
The nonparametric Mann-Whitney U-test (2 groups) and the Kruskal-Wallis test (3
groups) were applied to determine statistical differences. Furthermore, multiple
regression was applied to assess the combined effects of GSTMJ and aromatic-DNA
adduct levels on p53 accumulation. P<0.05 was considered significant.
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In phytoheamagglurinine stimulated lymphocytes that were incubated with 2.5
uM BPDE for 18 hours, BPDE-DNA adduct levels determined by ICC were
significantly increased as compared to nonexposed controls; median 40% (range 5-
867o, n=44) of the cells were positively stained in BPDE exposed cells vs. 1% (range
0-28%, n=ll) in controls (P<0.001). In BPDE treated cells, the median DNA adduct
level assessed by ^p.postlabeling was 583.3 adducts per 1(F nucleotides and ranged
from 23.2 to 1706.0 (percentage of variance: 86%). Parallel adduct analyses by means
of -^P-postlabeling and ICC in a subgroup of 22 individuals were highly correlated in
I'M w'fro treated lymphocytes (rs=0.73; P<0.01). The percentage of p53 positively
stained cells was 587,, (range 17-89%) in treated cells and 14% (range 3-40%, P<0.001)
in controls. As shown in Figure 1, p53 positivity was correlated with BPDE-DNA
adduct levels as determined by ICC (rs=0.66, P<0.001, n=44). The same holds true for
p53 positivity and adduct levels determined by ^P-postlabeling (r<i=0.56, P<0.001).
Percentage of cells
positively stained for
BPDE-DNA
Figure 1. Relationship between BPDE-DNA adducts and p53 expression in cultured peripheral blood
lymphocytes exposed in rifw to BPDE, assessed by immunocytochemistry and expressed as
percentage of cells positively stained.
To determine whether p53 accumulation is influenced by GSTMI, additional analysis
by multiple regression was performed and the final results showed that p53 levels
were related to both BPDE-DNA adduct levels (P=0.018) and the GSTMI genotype
(P=0.046). After adjustment for BPDE-DNA adduct levels, it was found that
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individuals lacking the CSTMI gene had significantly higher levda of p53 (median
51%, range 25-67%) as compared with individuals which were GSTMJ(+) (median
36%, range 24-49%, P=0.0031). The CSTMI genotype did not influence BPDE-DNA
adduct levels. J
Sltm B/opfs; tfetertion q/"p53 and DN/4 addurfs in rr/afion fo GSTM1 •'*?»
Coal tar treatment resulted in a significant increase of median aromatk-DNA
adduct levels in skin biopsy samples from 2.9 adducts per UV nucleotides (range: 0.7-
10.0) before treatment, to 63.3 adducts per 10" nucleotides (range: 10.9-276.2) as
determined by ^-P-postlabeling (19). P53 was increased in the epidermis of 7/10
individuals topically treated with coal tar (Figure 2).
Figure 2. P53 immunocytochemistry using DO-7 antibody in human skin before (A) and after (B)
treatment with coal-tar ointments for one week. Panel C and D represent the corresponding '^p.
postlabeling profiles.
Median stain densities before and after treatment with coal-tar ointment were
respectively 0.007 a.u. (range: 0.002-0.249) and 0.129 a.u. (range: 0.003-0.759)
(P=0.049). Biopsy-samples of untreated and treated skin (n=20) were classified as I, II
or III for p53 (see Materials and Methods section) and corresponding median DNA
adduct levels were 3.6 adducts per 10* nucleotides (range 0.6-51.6, n=ll), 91.1
adducts per 10* nucleotides (range 1.0-192.8, n=5) and 126.5 adducts per 10*
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nucleotides (range 11.2-276.2, n=4, P=0.010), respectively. Moreover, quantitative
assessment of p53-stain density was significantly correlated with aromaric-DNA
adduct levels (rs=0.50, p=0.029, n=20, Figure 3). In treated skin, aromatic DNA
adduct levels were higher in GSTM1(-/-) individuals (median: 192.8, range 13.6-
276.2, n=5) as compared with GSTM7(+) individuals (median: 49, range 10.9-106.7,
n=5). However, due to large interindividual variations and the low amount of
individuals, this difference did not reach statistical significance. A clear effect of the
GSTM1 genotype on p53 accumulation was observed; the basal layer of GSTM1(-/-)
individuals (n=5) contained high levels of p53 (median: 0.47 a.u., range 0.08-0.76).
Whereas, skin of GSTMI(+) patients (n=5) contained only low levels of p53 (median:
0.05 a.u., range 0.003-0.18)(P=0.026). Similar results were obtained by the semi-
quantitative approach.
HX) 150 200 250 300
Adducts per 10*
nucleotides
Figure 3. Relationship between aromatic-DNA adduct levels in human skin with or without coal-tar
treatment (adducts per 10** nucleotides) and p53 levels in the stratum basale of the epidermis as
assessed by quantitative immunocytochemistry (rs=0.502, P=0.029, n=20).
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Median baseline urinary excretion levels of 1-hydroxypyrene and 3-hydroxy-
B[.i]P were respectively 0.39 umol/mol creatinine (range: 0.12-1.57) and 0.01
umol/mol creatinine (range: <0.01-0.04), respectively. Urinary excretion of 1-
hydroxypyrene and 3-hydro\y-B[a]P was increased to 139.7 umol/mol creatinine
(median, range: 26.0-510.5) and 1.18 umol/mol creatinine (median, range: <0.01-2.14)
respectively, after 1 week of continuous application of coal tar ointments (19).
Interestingly, after 1 week of treatment, GSTM2(-/-) individuals had significantly
lower urinary concentrations of 1-hydroxypyTene (median: 70.4 umol/mol
creatinine, range 26.0-162.2) as compared with GSTM2(+) subjects (median: 205.7
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range 127.9-510.5, P=0.042). On the other hand, the median excretion of 3-hydroxy-
B[a]P was not significantly different between subjects with diffeivnt genotypes.
Median levels were 1.32 umol 3-hydroxy-B[a]P/mol creatinine (range 0.04-2.14) and
0.64 umol 3-hydroxy-B(a]P/mol creatinine (range: <detectionlimit- 1.52) for
respectively GSTM2(-/-) and GSTM 1(+) patients.
Discussion
In the present study, the relationship between aromatic-DNA adduct formation
and subsequent accumulation of p53 was examined in lymphinvU-s ol healthy
volunteers HI t'/'fro incubated with BPDE, and HI PI'IV in skin of ev/ema patients
topically treated with coal tar ointments. It was found that in both cases the levels of
DNA adducts and p53 accumulation were significantly increased and correlated, and
that the GSTMJ genotype seemed to influence this relationship, with GS7A1/ (-/-)
individuals having the highest levels of p53.
The results of the HI rifro study indicate that aromatic-DNA adduct formation
may result in an accumulation of p53, which may provide additional time for
effective DNA repair or may direct heavily damaged cells into apoptosis. However,
this correlation is not necessarily causal, since other mechanisms, related to BPDE-
exposure, may also result in accumulation of putatively wild type p53 and it is
possible that the level of aromatic-DNA adducts merely coincides. For example,
single strand breaks may initiate the accumulation of p53 (22) and it has also been
shown that certain carcinogenic agents may induce a change in the conformation of
the p53 protein from the wild-type to a mutant phenotype (23). Similarly, BPDK may
interact with the p53 protein and may so prolong its half-life. Additionally, we
observed an effect of GSTM] on p53 accumulation. Ramet et al. (24) demonstrated
that in carcinoma cell-lines, metabolism of B|a]P to diolepoxides is necessary for p53
accumulation to occur. GSTMI, which is known to catalyze the reaction of
glutathione with BPDE, may decrease the levels of diolepoxides and as a
consequence p53 expression is less increased as compared with individuals lacking
GSTM1-1 activity. Such an effect might explain our results regarding p53
accumulation. No effect of GSTM7 was observed on BPDE-DNA adduct formation.
This could be explained by p53 induced DNA repair (nucleotide excision repair);
incubations were performed over a period of 18 hours and p53 mediated
enhancement of DNA repair may reduce DNA adduct levels during this incubation
period. Previously, it was found that most of the BPDE-DNA adducts are removed
during the first 24 hours after exposure (25). Furthermore, p53 mediated cell-death of
highly damaged cells would result in decreased DNA adduct levels.
In normal unexposed skin, p53 is short-lived and therefore it is usually
undetectable by ICC. However, in one individual of our m two study, p53 was
readily detectable in untreated skin. Since we started this study in the summer, an
influence of UV-irradiation cannot be excluded. Short-term UV-radiation has been
found to increase p53 expression in normal skin (26). After 1 week of treatment with
coal tar ointments without further exposure to UV, p53 was detectable in most skin
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samples and was increased as compared to the pretreatment measurement in 7 out of
10 individuals. Aromatic-DNA adduct levels were significantly correlated with p53
levels. Similarly, Wolterbeek et al. (27) found a relationship between B[a]P-DNA
adducts and p53 accumulation in tracheal epithelium of hamsters. Furthermore,
Bjelogrlic et al. (28) observed an increase of p53 in mouse skin after treatment with
BPDL and P53 expression coincided with BPDE-DNA adduct levels. However, the
mean adduct level in skin of p53-positive mice did not significantly differ from that
in p53-negative mice. Although in the present study a significant relationship was
observed between aromatic-DNA adducts and accompanying p53 levels in the same
skin sample, large interindividual variation was present (Figure 3), indicating that
aromatic-DNA adducts are probably not predominant for p53 accumulation in skin
cells.
As in the in w'fro experiment with lymphocytes, an influence of the GSTM1
genotype was observed; the epidermis of GSTMI(-/-) individuals showed higher
levels of p53 in the stratum basale as compared to GSTM1(+) subjects. Although the
major GST isoenzyme in human skin seems to be of the Pi-class, GST's of the Mu-
class are present in relatively low concentrations (13). It has been shown that GST of
the Mu-class is present in cells of the stratum basale of normal human epidermis
(14). The enhanced levels o/ p53 in the basal layer in skin of GS7"MI(-/-) individuals
may imply that p53 mediated cellular responses in human skin are directly related to
GSTM1-1 activities after PAH exposure.
We found no statistically significant relationship between the GSTMJ genotype
and aromatic DNA adduct levels in coal-tar treated skin. Also in bronchial tissue of
smokers, Schoket et al. (29) recently observed no such correlation, which is contrary
to previous studies (10, 12, 30). In peripheral blood cells of smokers, significantly
different adduct levels determined by -^P-postlabeling in white blood cells of
GSTM1(-/-) and GSTMI(+) individuals were found (30), also in combination with
other polymorphic genotypes, like CVPI/U (31) or N/4T2 (32). Thus, the exact
influence of the GSTMJ polymorphism on PAH metabolism and adduct formation is
still not completely elucidated. The results of the present study suggest that p53
mediated induction of DNA repair might reduce aromatic-DNA adduct levels,
especially in GSTMJ(-/-) individuals.
In the present study, an effect of GSTM1 on PAH metabolism is evident from
the urinary analysis of 1-hydroxypyrene, although this effect was not observed
regarding urinary 3-hydroxy-B[a]P levels. Alexandrie et al. (33) also observed an
effect of GSTMJ on urinary 1-hydroxypyrene levels in an occupational setting.
However, their study showed opposite results; GSTMI(-/-) subjects excreted higher
levels of 1-hydroxypyrene as compared to GSTM1(+) subjects. At this moment, no
explanation can be given for these discrepancies.
Overall, it can be concluded that GSTMI and p53 accumulation may act in
concert as a protective mechanism against PAH induced DNA damage in human
cells. The results of the present study indicate that further research is necessary to
further elucidate the complex network of protective reactions after genotoxic
assaults.
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Chapter 9
Repair of oxidative DNA damage after acute oral
exposure to benzo[a]pyrene
R.W.L. Godschalk, P.A.E.L. Schilderman, E. van Agen, VV.M.R. Broekmans,
FJ. van Schooten, J.C.S. Kleinjans
Department of Health Risk Analysis and Toxicology,
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Abstract
Reactive oxygen species (ROS), produced during the metabolic conversion of
benzo[a]pyrene (B(a|P) to its reactive derivatives, may be involvt>d in B|a|P induced
carcinogenesis. Therefore, we studied the formation of 7-hydro-H-oxo-2'-
deoxyguanosine (8-oxodG) in lung, liver and heart of rats after a single oral dose of
B[a]P (10 mg/kg body weight) by means of high performance liquid
chromatography with electrochemical detection (HPLC-ECD). Additionally, urinary
excretion of 8-oxo-dG was studied using a competitive-ELISA. In control rats,
highest 8-oxo-dG levels were observed in liver (15.3±3.4, 8-oxo-dG per 10* dG),
followed by respectively lung (12.1±2.5) and heart (9.3±1.0). The corresponding 8-
oxo-dG levels in rats one day after treatment with a single oral dose of B|a|P, were
8.3±3.1 per 10* dG for liver DNA (P=0.04, Mann-Whitney U-test), 9.9±1.1 for lung
DNA (P=0.12) and 8.8±0.9 for heart DNA (P=0.83). Eleven days after exposure to
B[a]P, 8-oxo-dG levels further decreased in liver (6.0±l.l, P=0.004) and lung (.5.3*2.3,
P=0.05), whereas in heart-DNA no changes in 8-oxo-dG levels were observed.
Excretion of 8-oxo-dG in 24 hours urine of exposed rats, increased from day 1
(1134±351 ng 8-oxo-dG per 24 hours) to day 21 (2030±410 ng 8-oxo-dG per 24 hours,
P=0.002). In control rats, a mean excretion of 689±237 ng 8-oxo-dG/24 hours was
observed. These results indicate that acute exposure to B[a]P might induce non-
specific DNA repair activities that in contrast with the hypothesis, indirectly reduce
the level of oxidative DNA damage in target tissues for DNA adduct formation.
Benzo[a]pyrene (B[a]P) is a well studied polycyclic aromatic hydrocarbon,
which is known to be metabolized by cytochrome P450 mediated processes to certain
reactive diol-epoxides that can interact with DNA (1). However, other metabolic
routes have been described, which might be of importance for organs that contain
relatively low levels of cytochrome P450 (e.g., lung or stomach). For instance, B[a)P
can be metabolized via a one-electron oxidation pathway to a B[a]P-radical cation (2)
that may covalently bind to DNA (3). Additionally, B[a]P radical-cations are thought
to be precursors for the labile phenol, 6-OH-B(a]P (4). Auto-oxidation of this
derivative may ultimately result in the formation of B[a]P quinones. B[a|P quinones
are almost invariably found after metabolism of B[a]P, sometimes accounting for
more than 50% of the total metabolic yield (5). The B[a]P quinones formed are 6,12-,
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1,6- and 3,6-B[a]P dione, which can undergo redox-cycling to their corresponding
B[a)P diols coupled with molecular oxygen to form superoxide and hydroxyl
radicals by the Haber-Weiss and Fenton reactions (Figure 1) (6).
T
OH" + O2
8-oxo-dG
Flgura 1. Formation of reactive oxygen species (ROS) and 8-oxo-dG by redox-cycling of B|aJP-diones
The reactive oxygen species (ROS) produced can give rise to oxidative DNA damage,
e.g. 7-hydro-8-oxo-2'-deoxyguanosine (8-oxo-dG) formation and DNA single or
double strand breakage. 8-Oxo-dG and other kinds of oxidatively damaged bases
were found to be promutagenic lesions and may thereby contribute to the
development of B[a]P induced cancers (7). Indeed, increased levels of oxidatively
damaged bases have been observed in cells treated with B|a]P /'« z'ifro with (8) or
without (9) additional exposure to light and in livers of laboratory rodents orally
exposed to B[a|P (10). Thus, it is hypothesized that exposure to B[a]P generates free
radicals and may result in increased levels of oxidative DNA damage.
Fifteen male Lewis rats (250-350 gram bodyweight (bw.)) were exposed to a
single oral dose of B[a]P (10 mg B[a]P in tricaprylin/kg bw). Rats were housed
individually in metabolic cages to collect 24 hours urine samples and they were
provided with food (diet no. RSM-A, Hope Farms, Woerden, The Netherlands) and
water n</ IWnm. Rats were killed at 1, 2, 4, 11 and 21 days (3 rats per time-point) after
the treatment to study the time-course of 8-oxo-dG formation and B[a]P-related
bulky DNA adducts. Three control rats received vehiculum only (tricaprylin) and
were killed one day after treatment. Liver, lung and heart were removed and frozen
in -20"C until DNA isolation. DNA was isolated from these tissues by a standard
phenol extraction procedure and subsequently analyzed for the presence of 8-oxo-dG
by means of high performance liquid chromatography with electrochemical
detection (HPLC-FCD)(ll). The mobile phase consisted of 10% aqueous methanol
containing citric acid (30 mM). Elution was performed at a flow rate of 1.0 ml/min.
The limit of detection was 40 fmol absolute for 8-oxo-dG. 8-Oxo-dG excretion in 24
hours urine was studied using a competitive ELISA (obtained from the Japan
Institute for the Control of Aging, Fukuroi City, japan). A standard curve was used
to calculate the level of 8-o\o-dG in urine samples. Analysis of each sample was
performed in triplicate and the mean coefficient of variation was 4.5%±1.8%.
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Additionally, bulky DNA adducts were analyzed by nuclease PI enriched -^P-
postlabeling combined with thin layer chromatography (12).
In control rats, 8-oxo-dG levels were 15.3±3.4, 8-oxo-dG per UK* dG in liver,
12.1±2.5 in lung and 9.3±1.0 in heart, one day after oral application of vehiculum
only. The corresponding 8-oxo-dG levels in rats that were treated with a single oral
dose of B[alP were 8.3±3.1 per 10* dG for liver DNA (P=0.04, Mann-Whitney U-test),
9.9±1.1 for lung DNA (P=0.12) and 8.8±0.9 for heart DNA (P=0.83). In lung and liver,
the 8-oxo-dG levels continued to decrease, and reached minimal levels at 11 days
after exposure (liver: 6.0±l.l, P=0.004 and lung: 5.3±2.3, P=0.05). Whereas in heart-
DNA, no changes in 8-oxo-dG levels were observed (Table I and Figure 2).
20 0 5 10 IS 211 I) * 10 IS 20
Day* after exposure to BcnzoUlpyrene
Figure 2. Levels of 8-oxo-dG (per 10* dG) in rat liver (A), lung (B), and heart (C) at several time points
after a single oral dose of B[a]P (10 mg/ kg body weight). * P<0.05 as compared with controls, which
are shown at t=0.
These results seem to be in contrast with the observations of Kim and Lee (10), who
reported that 8-oxo-dG levels were significantly increased in liver DNA of female
Sprague-Dawley rats at 6-12 hours after exposure to B|a)P, and were reduced to
baseline levels after 24-96 hours. However, some major differences in experimental
conditions might explain the observed discrepancies. Firstly, the dose of B|a]P was
7.5 times higher in their experiment as compared with the present study, which
might result in other metabolic routes and/or higher levels of ROS generation.
Secondly, animals of different strains and gender have been used, which may differ
in (induction of) biotransformation and DNA repair capacities upon exposure to
B[aJP. Indeed, differences between males and females with regard to bulky-DNA
adduct formation have been reported in humans (13, 14) and in laboratory rodents
(15). Shugart and Kao (15) observed a higher rate of B[a)P diol-epoxide DNA adduct
removal from skin in male as compared with female mice, which suggests
differences in non-specific DNA repair activity or inducibility. Also, 8-oxo-dG is
repaired by non-specific DNA repair enzymes and is released as deoxynucleotides.
In humans, higher urinary 8-oxo-dG levels were found in males than in females (16),
but this may also be related to a higher metabolic rate in men with increased
availability of ROS.
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Non-specific DNA repair is likely to be involved in decreasing 8-oxo-dG leveb
in lung and liver of rats exposed to B[a]P, since higher urinary 8-oxo-dG levels were
found in exposed rats (1135±351 ng 8-oxo-dG/24 hours) as compared with controls
(689±237). From day 1 to day 21, urinary excretion of 8-oxo-dG gradually increased
from 1135±351 ng 8-oxo-dG/24 hours to 2030±410 (P=0.002, Figure 3).
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Figure 3. Total urinary excretion of 8-oxo-dG per 24 hours (ng 8-oxo-dG/ 24 hours) after acute oral
exposure to B|n]P. * P<0.05 as compared with controls.
' Still, it is possible that ROS and 8-oxo-dG are formed due to the metabolic
conversion of B[a]P. However, an overcompensation by DNA repair ultimately
results in decreased overall 8-oxo-dG levels in lung and liver, but not in heart. The
observed changes in 8-oxo-dG levels are in agreement with the reported ranking
order of DNA repair activities in these tissues: liver> lung> heart (17). No
conclusions can be made regarding specific DNA repair glycosylases, because in that
case 8-oxo-dG's will be released from the DNA as free damaged bases, 8-oxo-guanine
(8-oxo-Gua) (18), which were not detected in the present experiment.
B[.\1P related bulky DNA adducts at day 2 after exposure were highest in
respectively heart (lb.5±5.1 adducts per 10** nucleotides), lung (6.9±2.3) and liver
(2.7t0.4) (Table I).
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Table I. Urinary excretion of 8-oxo-dC and DNA adduct levels (bulky DNA adduets and 8-oxo-dG
levels) in rat liver, lung, and heart at several time points after acute oral exposure to B(a]P.
Control
Bulky DNA adducts •
Liver
Lung
Heart
<d.L
<d.l.
<d.l.
8-Oxo-dG*>
Liver
Lung
Heart
153 ± 3.4
12.1 ± 2 3
9.3 ±1.0
Urinary 8-oxo-dG '
689 ±
237
Days after
1
1.8 ±1.3
6.3 ± 3.7
13.4 ± 4.9
8.3 ± 3.1
9.9 ±1.1
8.8 ± 0.9
1134 ±
351
BlalP exposure
2
2.7 ±0.4
6.9 ± 2.3
16.5 ± 5.1
7.1 ± 2.1
10.9 ±1.3
10.9 ±1.2
1160 ±
143
4
13 ±1.3
5.5 ± 1.7
14.4 ± 5.6
6.1 ± 1.6
6.1 ± 4.2
10.6 t 4.0
1230 ±
246
11
0.5 ± 0.4
5.9 ±1.9
10.5 ± 5.5
6.0 ± 1.1
5.3 ± 2.3
9 6 t 2.2
1617*
217
21
0.2 ± 0.1
5.0 ±1.5
4.0 ± 3.0
8.8 ± 1.8
6.9 ± 2.7
8.9 ± 0.7
2030 ±
410
a DNA adducts per 10* nucleorides, <d.l.: below detection limit,
b amount of 8-oxo-dG per 10^ dG
c ng 8-oxo-dG per 24 hours
These maximal bulky-DNA adduct levels were inversely related with changes in 8-
oxo-dG levels in respectively liver, lung and heart. Bulky DNA adduct levels steadily
decreased from day 2 to day 21 after exposure in all three organs. Over this period,
no direct link could be observed between the removal of bulky-DNA adducts and
changes in 8-oxo-dG. For example in heart, B[a]P related DNA adduct levels
significantly decreased from day 2 to day 21 after exposure, whereas 8-oxo-dG levels
did not change. Nonetheless, the removal of 8-oxo-dG from lung and liver after
exposure to B[a]P, might be due to non-specific DNA repair mechanisms, primarily
induced to repair bulky-DNA adducts; bulky DNA adducts are removed by NER,
which aspecifically and simultaneously removes endogenously formed 8-oxo-dG.
Our results indicate that acute exposure to B[a]P might induce non-specific DNA repair
of DNA oxidation products.
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Abstract
DNA adduct analysis is often used for biomonitoring individuals exposed to
polycyclic aromatic hydrocarbons (PAH). The 32p-fK>stlabeling assay is routinely
applied to study the formation of aromatic bulky adducts, but cannot positively
identify individual adduct types. Recently, an HPLC assay with fluorescence
detection (HPLC-FD) was developed which was sufficiently sensitive to detect
adducts formed by benzo[a]pyrene (B[a]P) diolepoxide isomers [(±)anti- and (±)syn-
BPDE] in occupationally exposed subjects (Rojas et al., Carcinogenesis, 16 (1995)
1373-1376). In this study, we compared both techniques using DNA samples of rats
which were treated i.p. with B[a]P (10 mg/kg bw). The internal dose was assessed
by measuring 3-OH-B[a]P excretion in urine. The detection limit of the HPLC-FD
assay varied from 0.5 to 7.4 adducts per 10" nucleotides, while the detection limit of
the *2P-postlabeling assay was around 1 adduct per 10^  nucleotides. HPLC-FD
analysis showed that BPDE-DNA adduct levels were highest in respectively heart,
lung and liver. The most predominant B[a]P-tetrol was the 1-1 isomer, which derives
from hydrolysis of the major reaction product of DNA and (+)-anti-BPDE. 32p.
postlabeling analysis revealed an adduct spot that comigrated with a pH]BPDE-
DNA standard. The putative BPDE-DNA adduct levels were highest in heart
followed by lung and liver and correlated significantly with tetrol 1-1 levels
determined by HPLC-FD (r=0.72, P= 0.006). In samples in which both tetrol 1-1 and
II-2 were detected by means of HPLC-FD, this correlation was even better (r=0.95,
P=0.01). Estimated half-lives of BPDE-DNA adducts were in the ranking order heart,
lung and liver for both techniques. By -^^P-postlabeling also other adducts than
BPDE-DNA were found, resulting in highest total DNA adduct levels in respectively
liver, heart and lung. Furthermore, mean 24 hr urinary excretion of 3-OH-B[a]P was
related to BPDE-DNA adduct levels in lung, liver and heart. The 32p-postlabeling
assay is sensitive and capable of detecting exposures to complex mixtures, whereas
the HPLC-FD assay can be used to identify BPDE-isomers and might therefore be of
value in risk assessment of individuals exposed to PAH.
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Introduction '
Polycydic aromatic hydrocarbons (PAH) are ubiquitous environmental
pollutants and uptake of PAH is thought to be involved in the induction of cancer.
Monitoring the concentration of PAH in the ambient air or in urine will represent the
external and internal dose respectively, but will not represent the dose th.it
eventually affects target sites. Ultimate reactive metabolites may react with DNA,
giving rise to DNA adducts (1). Upon cellular replication PAH-DNA adducts, if not
recognized and removed by DNA-repair, may result in structural changes of the
generic code (2). Therefore, DNA adduct analysis yields relevant information to
evaluate the effective carcinogen exposure of tissues and cells and would provide a
means for identifying groups or individuals at high risk. However, experiments with
laboratory rodents show that PAH-DNA adduct formation and tumor induction is
not always quantitatively interrelated: similar adduct levels are formed in
susceptible and resistant species, strains or tissues (1). Differences in adduct stability
may be involved and additionally not all adducts may have equal significance in
terms of risk of gene mutations and cancer. Exposure to a single carcinogen usually
leads to the formation of several types of DNA adducts, that may differ in their rate
of formation and repair, as well as their biological effectivity. Benzo[a)pyrene (B|a|P)
is often used as a representative for the PAH family in both ;>i i»/7w and »i I'/ro
studies. Biorransformation of this compound results in four reactive stereoisomers;
(±)anti- and (±)syn-benzo[a]pyrene-diol-epoxide (BPDE) (1). Anti-BPDF is reported
to be more mutagenic than syn-BPDE. Moreover, (+)anti-BPDE has been found to
possess higher biological activity than (-)anti-BPDE (3). So, theoretically,
identification of pivotal DNA adducts measured at target sites or in well established
surrogate tissues may improve the reliability of DNA adduct analysis in molecular
epidemiological studies.
Sensitive immunological assays have been used to study the formation of
aromatic bulky DNA adducts, but specific antibodies may cross-react with
structurally related compounds and are therefore rather group specific than
compound specific (4). Nowadays, the ^P-postlabeling assay with thin layer
chromatography (TLC) is routinely applied. This assay is sensitive, but unable to
distinguish between individual PAH-DNA adducts. Co-chromatography with a
known DNA adduct is usually not sufficient for definite identification. Separation of
^P-postlabeled DNA adducts with HPLC seems to be a promising technique to
detect specific DNA adducts formed upon exposure to complex mixtures (5, 6).
Recently, an HPLC assay with fluorescence detection (HPLC-FD) was developed by
Alexandrov et al. (7) that enables the separate analysis of stereoisomers of BPDE
without the use of radioactivity. Although this technique is less sensitive, in DNA of
PAH exposed coke oven workers the tetrols of B[a]P could be detected (8) and a
good correlation between HPLC-FD and ^p.postlabeling was found in smoking lung
cancer patients and aluminum workers (9). However, Pfau et al. (5) demonstrated
that the major adducts formed by B[a]P and benzo[bjfluoranthene were not resolved
on TLC. Thus, low resolution may trouble quantification of BPDE-DNA by '*P-
postlabeling in individuals exposed to complex chemical mixtures. In the present
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study, we applied the HPLC-FD technique in a controlled experimental setting of
B[aJP exposed laboratory rodents. Since it is suggested that next to adduct types,
adduct levels and persistence may be important factors in B(a]P induced
carcinogenesis, adduct kinetics were examined over a period of 11 days by both
techniques. For assessing the internal whole body dose, we additionally measured a
urinary metabolite of B[aJP: 3-OH-B[a]P.
Materials & Methods
All solutions used were sterile. B[a]P was purchased from Sigma (St. Louis, MO,
USA). All other chemicals were purchased from Merck (Darmstadt, Germany).
Water was purified by means of a milli-Q purification system.
frcwfmen/
Ten male Lewis rats weighing 270-320 g were used. The animals were housed
individually in metabolic cages for collection of urine, in a room maintained at 25°C,
50% humidity and a 12 hr light/dark cycle. Standard rodent lab chow (diet no. RSM-
A, Hope Farms, Woerden, The Netherlands) and water were provided ad //Wi/m. 24
hours-urine was collected. The samples were weighed and stored at -20°C until
analysis. B[a]P was initially dissolved in hexane and added to sunflower oil.
Evaporation of the hexane resulted in a B[a]P concentration of 2 mg/ml oil. Eight
rats were injected intra-peritoneally with 0.05 ml of B[a]P-solution per 10 gram
bodyweight to obtain a final dose of 10 mg/kg bodyweight. This treatment did not
influence the eating and drinking behavior, as determined by reweighing the
supplied food and water. Bodyweight, organ weight and urine excretion were
constant during the experiment. To examine the time-course of adduct formation
and persistence, the rats were killed 1, 2, 4 and 11 days after treatment (two rats per
time-point). To assess background levels, 2 rats received sunflower oil only and were
killed the following day. Lung, liver and heart were removed, washed with PBS and
quickly frozen at -20°C until DNA isolation.
DN/4 is
Approximately 1 gram of tissue was washed with 0.25 M sucrose/ 0.1 M Tris-HCl
(pH 7.4) and homogenized with a potter (1000 rpm) in 1% SDS/ 1 mM EDTA. The
solutions were incubated overnight at 37°C with 0.5 mg Proteinase K. DNA was
extracted with phenol: chloroform: isoamylalcohol (25:24:1, v /v /v) and chloroform:
isoamylalcohol (24:1, v/v) respectively. The DNA was precipitated with two
volumes of cold ethanol after addition of 1/30 volume 3M sodiumacetate, pH 5.3
and washed with 70% ethanol . Subsequently, DNA was dissolved in 5 mM Tris/ 1
mM KDTA, pH 7.4. RNase Tl (50 U/ml) and RNase A (100 ug/ml) were added,
followed by 30' of incubation at 37°C. liver DNA was also treated with a-amylase
(5(1 ug/ul). The solutions were extracted with respectively chloroform:
isoamylalcohol (24:1, v/v) and ether. DNA was precipitated from the aqueous phase
with cold ethanol, washed with 70% ethanol and dissolved in 2 mM Tris, pH 7,4.
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Concentration and purity were determined spectrophotomerrically by absorbanct at
230, 260 and 280 run. The final volume was adjusted to achieve a DNA-concentraHon
of 2 mg/ml.
The '2p-postlabeling assay was performed as described by Reddy and Randor.ith (10)
with some modifications. DNA (ca. 10 ug) was digested using micrococcal
endonuclease (0.4 Units) and spleen phosphodiesterase (2.8 ug) for 3 hours at 37°C.
Subsequently, half of the digest was treated with nuclease PI (6.3 ug) for 40 minutes
at 37°C. The modified nucleotides were labeled with [y-*-P]-ATP (50 uCi/ sample) by
incubation with T4-polynucleotide kinase (5.0 Units) for 30 minutes at 37"C. |V'*''|-
ATP was synthesized as described by Walseth and Johnson (11). NP1-efficiency and
ATP-excess were checked with an aliquot of the NP1 treated fraction by one
dimensional chromatography on poly(ethylenimine)(PEl)-cellulose sheets from
Merck, Germany (solvent: 0.12 M Nar^PQi pH 6.8). Radiolabeled adduct nucleotide
biphosphates were separated by chromatography on PF.I-cellulose sheets from
Machery Nagel, Germany. The following solvent systems were used: Dl, 1 M
NaH2PC>4 pH6.5; D2, 8.5 M urea, 5.3 M lithiumformate pH 3.5; D3, 1.2 M
lithiumchloride, 0.5 M Tris, 8.5 M urea pH 8.0; D4, 1.7 M NaF^PO., pH 6.0.
Additionally, butanol extraction according to Gallagher et al. (12) was used as
adduct enrichment method. In each experiment, 3 standards of PHJBPDE modified
DNA with known modification levels (1 per 10?, 10", 10** nucleotides) were parallelly
run for quantitation purposes. Quantitation was performed by using phosphor
imaging technology (Molecular Dynamics™, Sunnyvale) with which detection limits
of <1 adduct per 10** nucleotides (nt.) can be obtained. The remaining half of the
digest was used to determine the final amount of DNA in the assay; the normal
nucleotides were labeled with 32P (15 uCi/ sample) by incubation with T4-
polynucleotide kinase (2.5 Units) for 30 minutes at 37°C. Nucleotides were separated
by one dimensional chromatography on PEI-cellulose sheets from Merck (solvent:
0.12 M NaH2PC>4 pH 6.8); samples with apparent protein or RNA contamination
were discarded. A dAp standard (27.5 pmole/ul) was labeled in each experiment for
quantitation purposes. Interassay variation for BPDE-DNA was 17%± 5.5 (n=13).
BMP-Te/ro/ flfw/ys/s «>/r/i HPLC-FD
The method used was initially described by Alexandrov et al. (7) and modified by
Rojas et al. (9). Briefly, (i.) adducted DNA was hydrolyzed with 0.1 N HC1 for 4
hours at 90°C. (ii.) BPDE-tetrols were concentrated on a pre-column. (iii.) C18-HPLC
and monitoring of the fluorescence were performed as described by Alexandrov et
al. (7). The fluorescence signals were integrated. The amount of B[a]P-tetrols in the
samples and the detection limit were determined from a standard curve, generated
from the fluorescence peak heights of BPDE-tetrol standards each time when
analyzing a set of samples. The values thus obtained for B(alP-tetrols correspond to
the quantities of BPDE-DNA adducts. Tetrol 1-1 and tetrol II-2 represent adducts
formed by respectively anti-BPDE and syn-BPDE. The amount of DNA used varied
from 60 to 100 ug. The detection limit varied due to interassay variation: mean
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detection limits for tetrol 1-1 as well as II-2 were 0.8 per 10" nt. (range 0.6-1.2;
variation 277o) for lung and 0.6 (range 0.5-0.9; variation 21%) for liver. For heart
DNA the detection limits were 1.7 per 10* nt. (range 0.6-2.9; variation 47%) for terrol
1-1 and 3.8 (range 1.1-7.4; variation 52%) for terrol II-2. Overall, the mean detection
limit was 2.1 adducts per 10* nt. (range 0.5-7.4; variation 89%).
3-OH-B/a/P m r<rt unw
Detection of 3-OH-B[a]P in 24-hours urine was performed as described by
Jongeneelen et al. (13). The method consisted of enzymatic hydrolysis with 6-
glucuronidase and arylsulphatase, solid phase extraction on a Sep-pak C-18 cartridge
and elution with methanol. Reversed phase HPLC (Kratos solvent delivery system;
Column: Hypersil 5 ODS) and fluorescence detection (Perkin-Elmer LS-30) were
employed, using excitation and emission wavelengths of 253 nm and 432 nm. Peak
area was used for quantification. The detection limit was 200 ng 3-OH-B[a]P per liter
urine. Day-to-day variation and intra-assay variation were respectively 14% and 6%.
For each rat, mean 24 hr urinary excretion of 3-OH-B[a]P was calculated as
cumulative excretion divided by time (days) after exposure.
Sfafisfics
Results are presented as mean ± standard error of the mean. Correlation coefficients
were calculated to examine the relation between BPDE-DNA adducts in several
tissues determined by means of HPLC-FD and -^P-postlabeling. P< 0.05 is
considered to be significant.
Results
DM4 m/i/irfcf ana/i/si's m raf fissues by -'^ P-posf/flbW/Mg and HPLC-FD.
In all tissues studied, an adduct was detected by ^p.postlabeling (adduct 1)
that comigrated with the FHJBPDE-DNA standard (Figure 1, Panel A and B).
Additionally, a second adduct (adduct 2) was detected in liver, lung and heart. Only
in liver DNA a third major adduct was found (adduct 3) which had a higher
migration rate in solvent D3, compared to the ['HjBPDE-DNA standard.
Interestingly, this adduct did not appear in the chromatograms after butanol
enrichment. Using HPLC-FD analysis, it was possible to detect BPDE-DNA adducts
in heart and lung. In liver DNA, a fluorescence signal of terrol 1-1 was observed on
day 2, but this signal was equal to the arbitrary cut-off point of 0.9 adducts per 10"
nt. Thus in liver DNA, no BPDE-DNA adducts were detected in higher
concentrations than 0.9 adducts per 10" nt.
rcsw/fs of fuMurf ana/ys/s /« raf fissure
•^P-postlabeling of the DNA of the tissues studied showed similar adduct-time
relationships over a period of 11 days (Figure 2). In lung, liver and heart, all DNA
adduct levels increased to a maximum around day 4. The maximal levels of adduct 1
in lung DNA (3.1 ± 0.9 adducts per 108 nt.) and liver DNA (2.9 ± 0.7) were about 2
times lower than in heart tissue (6.3 ± 0.6) (Figure 2-1).
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Figure 1. DNA adduct profiles determined by ^P-postlabeling. The origin is located at the lower left
corner and was excised before analysis. All visible non-numbered spots were also found in rats
h-eated with sunflower oil only. A: representative chromatogram of liver-DNA ol Bl<i|l' treated rats. B:
[3H1BPDE modified DNA (1 adduct per 10* nt.).
Adduct 2 also reached maximal levels at day 4; about 0.5 adducts per 10" nt. in lung
and liver, and 1 adduct per 10" nt. in heart tissue. In liver DNA, spot 3 was the
predominant one with a maximal level of 23.1 ± 7.7 adducts per 10" nt. at day 4. As a
result, the ranking order of total tissue DNA adduct levels was liver > heart > lung as
determined by 32P-postlabeling (Figure 2-II). Although the putative BPDH-DNA
adduct (spot 1) ranked heart> lung> liver.
In table 1 the results of the HPLC-FD analysis are summarized. In lung DNA
only tetrol I-l on day 4 and 11 could be quantitated, indicating a maximal adduct
level of 1.4 ± 0.1 adducts per 10" nt. At other time points, concentrations of I-l and II-
2 were below 1 adduct per 10" nt. In heart tissue, both tetrol I-l and 11-2 were
detected. Due to the relatively high detection limits, tetrol II-2 was found in a limited
number of samples. At day 2, tetrol I-l concentrations reached up to 2.0 ± 0.3 adducts
per 10" nt., and remained stable until day 11 (2.0 ± 0.7 adducts per 10" nt.). At any
time-point, tetrol I-l levels were not higher than 0.9 adducts per 10" nt. in liver DNA.
Suprisingly, on day 0 (control rats) in heart, tetrol I-l could be detected by HPLC-FD
as well as BPDE-DNA adducts were observed by ^p.postlabeling.
Overall, there is a good quantitative relationship between HPLC-FD and the
^P-postlabeling method; when BPDE-DNA adduct levels as determined by means of
32P-postlabeling were compared with total DNA adduct levels by HPLC-FD (i.e.
tetrol I-l plus II-2), a significant correlation coefficient of 0.95 (p=0.01, n=5) was
found, with a slope near to 1.0 (Figure 3). Furthermore, a good correlation was found
between BPDE-DNA by ^p.postlabeling and tetrol I-l only (r=0.72, p=0.006).
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The estimated half-lives of BPDE-DNA adducts in days were determined from
the exponential decay curves of a log-linear plot as calculated on the basis of 32p-
postlabeling and HPLC-FD. BPDE-DNA was most persisting in heart DNA (ca. 30
days), followed by respectively lung (23 days) and liver (7 days) as determined by
•^P-postlabeling. Half-lives determined by HPLC-FD were calculated for tetrol 1-1
only. Again, BPDE-DNA seemed to be most stable in heart (no decrease of tetrol 1-1
levels over the observation period) followed by lung DNA (14 days) and liver (<4
Figure 2. Kinetics of adduct levels in rat tissue (n=2 per time point) after a single injection of 10 mg
B|.\|I' / kg body weight. Adducts were detected by 'P-postlabeling as described in Materials and
Methods. Symbols: Liver (•) Heart (LJ) and Lung (•)(error bars sometimes within the size of the
symbol). 1: putative BPDE-DNA adduct levels, II: Total DNA adduct levels.
3-OH-BMP crrrrf/oH »i 24-/ici/rs
To assess the internal dose, we measured a major B[a]P metabolite, 3-OH-B[a]P,
in the 24-hours urine. Maximal values were observed at day 3 (251.8 ± 97.2 ng/ 24
hours), after which the excretion gradually decreased to day 11. Cumulative
excretion added up to only 889 ± 270 ng, that is 0.03% (±0.01%) of the total
administered dose. Low levels of 3-OH-B[a]P were also found in rats receiving
sunflower oil only (4.9 ± 0.5 ng/ 24 hours). Generally, the excretion profile of 3-OH-
B[a]P did not correlate with the rate of DNA adduct formation in tissues. However,
the mean 24 hr excretion of 3-OH-B[a]P correlated with levels of DNA adducts in
internal organs determined by ^-P-postlabeling (Heart: r= 0.68, p= 0.026; Liver: r=
0.66, p= 0.036; Lung: r= 0.67, p= 0.035)(Figure 4) and HPLC-FD (Heart: r=0.86,
p=0.06).
138
cAdducts / 10" nucleotides
by " P-postlabeling
Figure 3. Relationship between BPDE-DNA adduct levels determined by ^P-postlabelinR and HPLC-
FD. (•) tetrol 1-1 plus tetrol 11-2 (tetrol II-2 was detected in heart tissue only); r=0.95, p*().O1 and (i))
Tetrol 1-1 only; r=0.72, p=0.006.
Discussion
Environmental and occupational exposure of humans mainly implies exposure
to complex mixtures like PAH. Exposure to PAH results in a broad spectrum of
different types of adducts of which specific types may account for most of the
carcinogenicity (14). Therefore, identification of critical DNA adducts may be of
major importance in the assessment of the biologically effective dose and subsequent
risk estimates. Indeed, the results of a study by Denissenko et al. (15) suggest that
BPDE-DNA adducts may play an important role in the etiology of human lung
cancer. In this study, we found a good correlation between BPDE-DNA adduct
quantification by means of the routinely used ^p.postlabeling and by a recently
developed HPLC-FD assay in tissues of rats that were intraperitoneally exposed to
B[a]P. The major advantage of this HPLC-FD assay is the ability to identify BPDE
isomers that have covalently bound to DNA. The most mutagenic and tumorigenic
BPDE isomer in mammalian cells is anti-BPDE, which predominantly forms adducts
with the exocyclic N^-amino group of guanine in DNA. This covalent binding
process is believed to be an early event in B[a]P induced carcinogenesis. Previously,
the HPLC-FD assay was applied to white blood cell DNA of aluminum workers and
smoking lung cancer patients by Rojas et al. (9). Moreover, this assay was found to be
sufficiently sensitive to detect BPDE-DNA adducts in coke oven workers (8);
putative BPDE-DNA adduct
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Figure 4. Relationship between the mean 24 hours urinary excretion of 3-OH-B|a]P and BPDE-DNA
adducts in tissues (1= Liver, r=0.66, p=0.036; 11= Lung, r=0.67, p=0.035; m= Heart, r=0.68, p=0.026)
determined by -^P-postlabeling,
levels in white blood cells determined by means of -^P-postlabeling were correlated
with HPI.C-FD. However, since these subjects were exposed to complex chemical
mixtures and the resolution of TLC in -^P-postlabeling is low (5), unknown adducts
m.iy comigrate with the BPDE-DNA adduct spot. Therefore in the present study, an
animal model was used with exposure to a single compound to further investigate
the value of this technique.
B|a]P induced DNA adducts and carcinogenesis have been extensively studied
in rats and a wide range of tumors was found, depending on the route of
administration. Overall, the most important target sites seem to be pulmonary,
gastric and mammary tissues (14, 16). Exposure via i.p. injection of B[a]P most
frequently leads to the formation of rumors in the peritoneum and lung (17). Reasons
for differences in tissue susceptibility are still under intensive investigation.
Therefore, we also examined inter-organ differences with regard to maximal DNA
adduct levels and adduct persistence. It should be mentioned, however, that accurate
inter-organ comparisons for susceptibility to carcinogens can only be made with
consideration of intra-organ cell heterogeneity, cell specific adducts and rates of cell
turnover.
After a single i.p. injection of B[a]P, using ^p.postlabeling we found highest
total adduct levels in liver > heart > lung. Other studies found similar adduct
distributions and kinetics in rat organs after i.p. exposure to B[a)P (16, 18). In these
studies, peak DNA adduct levels were also observed at approximately 3-4 days after
a single i.p. administration of B[a]P. Although the lung is a major site for B[a]P-
carcinogenesis, the total amount of liver and heart DNA adducts at day 4 after
exposure was much higher. This indicates that there is no quantitative relationship
between the extent of covalent reaction of B[a]P metabolites with DNA and tissue
susceptibility for rumor induction. Differences in adduct types and adduct
conformation may be involved (19). With respect to adduct types, using the HPLC-
FD assay we found higher levels of B[a]P tetrol 1-1 in lung compared to liver DNA.
The 1-1 tetrol derives from hydrolysis of anti-BPDE, which is known to be the most
potent tumor inducing form of BPDE (1). On the contrary, maximal putative BPDE-
DNA adduct levels determined by - '^P-postlabeling were not significantly different
for lung (3.1 ± 0.9) and liver (2.9 ± 0.7). A possible explanation for this discrepancy is
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that in liver the BPDE-DNA spot determined by -^P-postlabeling may contain
adducts formed by multiple BPDE-isomers. Using HPLC-FD however, the separate
tetrol levels were not higher than the detection limit for liver DNA. In lung, the
BPDE-DNA spot is predominantly formed by tetrol 1-1 (>45%), that can be detected
by HPLC-FD. In those samples in which both tetrol 1-1 and 11-2 were detected, a good
correlation between both techniques was found (r=0.95). HPLC-FD analysis resulted
in highest adduct levels in respectively heart, lung and liver. In the present study,
using a high dose of B[a]P and large quantities of DNA, most tissues .inalvmi
seemed to contain adduct levels at or below the detection limits ot the HIM t ID
assay. These findings could question the applicability of HPLC-FD in human
biomonitoring. However, several studies already showed that this assay is
sufficiently sensitive to detect BPDE-DNA in human lung, aorta, colon mucosa and
also in lymphocytes of cigarette smokers and occupationally exposed individuals (7-
9, 20, 21). Another advantage of this technique is that it does not require the
application of radioactivity.
Table I. BPDE-DNA adduct leveb (adducts per 10* nucleotides) determined by HPLC-FD In rati
acutely exposed to B[a)P.
Day
0
1
2
4
11
Liver
Tetrol 1-1
<0.5*
<0.8
•0.9
<0.5
<0.6
Lung
Tetrol 1-1
<0.7
<0.6
<1.2
1.4 ±0.1
1.0"
Heart
Tetrol 1-1
0.8 ± 0.0
1.9"
2.0 ± 0.3
2.0 ± 0.3
2.0 ± 0.7
Tetrol n-2
1.6"
1.2"
2.7"
<5.9
<5.6
' DNA adduct level below detection limit as indicated
" Single value; other sample below detection limit
Differences in adduct persistence have also been suggested to be involved in
tumorigenesis. In our experiment the persistence of total adduct levels, determined
by '2p.postlabeling, was similar between liver and lung. By contrast, the persistence
of BPDE-DNA adducts was highest in heart followed by respectively lung and liver
calculated on basis of ^p.postlabeling. Estimated half-lives calculated on basis of
HPLC-FD (tetrol 1-1 only) were similar as compared with ^p.postlabeling.
Furthermore, these results are in agreement with Nesnow et al. (18) and Qu et al. (22)
after respectively single or multiple i.p. administrations of B[a]P. However, adduct
persistence alone is not sufficient to explain the rumorigenic potencies of PAH (14).
High adduct levels and adduct persistence in heart will rarely lead to tumor
formation, because heart muscle cells do not proliferate, which is a prerequisite for
the fixation of DNA damage. In short, the level and persistence of BPDE-DNA in
lung and liver coincides with the tissue's susceptibility for tumor induction and may
therefore be of importance in the assessment of the biologically effective dose. By
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^P-postlabeling, information about the characteristics and identity of an unknown
adduct can only be obtained if several solvent systems or enrichment procedures are
used. For instance, adduct 3 (Figure 1) was NP1 resistant, but could not be found
after using the butanol enrichment method. Obviously, this compound is not
sufficiently hydrophobic to be extracted with butanol.
Additionally, we have studied the excretion of 3-OH-B[a]P as a measure of the
internal whole body dose. The excretion of 3-OH-B[a]P reached a maximum on day 3
and the cumulative excretion added up to only 0.03% of the total dose of exposure. 3-
OH-B|a|P kinetics did not coincide with adduct levels in tissues. Nonetheless, at the
individual level significant correlations were found between the mean 24 hr
excretion of 3-OH-B[a]P and DNA adduct levels in organs, i.e. rats with a higher
excretion of 3-OH-B[«i|P had higher adduct levels in lung, liver or heart tissue
determined by -^P-postlabeling and HPLC-FD. Thus, monitoring the urinary
excretion of 3-OH-B|a]P over a prolonged period of time may reflect DNA adduct
formation in internal organs, while a single measurement of 3-OH-B[a]P in the urine
does not. Furthermore, Likhachev et al. (23) found high levels of B[a]P-7,8-diol, a
precursor of BPDF, in the urine of B[a]P exposed rats, which correlated with the
latency of tumor formation. We also found a urinary compound with co-
chromatographic characteristics of B|a)P-7,8-diol, but spectrum analysis showed that
this compound was not B[ajP-7,8-diof (data not shown).
A thorough understanding of the formation of DNA adduct types in target-cells
or a well established surrogate source of exposed DNA will permit us to use PAH-
DNA adducts as an effective biomarker (24). Our results show that adduct
identification by means of HPLC-FD might increase the applicability of DNA adduct
measurements in the assessment of the biologically effective dose. The ^2p.
postlabeling assay is sensitive and capable of detecting exposures to complex
mixtures. On the other hand, the HPLC-FD assay can be used to identify BPDE-
isomers with different biological effects and might therefore be of value in risk
assessment of individuals exposed to PAH.
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Abstract
32p-postlabeling is a widely applied assay for the analysis of carcinogen-DNA
adducts. Optimization of most steps in this assay has been given attention, but
influences of DNA isolation and DNA purity on adduct quantitation have not been
investigated systematically. In this study, DNA was isolated from human
lymphocytes exposed to benzo[a|pyrene (B[a]P, 10 uM) for 18 hours and from liver
of rats i.p. treated with B|a]P (10 mg/kg body weight) using two different DNA
isolation methods: a phenol-extraction and a salting out procedure. Subsequently,
DNA was analyzed by nuclease PI (NP1) or butanol enriched ^P-postlabeling.
Influences of RNA-contamination were studied by labeling RNA, isolated from I'M
pirro exposed lymphocytes. In the in n/ro experiment, DNA adduct levels were
significantly higher using the salting out procedure (63.2±13.7 adducts per 10"
nucleotides, n=9) as compared with the phenol-extraction (14.3±0.8). RNA was ca. 4
times less efficiently labeled as compared to DNA. Nonetheless, RNA contamination
of DNA samples may result in an overestimation of DNA adduct levels when
butanol enrichment is used, because RNA adduct levels seemed to be substantially
higher than DNA adduct levels in the same cells. DNA adduct analysis by nuclease
PI enrichment is probably less affected, since RNA adducts appeared to be NP1
sensitive, /n i»iz«o, three different adducts were found by NP1 enriched ^P-
postlabeling in the liver of B|a]P exposed rats. Again, DNA adduct levels were
significantly higher using salting out as compared to phenol extraction for the
adduct which comigrated with the BPDE-DNA adduct standard (adduct 1) and an
unknown adduct (adduct 2). However, the results were the opposite for another
B[a]P-derived DNA adduct (adduct 3). Our results suggest that differences in DNA
isolation procedures as well as RNA contamination influence quantitative DNA
adduct analysis by -^P-postlabeling.
Introduction
Binding of carcinogens to DNA is thought to play a crucial role in the multistep
process of carcinogenesis. Therefore, DNA adduct measurements are considered to
be a relevant indicator for carcinogen exposure. Several studies even aimed at
providing an improved basis for risk assessment by DNA-adduct measurements (1,
2). However, for these purposes sensitive and accurate assays are obligatory. Several
methods for DNA adduct analysis have been developed during the last two decades.
At this moment '-P-postlabeling is the most sensitive assay that can be applied to
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detect several kinds of DNA damages such as bulky-DNA adducts (3), oxidative and
UV-irradiation-induced damage (4), a Iky la ted bases (5) or apurinic sites (6). An
advantage of ^P-postlabeling is that it needs only small amounts of DNA, which
makes this assay suitable for the analysis of human (biopsy) samples. A
disadvantage of this assay is its inability to identify adduct types. In this area, other
assays have been developed, such as HPLC-FD (7) or 32p-postlabeling combined
with HPLC and on-line detection of radioactivity (8), but these assays never reached
the detection limits obtained by ^p.postlabeling with TLC. Many steps in the '*p.
postlabeling assay are optimized especially for bulky-DNA adducts and under
optimal conditions detection limits of one adduct per 10M0'" nucleotides are
reported (9). However, some aspects that may influence adduct analysis, are
underrecognized. For example, proper DNA isolation is a critical step for '2p.
postlabeling, but the exact influences of different DNA isolation techniques on
adduct recoveries are largely uninvestigated. Furthermore, impurities of DNA
samples may hamper accurate quantitative analysis and this problem certainly
deserves more attention. The -^P-postlabeling assay was originally developed to
study nucleic acids including RNA-derived ribonucleotides (10) and therefore,
contamination of DNA samples by RNA may be a disturbing factor, because normal
and adducted RNA nucleotides may additionally be labeled. Additionally, RNA
contamination may intpr/wp w.hen .assessing the D.N'.4 •rewAewf i^*
spectrophotometrical analysis. In the present study, DNA adducts were analyzed by
nuclease PI (NPl) as well as butanol enriched -^P-postlabeling in lymphocytes after
18 hours of i»i t'/fro exposure to 10 uM benzo[a]pyrene (B[a]P) and in liver-DNA of
rats i.p. treated with 10 mg B[a]P per kg body weight. DNA was isolated by a
routinely used phenol extraction method (11) and a salting out procedure as
described by Miller et al. (12). From the in pifro treated cells also RNA was isolated
by a procedure based on phenol extraction, analyzed by ^p.postlabeling and
subsequently compared with DNA adduct levels.
Materials & Methods
C/KVWKYI/S
All solutions used were sterile. B[a]P was purchased from Sigma (St. Louis, MO,
USA). RPMI 1640, streptomycin/penicillin, L-glutamin and fetal calf serum (FCS)
were all obtained from Gibco (Europe). Lymphoprep™ (1.077 g/ml) was obtained
from Nycomed (Oslo, Norway). All other chemicals were purchased from Merck
(Darmstadt, Germany). Water was purified by means of a milli-Q purification
system.
ami ini'ufcirioH o/Zymp/tocyto;
Ten ml of peripheral blood of nine healthy nonsmoking volunteers was sampled by
venapuncture into EDTA-tubes. Polymorphonuclear cells (granulocytes) were
separated from lymphocytes and monocytes by gradient centrifugation on
lymphoprep according to Boyum (13). Mononuclear cell fractions were washed with
PBS and suspended at a concentration of 2x10* cells/ml in RPMI 1640,
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supplemented with 10% FCS, 2 mM L-glutamin, 10 IU/ml penicillin and 10 ug/ml
streptomycin. B[a]P was dissolved in dimethylsulfoxide (DMSO) and added to the
cells to yield a final concentration of 10 uM. In all incubations the DMSO
concentration did not exceed 0.5%. Cells were incubated for 18 hours (37W 5% CC^
95% O2). Viability was checked by means of trypan-blue exclusion. After the
incubations, cells were collected by centrifugation, washed with PBS and stored at -
20°C until DNA/RNA isolation. *v ii
o/Lrtvis ru/s u>ir/i
Six male Lewis rats weighing 270-320 g were used. The animals were housed
individually in a room maintained at 25°C, 50% humidity and a 12 hr light/dark
cycle. Standard rodent lab chow (diet no. RSM-A, Hope Farms, Woerden, The
Netherlands) and water were provided ad libitum. B[a]P was initially dissolved in
hexane and added to sunflower oil. Evaporation of the hexane resulted in a B|a|P
concentration of 2 mg/ml oil. Rats were injected intra-peritoneally with 0.05 ml of
B[a]P-solution per 10 gram bodyweight to obtain a final dose of 10 mg/kg
bodyweight. This treatment did not influence the eating and drinking behavior, as
determined by reweighing the supplied food and water. Rats were killed at 2, 4 and
11 days after treatment (two rats per time-point). The liver was removed, washed
with PBS and quickly frozen at -20°C until DNA isolation.
DN/4 /so/of/OH procedures
Lymphocytes were lysed with 2.5 ml SDS/NEP (75 mM NaCl, 25 mM KDTA, 50
mg/ml Proteinase K, 1% SDS) and incubated for 4 hours at 37°C. Approximately 1
gram of liver was washed with 0.25 M sucrose/ 0.1 M Tris-HCl (pH 7.4) and
homogenized with a potter (1000 rpm) in 17o SDS/ 1 mM HDTA and subsequently
incubated overnight at 37°C with 0.5 mg Proteinase K.
Phenol extraction (11); samples were extracted with equal volumes of phenol:
chloroform: isoamylalcohol (25:24:1, v /v /v) and chloroform: isoamylalcohol (24:1,
v/v) respectively. DNA was precipitated with two volumes of cold ethanol after
addition of 1/30 volume 3M sodiumacetate, pH 5.3 and washed with 70% ethanol.
Salting out procedure, i.e. selective precipitation by NaCl and ethanol (12); 1/3
volume of 6M NaCl was added to precipitate the proteins. Additionally, the aqueous
phase was once extracted with chloroform: isoamylalcohol (24:1, v/v). DNA was
precipitated with two volumes of cold ethanol and washed with 70% ethanol.
DNA samples were treated with RNase A (100 Mg/ml) and Tl (50 U/ml) for 30 min.
at 37°C and once extracted with chloroform: isoamylalcohol (24:1, v/v).
Subsequently, DNA was reprecipitated and dissolved in 2 mM Tris, pH 7,4.
Concentration and purity were determined spectrophotometrically by absorbance at
230, 260 and 280 nm (Table I). The final volume was adjusted to achieve a DNA-
concentration of 2 mg/ml (1 OD260= 50 ug/ul).
RN>4 Jso/flf/'oM procedure
RNA was isolated according to Chomczynski and Sacchi (14). The denaturing
solution was 4 M guanidinium-thiocyanate, 25 mM sodium citrate, pH 7.0; 0.5%
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sarcosyl, 0.1 M G-mercapto ethanol. After addition of 2 M sodium acetate (pH 4.0),
the aqueous phase was extracted with phenol and chlorofornvisoamyl alcohol (49:1).
The RNA was precipitated with 1 volume of cold isopropanol after addition of 1/20
volume of 2 M sodiumacetate. Subsequently, RNA was obtained by centrifugation at
10,000 g for 15 minutes at 4°C and washed with respectively the denaturing solution
as described above and 70% ethanol. Finally, RNA was dissolved in 2 mM Tris, pH
7.4. Concentration and purity were determined specrrophotomerrically by
absorbance at 230, 260 and 280 nm (Table I). The final volume was adjusted to
achieve a RNA-concentration of 2 mg/ml (1 OD260= 40
The Nl'l enriched ^p.postlabeling assay was performed as described by Van
Schooten et al. (15). Butanol enrichment was applied as described by Gallagher et al.
(16). NP1-efficiency, removal of normal nucleotides by butanol extraction and ATP-
excess were checked with an aliquot of the enriched fractions by one-dimensional
chromatography on poly(ethyleneimine)(PEI)-cellulose sheets from Merck, Germany
(solvent: 0.12 M NahhPO^ pH 6.8). Radiolabeled adduct nucleotide biphosphates
were separated by chromatography on PEI-cellulose sheets from Machery Nagel
(Germany). The following solvent systems were used: Dl, 1 M NaH2PO4 pH 6.5; D2,
8.5 M urea, 5.3 M lithium formate pH 3.5; D3, 1.2 M lithium chloride, 0.5 M Tris, 8.5
M urea pH 8.0; D4, 1.7 M NaH2PO4 pH 6.0. In each experiment, 3 standards of
PH]BPDE modified DNA with known modification levels (1 per 10?, 10 ,^ 10">
nucleotides) were run parallelly. Quantification was performed by using phosphor-
imaging technology (Molecular Dynamics™, Sunnyvale, CA, USA). The final
amount of DNA in the assay was determined by dilution and labeling of normal
nucleotides with excess (Y--^P]-ATP (15 uCi/ sample) by incubation with T4-
polynucleotide kinase (2.5 Units) for 30 minutes at 37°C. Excess of ATP was removed
by incubation with apyrase (12.5 mU) for 30 min. at 37°C. Nucleotides were
separated by one-dimensional chromatography on PEI-cellulose sheets from Merck
(solvent: 0.12 M NaH2PC>4 pH 6.8). A dAp standard (27.5 pmole/pl) was labeled in
each experiment for quantification purposes. Interassay variation was <25%.
Sto/ishcs
Data are presented as mean ± standard error of the mean. Non-parametric tests for
paired samples (Wilcoxon signed rank tests) were applied to evaluate the statistical
significance of differences between DNA isolation methodologies. P<0.05 was
considered significant.
Results
f itv flnd (juanf itof itv re^w/rs of DNA/ RN/1 iso/af ion and /afre/»>ig
For pure DNA, the spectral ratio A260/A280 should be -1.8 and the ratio
A230/A2t>0 -0.45. All DNA samples had ratios near these theoretical values as shown
in Table I, except for rat-liver DNA isolated by the salting out procedure (A260/A280:
1.67±0.01), which indicates that in these samples some residual proteins were
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present. The maximum absorption was found at ~260 nm, which indicates that the
DNA was not significantly contaminated with RNA, since RNA contamination
would result in a shift of the maximum towards 250 nm. Protein contamination
might result in a tailing spot at the origin in the labeling experiment. However, after
labeling an aliquot of the digested DNA and subsequent TLC separation of normal
nucleotides with 0.12 M NaHiPC^ (pH 6.8), no tailing was observed (a typical
chromatograph is shown in Figure 1). For RNA, a spectral ratio A260/A280 of
2.07±0.10 (Table 1) was found, which is in line with the theoretical value of -2.0.
Furthermore, in the chromatographs, no additional DNA-spots were observed, from
which it can be deduced that contamination with DNA is <1%.
Table I. Purity information on DNA and RNA samples after phenol extraction or salting out
procedure as described in Materials and Methods section of human lymphocytes and rat liver.
Spectral Ratio
A260/A280
A230/A260
DNA Yields
DNA of
lymphocytes
1.79 ±0.06
0.44 ± 0.01
33.3 * 4.0 *
Phenol extraction
RNA of
lymphocytes
2.07 ± 0.10
0.49 ± 0.02
24.3 ± 2.7 »
Liver DNA
of rats
1.81 ± 0.01
0.47 ± 0.01
8%±59*>
Salting out Procedure
DNA of
lymphocytes
1.77 ±0.03
0.42 ± 0.02
35.6 ± 3.7 •
Liver DNA
of rats
1.67 ±0.01
0.46 ± 0.01
909±34*>
a: DNA or RNA yield per 10? cells
b: DNA yield per gram liver tissue
After labeling of normal nucleotides, DNA and RNA nucleotides showed
distinct migration rates (Figure 1). RNA nucleotides migrated slower than DNA
nucleotides. The percentage of each dNp was near the theoretically expected value
(dTp: dCp: dAp: dGp= 29: 21: 29: 21), which indicates that hydrolysis was efficient
and there was no deficit of ATP in the labeling reaction. Since rRNA will comprise
most of the isolated ribonucleotides and the base-composition of rRNA in animal
cells from various sources are similar, a Cp-Gp content of ca. 55% was expected.
Indeed, in this experiment, the Cp-Gp content in total lymphocytic RNA appeared to
be53±l.l%.
As expected, spectrophotometrically determined DNA concentrations were
very well correlated with the DNA concentrations determined by 32p-postlabeling
(r=0.87, p<0.01). Interestingly, RNA concentrations showed a high correlation as well
(r=0.80, p<0.01), but the slope of the regression line was only 1 /4 of the slope found
with DNA. Thus, equal amounts of DNA and RNA determined by means of
spectrophotometry, showed a 4-fold difference in the amount of nucleotides if
determined by 32p-postlabeling (Figure 2). These results suggest that RNA is ca. 4
times less efficiently labeled as compared with DNA. The labeling of RNA was not
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significantly increased by prolonged incubation of RNA-nudeotides with T4-PNK
and [y-^pjATP for up to 2 hours (data not shown).
RNA DNA
dTp
(28.1*/.)
dCp
(21.7%)
dAp
(29.7%)
dGp
(21.4%)
OR1
Figure 1. labeling ot normal RNA and DNA nucleotides and adduct prohles in DNA (A) and RNA
(B) of B|a]P treated lymphocytes. Panel C shows DNA adduct spots in rat liver DNA, 11 days after i.p.
injection ot B[.i|P and DNA isolation by the salting out procedure. ORI= Origin.
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After incubation of lymphocytes with B[a]P for 18 hours, a conjunction of at
least three individual spots was found by ^-P-postlabeling in all samples, of which
the in between spot comigrated with a standard adduct formed by (±)anti-
benzo(a)pyrene-diolepoxide (BPDE-DNA) as shown in Figure 1 A. These spots could
not be resolved and therefore the whole region (all three spots) was used for
quanritation purposes and will be further refered to as B[a]P-derived DNA adducts
(B[a]P-DNA). B[a]P-DNA adduct levels were analyzed in three independent
experiments. In each experiment, three separate incubations of lymphocytes were
performed, from which DNA was isolated by both DNA extraction procedures
(overall, n=9 per isolation procedure). DNA adduct profiles obtained after both DNA
isolation procedures showed no qualitative differences, but the B[a|P-DNA adduct
spot was quantitatively more intense in the samples that were isolated by the salting
out procedure (63.2 ± 13.7 adducts per 10" nucleotides) as compared with the
frequently used phenol extraction method (14.3 ± 0.8)(P=0.001)(Table II). B|a]P-DNA
adduct levels in samples isolated by phenol extraction and subsequent analysis by
butanol enrichment were 11.9 ±1.9 adducts per 10" nucleotides. /» pi'w, in rats treated
with a single i.p. injection of B[a]P, adduct levels were determined in liver DNA by
NP1 enriched ^P-postlabeling (Table II). Three B[a]P related DNA adducts were
detected, one of which comigrated with the BPDE-DNA adduct standard (Figure 1,
panel C, spot#l). Again, BPDE-DNA adduct levels were higher after salting out
procedure as compared with the phenol extraction at all three studied time-points (2
rats per time-point). Two days after the i.p. injection of B[a]P, BPDH-DNA adduct
levels were 2.6±1.0 and 2.0±0.8 adducts per 10" nucleotides for respectively salting
out and phenol extraction procedures, followed by decreasing adduct levels at t=4
days (respectively 1.7±0.4 and l.l±0.8) and t=ll days (respectively 0.9±0.2 and
0.3±0.1). Overall, differences between these isolation methods were statistically
significant (n=6, P=0.013, paired statistical analysis by a Wilcoxon signed-rank test).
Adduct spot#2 was also more intense after DNA isolation by salting out (2.4±0.5,
3.6±1.2 and 5.3±0.9 at respectively t= 2, 4 and 11 days) as compared with phenol
extraction (respectively 0.8±0.4, 0.4±0.2 and <detectionlimit, overall P=0.012). On the
other hand, adduct spot#3 showed a better recovery using phenol extraction (2.8±0.9,
7.0±2.0 and 5.1 ±0.8 at respectively t= 2, 4 and 11 days) as compared with the salting
out procedure (respectively 1.6±0.2, 2.6±0.5 and 4.4±0.6, overall P=0.046).
DA//4 and RN/\ addwc/s in /ymp/jocy/es, m u/fro inrufra/ft/ zw7/r B/a/P
RNA adducts in lymphocytes exposed to B[a]P showed comparable
chromatographic characteristics as compared with DNA adducts (Figure 1, panel A
and B). DNA adduct levels analyzed by NP1- and butanol-enrichment were similar
(14.3 ± 0.8 adducts/ 10" nucleotides and 11.9 ± 1.9, respectively). Surprisingly using
butanol enrichment, the intensity of RNA adduct spots was ca. 12 fold higher as
compared to the intensity of the B[a]P-DNA adduct spots, while equal amounts of
DNA/RNA were used as determined by spectrophotometry. After correction for the
less efficient labeling of RNA nucleotides, RNA adduct levels appeared about 50-fold
higher than DNA adduct levels in the same treated cells (both isolated with a
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method based on phenol extraction) using butanol enrichment (651 ± 103 adducts/
10«), but not after NP1- enrichment (13.3 ±7.5). Thus, RNA adduct levels decreased
dramatically after nuclease PI treatment; only 2% of the butanol enriched level was
recovered.
24x10'
1 2 3 4
Spectrophotometrically determined
DNA/ RNA concentration lng/nl |
Figure 2. Labeling efficiency of DNA- and RNA-derived nucleotides (slopes: RNA=ca. 1/4 DNA),
determined by comparison of spectrophotometrical and labeling analysis, after isolation with methods
based on phenol extraction as described in Materials and Methods section.
Discussion
The results of the present study indicate that differences in DNA isolation
methodologies may have implications for the quantitative analysis of carcinogen-
DNA adducts. Since different laboratories may use divergent techniques to isolate
DNA, interlaboratory comparison is jeopardized. In the past, small-scale
interlaboratory comparisons have been performed (17, 18). In 1992 a larger
interlaboratory trial was conducted involving 15 different laboratories (19) and new
trials are ongoing. However, these studies did not consider the influence of DNA
isolation procedures since they applied DNA that was already isolated. Various
isolation methods are in use, such as phenol extraction, salting out procedures and
commercially available kits based on various principles for DNA purification.
Furthermore, variations on each of these techniques are likely to occur, which raises
tho question whether or not adduct recoveries and labeling is affected by these
variations. The results of the /» i>»7ro experiment showed almost 5-fold differences in
adduct recoveries between the two different isolation procedures. This discrepancy
could be due to inadequate purification of DNA by the salting out procedure.
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because it has been demonstrated that terrol-derivates of B(a]P can become *-P-
labeled in the absence of nucleic acids in in iwfro experiments (20). However, labeling
of tetrols did not seem to present a problem in analyzing DNA extracted from
human or mammalian tissue. In the present study, differences between the two DNA
isolation procedures were also present in t'l'tv, although less pronounced (ca. 1.5-
fold), indicating that the differences between isolation procedures can not completely
be explained by insufficient purification from tetrol-derivatives. The results were not
consistent for all adduct types and therefore further research is needed to find out
what method is best for adduct recoveries after exposure to different complex
mixtures. Recently, Brescia et al. (21) used a salting out procedure for DNA isolation
from white blood cells and lymphocytes of coke oven workers. In a relevant fraction
of DNA samples (54% and 30% for WBC and lymphocytes respectively), DNA
adducts were detected with similar chromatographic characteristics as compared
with their BPDE-modified DNA standard. Unfortunately, no further identification of
adducts was attempted.
Table II. DNA and RNA adduct levels after phenol extraction or salting out procedure using either
NP1 or Butanol enriched ^P-postlabeling after exposure to B|a)P.
DNA
lymphocytes
RNA
lymphocytes
Liver DNA of rats
i.p. exposed to B|a|P
Phenol
Extraction
Salting out
Procedure
14.3 ±0.8 »
11.9 ± 1.9 ^
63.2 ± 13.7*
N.P.
13.3 ± 7.5 •
651 ± 103 •»
N.P.
N.P.
Spot
t=0
t=4
t - U
t=0
t=4
t=ll
#1
2.0 ± 0.8"
1.1 ±0.8
0.3 ±0.1
2.6 ± 1.0
1.7 ±0.4
0.9 ± 0.2
#2
0.8 ± 0.4
0.4 ± 0.2
N.D.
2.4 ± 0.5
3.6 ± 1.2
5.3 ± 0.9
#3
2.8 ± 0.9
7.0 ± 2.0
5.1 ±0.8
1.6 ±0.2
2.6 ± 0.5
4.4 ± 0.6
a: NP1 enrichment, b: Butanol enrichment
N.P.: Not Performed, N.D.: Not Detected
Thus, if a method of adduct detection is applied that focuses on BPDE-DNA, for
example HPLC-FD, the salting out procedure for DNA isolation/purification seems
to be the method of choice. Furthermore, in our laboratory, no differences were
observed in recoveries of 8-oxo-dG analyzed by HPLC and electrochemical detection
using both DNA isolation methodologies (data not shown), but problems with
columns may arise using the salting out procedure. Furthermore, the present study
suggests that RNA contamination in DNA samples may trouble quantitative analysis
in the case butanol enrichment is applied. RNA contamination may result in an
overestimation of the actual DNA adduct level, because RNA adducts are labeled as
well. In our particular case (lymphocytes incubated with B[a]P), we can calculate that
for example 1% of RNA contamination leads to an overestimation of the DNA
adduct level for approximately 10%, assuming that in a mixture of RNA and DNA
derived nucleotides, the labeling efficiencies are similar to those found in the
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separate fractions. Low levels of RNA contamination may remain unnoticed, because
RNA was ca. 4-fold less efficiently labeled as DNA, which is not unexpected since
the ^p.postlabeling assay is optimized for DNA, not for RNA. NPl-enriched ^ p .
postlabeling is probably not affected by low RNA contamination, since RNA ad ducts
appeared to be NPl-sensitive. Indeed, Steenwinkel et al. (22) found only marginal
effects of RNA contamination on quantitative adduct analysis using NPl enriched
32p-postlabeling. B[a]P derived RNA adduct levels were higher in m u/fro exposed
lymphocytes as compared with DNA adduct levels in the same cells. /« UJTO, similar
results were reported by Weyand et al. (23) in rats intratracheally exposed to
PH]B[a]P. These differences between DNA and RNA adduct levels can be explained
by the absence of repair for RNA, the better accessibility of RNA for electrophiles
and the differences in location within the cell. Moreover, high RNA adduct levels
suggest a possible role for RNA adducts as a an alternative to DNA dosimetry in
biomonitoring studies.
In the present study, no information could be obtained regarding adduct
formation in mitochondrial DNA (mtDNA) or RNA (mtRNA), which will most
probably differ in adduct levels as compared with nuclear DNA or cellular RNA. In
previous studies, it was found that covalent binding of PH]B[a]P to mtDNA was 4 to
over 5(X) times greater as compared with nDNA (24, 25). Recent studies, using ^ p .
postlabeling for adduct quantitation confirmed these results (26). The two DNA
isolation procedures used in this study may give different yields of mitochondrial
contaminants (as well as losses in matrix associated DNA), which could partly
explain the observed differences in DNA adduct levels. For this reason, several
laboratories avoid contamination of nDNA with (mt)RNA or mtDNA by starting the
DNA extraction with isolated nuclei rather than cells or homogenized tissues.
Nonetheless, the isolation procedures as studied in the present work are frequently
and routinely applied in most other laboratories, and the results show that a critical
evaluation of these techniques is necessary for future research.
In conclusion, differences in DNA isolation methods may partly be responsible
for interlaboratory differences. Influences of DNA isolation and purification should
be further investigated to obtain the most appropriate method, but it seems
impossible to provide a generalized protocol for DNA isolation, since various types
of adducts may be recovered differently with specific isolation procedures. RNA
contamination in DNA samples may lead to overestimation of adduct levels by
butanol enriched ^p.postlabeling, whereas adduct analysis after NPl enrichment is
probably less affected.
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Chapter 12
Summary and General Discussion
« PAH have been found to be carcinogenic in laboratory animals and are
suspected to be carcinogenic in humans (1). To study the association between
exposure to PAH and cancer risk, classic epidemiologic.il techniques can be
employed. However, these techniques are usually compromised by the lack of
quantitative exposure data and may therefore not be applicable for the assessment of
exposure or risk at the individual level. Molecular epidemiology, which aims to
integrate techniques of analytical chemistry, biochemistry, molecular biology and
epidemiology, has the potential to contribute to cancer research in a number of areas,
including assessment of biologically effective exposure to carcinogens and the early
identification of individuals at potentially high cancer risk.
Until now, many molecular epidemiological studies have focused on PAH-
DNA interaction products, i.e., DNA adducts, as measure of exposure to PAH
(reviewed in 2, 3). However, this field of research is still at an early stage of
development at which studies must be considered as small scale pilot studies'.
Therefore, the validation of DNA adduct measurements needs further attention to
improve their applicability in human field studies. Several aspects of DNA adduct
formation should be known to optimize study designs and subsequent interpretation
of the results (see Chapter 1.6). Some validity criteria for the use of DNA adduct
measurements in human exposure monitoring have been studied and presented in
this thesis.
Ideally, PAH-DNA adducts should be measured in organs in which PAH might
induce cancer, such as human lung or skin. However, samples from these target
organs can only be obtained in an invasive manner, and are therefore not useful for
routine biomonitoring. In the past, white blood cells (WBC) have been used as
surrogate source of exposed DNA, because they can easily be sampled, were found
to metabolize PAH to their DNA binding derivatives (4) and provide sufficient
amounts of DNA for most methods of DNA adduct analysis. The various
subpopulations of WBC (i.e., monocytes, lymphocytes and granulocytes) differ in
life-span, as well as metabolizing (5) and repair capacity (6). Therefore, separation of
these subsets might be necessary in DNA adduct analysis. Another surrogate source
of DNA, used for the analysis of DNA adducts specifically in relation to inhalatory
exposure, are the cells obtained by broncho-alveolar lavages (BAL-cells) (7). Previous
studies in smoking subjects indicated that BAL-cells or mononuclear blood cells
(MNC, i.e., monocytes and lymphocytes) would provide more promising results as
compared with total WBC or granulocytes (7, 8), but these cell-types were never
compared in one single study. Thus, in the present thesis, DNA adduct formation in
different WBC-subpopulations and BAL-cells of smokers were compared (Chapter 2)
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to select the most appropriate cell-type for biomonitoring PAH exposure. Aromatic-
DNA adduct levels appeared to be highest in BAL-cells, followed by respectively
MNC and granulocytes. These results suggest that DNA adduct measurements in
BAL-cells or MNC would provide the most sensitive analysis for assessing exposure
to inhaled genotoxic compounds.
The formation of covalent PAH-DNA adducts has been studied in smokers and
in occupationally exposed individuals as a quantitative measure of exposure to PAH
(reviewed in 2). Higher DNA adduct levels or a higher proportion of individuals
with detectable DNA adduct levels in WBC (subsets) were observed in highly
exposed individuals as compared with low/non exposed subjects. In the study
presented in Chapter 3 of this thesis, DNA adduct levels in MNC of smokers and
aluminum workers also appeared to be related with exposure (exposure to cigarette-
smoke or cigarette-tar per day and PAH in ambient air, respectively), but at high
exposure levels saturation of DNA adduct formation was apparent. Several
mechanisms that generate non-linearity of the dose-response curves can be involved
(9), but the present data do not warrant firm conclusions. Furthermore, it was found
that cigarette-smoke may indirectly influence dose-response relationships in WBC of
individuals who were additionally exposed via their work environment. It has been
reported that smoking cigarettes may enhance adduct formation by other exposures
(10), and thus, the shape of the dose-response curve of occupationally exposed
smokers might be different as compared with occupationally exposed nonsmokers.
Overall, these results seem to indicate that the level of aromatic-DNA adducts in
MNC reflects exposure to PAH, but at high exposures non-linearities may occur. In
BAL-cells, no relationship between aromatic-DNA adducts and the amount of
cigarettes smoked per day was observed. BAL cells are highly and directly exposed
to tobacco smoke and therefore, saturation might have occurred at lower numbers of
cigarettes smoked per day.
Several studies in smoking subjects indicated that inhalation of" PAH might not
be the only relevant exposure route for adduct formation in WBC; ingestion or
dermal contact with PAH may also be involved (11-13). For a better understanding
of data obtained by DNA adduct analysis in humans, it is important to know the
contribution of the different exposure routes to DNA adduct formation in different
WBC-stibpopulations. Therefore, in Chapter 4, exposure route dependent adduct
formation by B[a|P was studied in rats acutely exposed to BfajP via intra-traehea!
instillation, gavage and dermal application (since WBC of Lewis-rats consist for
more than 95% of lymphocytes, separation of subpopulations was not performed).
Higher adduct levels were observed in WBC after intratracheal and oral exposure of
rats as compared with dermal application of B[a]P. In the same rats, similar results
were found for lung tissue, which is a major target organ for B{a|P induced
carcinogenesis (1). A relation between DNA adduct levels in WBC and lung tissue
was found. This relationship was independent from the route of exposure. Initially,
in human studies a relationship between DNA adducts in WBC and lung was not
observed (14, 15). but in a more recent study using MNC instead ot total WBC, this
relationship was actually found (lfo>. Also in eczema patients topically treated with
coal-tar ointments, it was suggested that analysis of total WBC instead of MNC
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would decrease the strenght of the relationship between adduct levels in target tissue
(skin) and surrogate tissue (Chapter 7). Overall, these results indicate that DNA
adduct formation in MNC might reflect DNA adduct levels in relevant target organs.
To investigate whether DNA adduct measurements have the ability to integrate
exposure over a relatively long period of time (a few weeks up to a few months),
adduct removal was studied in smokers who stopped smoking for a period of 22
weeks (Chapter 5). DNA adduct levels in MNC were significantly reduced over this
period of smoking abstinence, but were still detectable in ca. 60% of the volunteers as
compared with ca. 30% in a group of never-smokers. The calculated half-life of
aromatic-DNA adducts in MNC was approximately 12 weeks, based on
logarithmically transformed DNA adduct levels. When a linear model for adduct
removal was applied, aromatic-DNA adduct levels in MNC would reach
background levels after 25 weeks of smoking cessation. Additionally, DNA adduct
formation and removal was studied in separated WBC-subpopulations of
individuals topically treated with coal-tar ointments for a short period of time
(Chapter 7). After one week of treatment, aromatic-DNA adduct levels were
significantly increased in the monocyte, lymphocyte and granulocyte fractions.
However, one week after the end of treatment, DNA adduct levels in monocytes and
granulocytes were back to base-line levels, whereas in the lymphocyte fraction
adduct levels were more persistent. These data indicate that if exposure changes,
DNA adduct levels in WBC subpopulations change accordingly. Thus, to study prior
exposures to aromatic compounds after a period of non-exposure, the lymphocyte
fraction should be used as surrogate tissue. However, if a particular research
question focuses on recent exposure only and bias by previous exposures is not
wanted, the monocyte fraction could also be of importance.
If exposure is continued, aromatic-DNA adduct levels should remain constant.
Until now, however, little information on intra-individual variations in aromatic-
DNA adduct levels is available (17). In Chapter 3, intra-individual variation in DNA
adduct levels was studied in MNC and BAL-cells from smoking volunteers, by
resampling after a period of respectively 2 or 6 months. In MNC of smokers, the
intra-individual variation was found to be low over a period of 2 months, but
resampling after a period of 6 months resulted in significantly higher DNA adduct
levels than in the first sampling of MNC. In this study, the timing of sampling
corresponded with a summer and winter period, respectively and it has been
described that environmental exposure is higher in winter as compared with
summer (18). However, other possible explanations cannot be excluded, for example,
differences in dietary habits between the two sampling periods. In BAL-cells, intra-
individual variation in DNA adduct levels over a period of 6 months was found to
be low; both samplings were well correlated.
Although DNA adduct levels in MNC correlated with the amount of cigarettes
smoked per day, large interindividual variations were observed. This means that
DNA adduct levels in two individuals with similar exposure levels can differ
significantly. Several sources for interindividual variation were identified in this
thesis; genetic polymorphisms in GSTM7 and N/4T2 genes that encode for enzymes
involved in phase II biotransformation of xenobiotics (Chapter 5) and body
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composition (Chapter 6). Furthermore, observed variations may, at least partly, be
due to differences in DNA repair or induction of DNA repair. In rats acutely exposed
to B(a]P, increased urinary levels of 8-oxo-dG indicate that nonspecific DNA repair
activities were induced (Chapter 9). P53 protein accumulation may be involved in
this induction of DNA repair by exposure to PAH, since exposure to PAH was found
to increase P53 levels in human epidermis (Chapter 8), especially in individuals that
lack the CSTM1 gene. It is known that P53 is involved in cell-cycle arrest to provide
sufficient time for DNA repair. Interindividual differences in adduct formation after
PAH exposure are in line with the susceptibility to develop specific cancers, and it
can be suggested that DNA adducts can be of use in identifying individuals at high
risk (19).
The internal dose of PAH is often assessed by measuring hydroxylated
metabolites (e.g., 3-OH-B[a]P and 1-OH-pyrene) in urine of exposed animals and
humans (20). These measurements, however, do not represent the biologically
effective dose at target tissue level and reflect exposure only over a short period of
time. Nonetheless, in rats acutely exposed to B[a)P a relationship between 3-OH-
B|a]P excretion and DNA adduct levels in target organs was observed (Chapter 4
and 10). Moreover, in coal-tar treated patients a relationship was found between
urinary 3-OH-B|a|P levels and specifically BPDE-DNA adducts (Chapter 7). Overall,
3-OH-B[a)P excretion was significantly increased after exposure to PAH, and
reduced to base-line levels within one or two weeks after exposure stopped. DNA
adducts, however, were still present in high quantities. These results question the
use of urinary metabolites to assess long term exposure to PAH.
In the present thesis, the emphasis was on studies regarding DNA adduct
formation after exposure to aromatic compounds of various sources (for example,
cigarette smoke or coal tar ointment). In Chapter 10 and 11, several technical aspects
of DNA adduct analysis are discussed. When DNA adduct analysis is applied in
human biomonitoring studies, the results should be reliable and reproducible with
low interassay and interlaboratory variations. The ^p.postlabeling assay is a
routinely and widely used technique, due to its sensitivity and it requires only small
amounts of DNA (21). However, specific DNA adducts cannot be identified, and
therefore, new techniques were introduced, such as HPLC with fluorescence
detection for the detection of specifically BPDE-DNA (Chapter 10) (22). Researchers
in the field of molecular epidemiology should be aware of the advantages and
disadvantages of each technique for DNA adduct detection, to facilitate their
selection of a technique for a particular study.
Overall, it can be concluded that there is sufficient scientific basis to justify the
application of DNA adduct measurements in PAH exposure assessment.
Furthermore, the results of the present thesis may open doors for new applications of
DNA adduct measurements, especially in the field of cancer prevention. For
example, DNA adduct measurements can be useful in testing the efficiency of
exposure intervention trials.
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Samenvatting
Polycydische aromatische koolwaterstoffen (PAK) vormen een groep van
verbindingen, die ontstaan als gevolg van onvolledige verbranding van organisch
materiaal. Veel PAK blijken kankerverwekkend te zijn in proefdioron on or wordt
verondersteld dat ze ook kankerverwekkend kunnen zijn in monson. Bep.ialdo
vormen van kanker komen namelijk vaker voor in mensen die beroepsmatig worden
blootgesteld aan PAK, dan onder de gehele bevolking. PAK zijn in staat kanker te
veroorzaken doordat ze in het lichaam omgezet worden tot reactievo producten,
welke kunnen reageren met het erfelijk materiaal (DNA) in de eel, waardoor zgn.
PAK-DNA addukten worden gevormd. Deze DNA addukten kunnen vervolgens
leiden tot DNA mutaties, die de normale processen van celgroei ontrogolon. Poor
deze verstoring van de celgroei kan het proces dat uiteindelijk leidt tot kanker
geinitieerd worden.
De gemiddelde bevolking kan op drie manieren worden blootgesteld aan PAK,
te weten oraal (bv. verontreinigde voeding), inhalatoir (bv. sigarettonrook) en
dermaal (bv. koolteer houdende zalven). De kankerepidemiologie heeft behoofte ann
gevoelige methoden voor de bepaling van deze blootstelling aan PAK en do hieruit
voorrvloeiende verhoogde kans op kanker. Bepaling van de hoeveelheid PAK-DNA
addukten in lichaamscellen zou voor dit doel een ideale maat kunnen zijn, aangezien
DNA addukten een indruk geven van de "biologiseh effectiovo dosis". Dit is de
hoeveelheid geactiveerde PAK dat uiteindelijk wordt gobonden aan DNA. Organen
waarin PAK kanker zouden kunnen veroorzaken (bv. long) zijn center niot
bereikbaar voor routinematig onderzoek en dus moet or gezocht wordon naar
andere geschikte bronnen van DNA. Het meest gebruikte surrogaat' weefsel wordt
gevormd door makkelijk te bereiken witte bloed cellen (WBC). WBC kunnen worden
onderverdeeld in een aantal subpopularies, namelijk monocyten, lymfocyten on
granulocyten. Een andere belangrijke bron van blootgestelde cellen wordt gevormd
door cellen verkregen uit de long door middel van een longspoeling (broncho-
alveolaire lavage; BAL-cellen). Echter, voordat DNA addukten in WBC-
subpopulaties of BAL-cellen doeltreffend kunnen worden toegepast in het
vaststellen van blootstelling aan PAK, dienen een aantal aspecten van DNA addukt
vorming in deze cellen bekend te zijn:
In hoofdstuk 2 van dit proefschrift werden DNA addukt niveaus in
verschillende WBC-subpopulaties en BAL-cellen van rokers besrudeerd, om vast te
stellen welke cel-typen het meest geschikt zouden kunnen zijn om de mate van
blootstelling aan PAK via sigarettenrook te bepalen. Aromatische-DNA addukt
niveaus bleken het hoogst te zijn in BAL-cellen, gevolgd door respectievelijk
mononucleaire bloedcellen (MNC, dit zijn monocyten plus lymfocyten) en
granulocyten. Deze resultaten geven aan dat de bepaling van DNA addukten in
BAL-cellen of MNC mogelijk de meest gevoelige analyses zijn om blootstelling aan
aromatische verbindingen vast te stellen. Verder bleken de DNA addukt niveaus in
MNC gerelateerd te zijn aan de mate van blootstelling; hoe meer iemand is
blootgesteld, des te hoger is het DNA addukt niveau. Bij zeer hoge blootstellingen
daarentegen, bleken de DNA addukt niveaus verhoudingsgewijs niet verder te
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steigen (Hoofdstuk 3). Een relatie tussen het aantal sigaretten dat per dag gerookt
werd en het DNA addukt niveau in BAL-cellen werd niet aangetoond. Dit zou
verklaard kunnen worden door het feit dat BAL-cellen direct en sterk zijn
blootgesteld aan geinhaleerde carcinogenen, waardoor een verzadiging van de DNA
addukt vorming eerder kan optreden dan in het perifere bloed.
Inhalatie van PAK via bv. sigarettenrook is niet de enige route waarlangs PAK
het lichaam kunnen binnendringen en waama DNA addukten in WBC gevormd
kunnen worden. Vandaar dat in hoofdstuk 4 in proefdieren (ratten) werd
onderzocht, welke invloed verschillende blootstellings-routes kunnen hebben op de
DNA addukt vorming in WBC door benzo(a)pyreen (B[a]P, een belangrijke
carcinogene PAK). De hoogste DNA addukt niveaus in WBC werden gevonden na
orale en intra-tracheale blootstelling, terwijl de laagste DNA addukt niveaus werden
gevonden na dermale toediening van B[a]P. DNA addukt niveaus in WBC waren
gerclateerd aan die in de long, en deze relatie was onafhankelijk van de
blootstellingsroute. Over het algemeen werden statistisch significante relaties
waargenomen tussen DNA addukt niveaus in WBC en relevante doelwitorganen
(die organen waarin PAK kanker kunnen induceren). Ook in eczeem patienten, die
dermaal behandeld werden met koolteer zalven, waarin hoge concentraties PAK
voorkomen, werd een relatie aangetoond tussen het DNA addukt niveau in MNC en
de huid (hoofdstuk 7). De resultaten van deze studies met zowel proefdieren als
patienten, geven aan dat DNA addukten in MNC gebruikt kunnen worden als maat
voor do hoeveelheid DNA schade in relevante doelwitorganen.
Om te bestuderen of DNA addukt metingen de mogelijkheid bieden om
blootstelling over een relatief lange periode vast te stellen (weken tot maanden),
werd de DNA addukt verwijdering bestudeerd in MNC van vrijwilligers die stopten
met roken voor een periode van tenminste 22 weken (Hoofdstuk 5). Na het stoppen
met roken waren de DNA addukt niveaus duidelijk gedaald, maar waren nog steeds
aantoonbaar in 60% van de vrijwilligers. Ter vergelijking werd ook de aanwezigheid
van DNA addukten bestudeerd in MNC van een groep vrijwilligers die nog nooit
gerookt hadden. In deze personen werden in slechts 30% van de personen DNA
addukten gedetecteerd. De halfwaardetijd (de tijd waarin het addukt niveau is
gehalveerd) in MNC werd geschat op circa 12 weken. DNA addukt vermindering
werd ook bestudeerd in WBC-subpopulaties van de eczeem patienten behandeld
met koolteer zalf (hoofdstuk 7). De aanwezigheid van DNA addukten in de
monocyten en granulocyten fractie bleek veel korter te zijn dan die in de lymfocyten
fractie. Dit komt goed overeen met de levensduur van deze celtypes. DNA addukt
metingen in lymfocyten zijn dus geschikt om langdurige blootstelling aan PAK vast
te stellen, of om PAK belasting vast te stellen na een periode waarin geen verdere
blootstelling plaatsvond. DNA addukten in monocyten kunnen mogelijk gebruikt
worden bij het vaststellen van blootstelling over een korte periode, zonder
verstoring van de resultaten door blootstellingen die verder in het verleden
plaatsvonden. Deze resultaten geven aan dat een verlaging van de blootstelling aan
PAK, gepaard gaat met een daling van het DNA adduct niveau in WBC-
subpopulaties.
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Dit houdt ook in dat indien de blootstelling gelijk blijft, het adduct niveau niet
zou mogen veranderen. Tot nu toe zijn er weinig studies beschikbaar die ingaan op
dit aspect (binnenpersoons of intraindividuele variatie). In hoofdstuk 3 wordt een
studie beschreven waarin de intraindividuele variatie werd bestudeerd door
herhaaldelijke metingen van DNA addukten in MNC en BAL-cellen van rokers over
een periode van 2 tot 6 maanden. In MNC van deze rokers bleek de intraindividuele
variatie klein te zijn over een periode van 2 maanden. Echter, na eon half jaar bleken
de DNA addukt niveaus in dezelfde personen te zijn verhoogd, terwijl ze niet meer
of minder waren gaan roken. Een mogelijke verklaring voor deze waarneming is dat
in de winterperiode (2' meting), hogere PAK-concentraties gemeten worden in de
buitenlucht dan in de zomer (V meting). Andere mogelijke vorklaringen kunnon
echter niet worden uitgesloten. De intraindividuele variatie in BAL-cellen was klein
over een periode van 6 maanden; beide metingen in BAL<ellen bleken goed met
elkaar overeen te stemmen.
Hoewel DNA addukten in MNC goed correleerden met het aantal sigaretten
dat dagelijks geconsumeerd werd, werden er toch grote interindividuele variaties
(tussenpersoons variatie) waargenomen. Dat wil zeggen dat twee personen met een
gelijk rookgedrag, toch verschillende DNA addukt niveaus in MNC kunnen hebben.
Verschillende mogelijke bronnen voor deze variatie werden in dit proofschrift
verder bestudeerd. Een mogelijke bron voor deze interindividuele variatie is de
naruurlijke genetische variatie in genen welke coderen voor enzymen die
carcinogenen kunnen detoxificeren. Rokers met het GSTMH-/-) en/of hot /SMT2
langzame acetyleerders genotype hadden hogere DNA addukt niveaus in hun MNC
dan rokers met het GSTM1(+) en/of het M4T2 snelle acetyleerders genotype
(hoofdstuk 5). Ook de lichaamssamenstelling van rokers zou een rol kunnen spelen
in variaties in DNA addukt niveaus tussen personen met een ogenschijnlijk gelijke
blootstelling (hoofdstuk 6). Rokers met een hoge 'body mass index' (BMI, dit is
gewicht/lengte") hadden een lager DNA adduct niveau dan rokers met een lage
BMI. Als laatste werden DNA herstel activiteiten of de inducrie hiervan bestudeerd
als bron van variatie in DNA addukt niveau (hoofdstuk 9). Het eiwit P53 kan hierbij
een belangrijke rol spelen, omdat blootstelling aan PAK de concentrates van dit
eiwit in epidermale cellen doet stijgen. Van P53 is bekend dat het de celdeling remt,
waardoor de cellen voldoende tijd krijgen om adequaat te reageren op de schade die
is aangericht door carcinogenen.
In beroepsmatig blootgestelde individuen wordt de interne dosis van PAK
vaak vastgesteld door middel van metingen van PAK-metabolieten in urine (bijv. 3-
hydroxy-benzo[a]pyreen en/of 1-hydroxy-pyreen). Deze metingen zijn echter niet
representatief voor de biologisch effectieve dosis en geeft de blootstelling aan PAK
over een slechts korte periode weer. Desalniettemin, werden goede correlaties
waargenomen tussen de 3-hydroxy-B[a]P uitscheiding in de urine en de DNA
addukt vorming in doelwit organen van ratten die acuut werden blootgesteld aan
B[a]P. In dit experiment valt op dat de 3-hydroxy-B[a)P concentraties in de urine en
het DNA addukt niveau kort na de acute blootstelling verhoogd zijn. Binnen een a
twee weken is de 3-hydroxy-B[a]P concentratie weer terug op basis niveau, terwijl
DNA addukten nog in grote hoeveelheden in de organen gevonden kunnen worden.
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In patienten behandeld met koolteer zalven werd een vergelijkbare relatie
waargenomen tussen 3-hydroxy-B[a]P in de urine en een specifiek addukt gevormd
door B[a]P.
De nadruk van dit proefschrift ligt op DNA addukt bepalingen na blootstelling
aan aromatische verbindingen. Indien DNA addukten inderdaad worden toegepast
in het vaststellen van PAK-blootstelling, dan moeten de resultaten van deze
metingen en de technieken waarmee deze verkregen worden, betrouwbaar en
reproduceerbaar zijn. De 'P-postlabeling methode is een veelvuldig toegepaste
techniek met een zeer grote gevoeligheid, en waarmee addukten kunnen worden
aangetoond in slechts kleine hoeveelheden DNA. Helaas is deze techniek niet in
staat om addukten te identificeren en daarom werden nieuwe technieken
geintroduceerd zoals een HPLC-fluorescentie methode (hoofdstuk 10). Met deze
techniek kunnen specifieke B[a]P gerelateerde DNA addukten gedetecteerd worden.
Onderzoekers in de moleculaire epidemiologie dienen er zich van bewust te zijn dat
elke techniek haar eigen voor- en nadelen heeft, opdat een juiste keuze gemaakt kan
worden voor de toepassing van een bepaalde techniek in een experiment of studie.
In het algemeen kan geconcludeerd worden dat er voldoende
wetenschappelijke basis is om DNA addukt metingen toe te passen in het vaststellen
van de biologisch effectieve dosis na blootstelling aan PAK. Verder kunnen de
resultaten van dit proefschrift als basis dienen voor nieuwe toepassingen van DNA
addukt metingen, bijvoorbeeld op het gebied van kanker (chemo)preventie.
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de afdeling 'Cancer risk factors and toxicology' van het Deutsche Krebs Forschungs
Zentrum (DKFZ) te Heidelberg in Duitsland.
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